ESCÁNER DE ACCIONES AMERICANAS DE TRADINGCERO.COM (VERSIÓN 1.0) Hora Nueva York:
(2021-03-19)Formato Y-M-D
IPOS AYER:
IPOS HOY: No hay IPOS previstas para hoy.
IPOS MAÑANA: No hay IPOS previstas para mañana.
CNTB >> Connect Biopharma Holding – NASDAQ – $15.00 – $17.00
– FNCH >> Finch Therapeutics Group – NASDAQ – $15.00 – $17.00
– TIL >> Instil Bi – NASDAQ – $17.00 – $19.00
– GLEE >> Gladstone Acquisiti – NASDAQ – $10.00
– LGV >> Longview Acquisition II – NYSE – $10.00
– LVRA >> Levere Holding – NASDAQ – $10.00
– KVSB >> Khosla Ventures Acquisition II – NASDAQ – $10.00
– KVSC >> Khosla Ventures Acquisition III – NASDAQ – $10.00
– AFAQ >> AF Acquisiti – NASDAQ – $10.00
IPOS HOY: No hay IPOS previstas para hoy.
IPOS MAÑANA: No hay IPOS previstas para mañana.
[ Escáners ] 1. Escáner de TODAS las Acciones.
2. Escáner de PennyStocks (<= $10).
3. Escáner de SmallCaps ($10 < y <= $80).
4. Escáner de LargeCaps ( > $80).
2. Escáner de PennyStocks (<= $10).
3. Escáner de SmallCaps ($10 < y <= $80).
4. Escáner de LargeCaps ( > $80).
[ Screener ] >> Screener de TradingCero.com
[ Calendario de Earnings ] >> Empresas que publicarán sus Informes de Resultados próximamente
[ Calendario de IPOS ] >> Empresas que debutarán en WallStreet próximamente
[ Industrias / Sectores ] >> Listado de Insdustrias y Sectores en WallStreet
[ Panel Predictivo ] >> Acceso restringido
[ Descarga de Informes ] >> Acceso restringido
[ Registro de Cambios ] >> Registro de Cambios en el Escáner.
[ LISTADO DE EMPRESAS POR INDUSTRIA – PHARMACEUTICAL PREPARATION MANUFACTURING – PÁGINA ACTUALIZADA EL 2021-03-19 22:11:07 hrs (New York)]
NOMBRE DE LA EMPRESANombre de la Empresa |
SÍMBOLO (MC-SHF-SS)Nombre de la Acción junto a MC: Market Cap. SHF: Flotante SS: Porcentaje de Shorts |
ÚLT. CIERREÚltimo cierre en $ registrado en TradingCero |
ÚLTIMAS NOTICIAS (PON EL CURSOR ENCIMA)5 Últimas noticia sobre la EMPRESA |
|---|---|---|---|
Abbvie Inc …Abbvie Inc |
ABBV (184890, 1760, 0.87 %) | 103.77 | 5 High Dividend Yield Stocks Broadly Bought by Gurus …>> 5 High Dividend Yield Stocks Broadly Bought by Gurus >> Alpine Immune Sciences Inc ALPN Q4 2020 Earnings Call Transcript >> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc ABBV >> ETF looks to help private sector address womens issues >> AbbVie ABBV Down as FDA Extends Review of Rinvoq sNDA |
Abeona Therapeutics Inc …Abeona Therapeutics Inc |
ABEO (218.92, 84.39, 4.04 %) | 2.14 | Abeona Therapeutics NASDAQ ABEO Shareholders Are Down 85 On Their Shares …>> Abeona Therapeutics NASDAQ ABEO Shareholders Are Down 85 On Their Shares >> Billionaire Ken Griffin Pulls the Trigger on These 2 Penny Stocks >> Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference >> New Positive Phase 1 2 Interim Data Presented at WORLDSymposium Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeonas ABO 102 Gene Therapy >> Abeona Therapeutics Announces Clinical Investigator Webinar to Review ABO 102 and ABO 101 Clinical Data Presented at the 17th Annual WORLDSymposium |
ARCA biopharma Inc …ARCA biopharma Inc |
ABIO (39.05, 9.28, 2.13 %) | 4.06 | ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update …>> ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update >> Here s Why We re Not Too Worried About ARCA biopharma s NASDAQ ABIO Cash Burn Situation >> AB201 Development as a Potential Treatment for COVID 19 Receives U S FDA Fast Track Designation >> AB201 Development as a Potential Treatment for COVID 19 Receives U S FDA Fast Track Designation >> AB201 Development as a Potential Treatment for COVID 19 Receives U S FDA Fast Track Designation |
Abbott Laboratories …Abbott Laboratories |
ABT (209810, 1760, 0.56 %) | 118.11 | Could Abbott Laboratories Be a Millionaire Maker Stock …>> Could Abbott Laboratories Be a Millionaire Maker Stock >> This Is Why Abbott Labs Is a Great Stock to Buy Right Now >> ETF looks to help private sector address womens issues >> Veeva VEEV Application Completes Consent for First Patient >> Abbott ABT Stock Sinks As Market Gains What You Should Know |
Arbutus Biopharma Corp …Arbutus Biopharma Corp |
ABUS (355.05, 63.55, 5.15 %) | 3.61 | Arbutus Gets Go Ahead To Kick Off Phase 1a 1b Clinical Trial Of AB 836 …>> Arbutus Gets Go Ahead To Kick Off Phase 1a 1b Clinical Trial Of AB 836 >> Arbutus Receives Regulatory Approval to Initiate a Phase 1a 1b Clinical Trial with AB 836 an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B Infection >> Arbutus Biopharma ABUS Q4 2020 Earnings Call Transcript >> Arbutus Biopharma ABUS Reports Q4 Loss Tops Revenue Estimates >> Arbutus Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update |
Acadia Pharmaceuticals Inc …Acadia Pharmaceuticals Inc |
ACAD (4360, 158.33, 4.18 %) | 27.05 | HAGENS BERMAN NATIONAL TRIAL ATTORNEYS Investigating Acadia Pharmaceuticals ACAD For P …>> HAGENS BERMAN NATIONAL TRIAL ATTORNEYS Investigating Acadia Pharmaceuticals ACAD For Possible Securities Law Violations Encourages Investors with Losses to Contact Its Attorneys >> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc ACAD >> HAGENS BERMAN NATIONAL TRIAL ATTORNEYS Continues Investigation into Acadia Pharmaceuticals ACAD For Possible Securities Law Violations Encourages Investors with Losses to Contact Its Attorneys >> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc ACAD >> HAGENS BERMAN NATIONAL TRIAL ATTORNEYS Investigating Acadia Pharmaceuticals ACAD For Possible Securities Law Violations Encourages Investors with Losses to Contact Its Attorneys |
Acer Therapeutics Inc …Acer Therapeutics Inc |
ACER (48.15, 12.12, 0.76 %) | 3.44 | What s Happening With ACER Stock MGM Stock XPEV Stock …>> What s Happening With ACER Stock MGM Stock XPEV Stock >> Acer Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update >> Acer Therapeutics to Participate in March Virtual Investor Conferences >> Acer Therapeutics Announces Topline Results from its Bioequivalence Trial of ACER 001 Compared to BUPHENYL Under Fed Conditions >> Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER 001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease |
AC Immune SA …AC Immune SA |
ACIU (582.76, 34.3, 4.27 %) | 7.78 | AC Immune Announces New Clinical Results in Down Syndrome and Plans for Future Development …>> AC Immune Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti Amyloid Beta Vaccine >> AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases >> AC Immune to Present New Data from Alpha Synuclein and TDP 43 Programs at the AD PD 2021 Virtual Conference >> AC Immune to Highlight Promising Alzheimers Vaccine at the SVB Leerink 10th Annual Global Healthcare Conference >> This Dollar Stock Biotech Popped In Bullish Volume On Its Alzheimer s News |
Aclaris Therapeutics Inc …Aclaris Therapeutics Inc |
ACRS (1200, 42.28, 1.79 %) | 24.94 | Top Biotech Stocks for Q2 2021 …>> Top Biotech Stocks for Q2 2021 >> Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI 1777 for Moderate to Severe Atopic Dermatitis >> Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update >> Aclaris Therapeutics to Participate in Upcoming Investor Conferences >> Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference |
Acelrx Pharmaceuticals Inc …Acelrx Pharmaceuticals Inc |
ACRX (210.37, 88.6, 8.39 %) | 1.79 | SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx …>> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals Inc ACRX >> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals Inc ACRX >> AcelRx Pharmaceuticals ACRX Reports Q4 Loss Lags Revenue Estimates >> AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results >> AcelRx Pharmaceuticals Inc to Host Earnings Call |
Adc Therapeutics SA …Adc Therapeutics SA |
ADCT (2250, 39.85, 11.13 %) | 29.18 | ADC Therapeutics SA ADCT Q4 2020 Earnings Call Transcript …>> ADC Therapeutics SA ADCT Q4 2020 Earnings Call Transcript >> ADC Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Business Updates >> Adc Therapeutics SA to Host Earnings Call >> Loss Making ADC Therapeutics SA NYSE ADCT Expected To Breakeven In The Medium Term >> ADC Therapeutics to Host Fourth Quarter and Year End 2020 Financial Results Conference Call on March 18 2021 |
Adial Pharmaceuticals Inc …Adial Pharmaceuticals Inc |
ADIL (38.11, 11.64, 4.34 %) | 2.6 | Adial Founder and Chief Medical Officer Dr Bankole Johnson Featured Guest on The Black N …>> Adial Founder and Chief Medical Officer Dr Bankole Johnson Featured Guest on The Black News Channel >> Adial Announces Management Led 2 100 000 Above Market Private Placement at 3 00 Per Share >> Adial Schedules Town Hall to Discuss Positive Updates Regarding Pharmaceutical Pipeline and Business Expansion >> Adial Receives 1 425 Million in Net Proceeds from Exercise of Warrants >> Adial Pharmaceuticals Achieves 50 Enrollment in ONWARD Phase 3 Trial |
Adamis Pharmaceuticals Corp …Adamis Pharmaceuticals Corp |
ADMP (149, 92.94, 3.48 %) | 1.04 | Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the COVID 19 Challeng …>> Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the COVID 19 Challenged Hamster Model >> Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID 19 >> Adamis Pharma Shares Fall Despite US Patent Covering Naloxone >> Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate >> Adamis Pharmaceuticals and Human Immune Monitoring Center at Stanford University Announce Preliminary Tempol Data in Cells from COVID 19 Patients |
Adamas Pharmaceuticals Inc …Adamas Pharmaceuticals Inc |
ADMS (231.66, 27.75, 7.16 %) | 5.53 | Adamas Announces New Employment Inducement Grant …>> Adamas Announces New Employment Inducement Grant >> Strength Seen in Adamas ADMS Can Its 5 9 Jump Turn into More Strength >> Adamas Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares >> Adamas Pharmaceuticals Announces Pricing of Follow on Public Offering >> Adamas Pharmaceuticals Announces Launch of Follow on Public Offering |
Aditx Therapeutics Inc …Aditx Therapeutics Inc |
ADTX (43.8, 9.5, 3.25 %) | 3.3 | Eazy Testing Inc Becomes AditxtScore Channel Partner to Offer AditxtScore for COVID 19 I …>> Eazy Testing Inc Becomes AditxtScore Channel Partner to Offer AditxtScore for COVID 19 Immunity Status Monitoring with its Walk In Concierge and Pre Flight Services >> Immunologist and Clinical Transplant Expert Dolly B Tyan PhD Joins Aditxt as Senior VP of Clinical Development Transplantation >> Immunologist and Clinical Transplant Expert Dolly B Tyan PhD Joins Aditxt as Senior VP of Clinical Development Transplantation >> Immunologist and Clinical Transplant Expert Dolly B Tyan PhD Joins Aditxt as Senior VP of Clinical Development Transplantation >> Immunologist and Clinical Transplant Expert Dolly B Tyan PhD Joins Aditxt as Senior VP of Clinical Development Transplantation |
Advaxis, Inc. …Advaxis, Inc. |
ADXS (92.31, 105.83, 4.44 %) | 0.838 | Advaxis Reports First Quarter Ended January 31 2021 Financial Results and Provides a Busi …>> Advaxis Reports First Quarter Ended January 31 2021 Financial Results and Provides a Business Update >> Advaxis to Present at the American Association for Cancer Research AACR 2021 Annual Meeting >> Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update >> Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update >> Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update |
Affimed N.V. …Affimed N.V. |
AFMD (904.96, 82.4, 9.07 %) | 8.06 | Affimed Announces Presentations at the AACR Annual Meeting 2021 …>> Affimed Announces Presentations at the AACR Annual Meeting 2021 >> Why Affimed N V Stock Is Soaring Today >> Affimed To Continue Enrollment In AFM13 Lymphoma Study After Positive Interim Data >> Affimed Announces Continuation of REDIRECT a Registration directed Study of AFM13 in PTCL after Positive Preplanned Interim Futility Analysis >> The Daily Biotech Pulse Amgen Earnings GSK CureVac Vaccine Collaboration Mallinckrodt FDA Decision |
Agios Pharmaceuticals Inc …Agios Pharmaceuticals Inc |
AGIO (3490, 61.51, 9.47 %) | 48.54 | Agios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease …>> Agios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease >> Agios Submits Supplemental New Drug Application to FDA for TIBSOVO ivosidenib tablets for Patients with Previously Treated IDH1 Mutant Cholangiocarcinoma >> Time To Worry Analysts Just Downgraded Their Agios Pharmaceuticals Inc NASDAQ AGIO Outlook >> Benzinga s Top Ratings Upgrades Downgrades For February 26 2021 >> Agios AGIO Q4 Loss In Line Revenues Surpass Estimates |
Aeglea BioTherapeutics Inc …Aeglea BioTherapeutics Inc |
AGLE (390.25, 46.71, 3.88 %) | 7.48 | Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Cor …>> Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights >> Aeglea BioTherapeutics Appoints Sara Brownstein to Board of Directors >> We Think Aeglea BioTherapeutics NASDAQ AGLE Needs To Drive Business Growth Carefully >> 10 Best Small Cap Biotech Stocks Under 10 in 2021 >> 10 Best Small Cap Biotech Stocks Under 10 in 2021 |
Agile Therapeutics Inc …Agile Therapeutics Inc |
AGRX (182.26, 67.1, 3.99 %) | 2.05 | Agile Therapeutics to Present at Upcoming March Investor Conferences …>> Agile Therapeutics to Present at Upcoming March Investor Conferences >> Agile Therapeutics AGRX Q4 2020 Earnings Call Transcript >> Agile Therapeutics AGRX Reports Q4 Loss Misses Revenue Estimates >> Agile Therapeutics Reports Fourth Quarter amp Full Year 2020 Financial Results Expands Loan Facility With Perceptive Advisors >> Agile Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on Monday March 1 2021 |
Akebia Therapeutics Inc. …Akebia Therapeutics Inc. |
AKBA (559.92, 142.95, 17.84 %) | 3.33 | Akebia Therapeutics Celebrates World Kidney Day and National Kidney Month …>> Akebia Therapeutics Celebrates World Kidney Day and National Kidney Month >> Is Akebia Therapeutics NASDAQ AKBA Using Debt Sensibly >> Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 c 4 >> Looking Into Akebia Therapeutics s Return On Capital Employed >> Why Akebia Therapeutics Stock Is Plunging Today |
Akero Therapeutics Inc …Akero Therapeutics Inc |
AKRO (1140, 29.75, 7.48 %) | 32.01 | Akero Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results …>> Akero Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results >> We re Hopeful That Akero Therapeutics NASDAQ AKRO Will Use Its Cash Wisely >> Akero Therapeutics Initiates Phase 2b HARMONY Study of Efruxifermin EFX for the Treatment of NASH >> Akero Therapeutics to Participate in Upcoming Virtual Healthcare Conferences in March >> Akero Therapeutics to Present at the 39th Annual J P Morgan Healthcare Conference |
Akouos Inc …Akouos Inc |
AKUS (738.85, 19.07, 11.61 %) | 19.86 | Akouos and Blueprint Genetics Announce the Resonate Program to Improve Access to Genetic T …>> Akouos and Blueprint Genetics Announce the Resonate Program to Improve Access to Genetic Testing for Individuals with Auditory Neuropathy >> Have Insiders Been Buying Akouos Inc NASDAQ AKUS Shares >> Is AKUS A Good Stock To Buy >> Akouos to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference >> Akouos Reports Third Quarter 2020 Financial Results and Provides Business Highlights |
Albireo Pharma Inc …Albireo Pharma Inc |
ALBO (711.91, 16.06, 9.8 %) | 34.64 | Industry Analysts Just Made A Captivating Upgrade To Their Albireo Pharma Inc NASDAQ AL …>> Industry Analysts Just Made A Captivating Upgrade To Their Albireo Pharma Inc NASDAQ ALBO Revenue Forecasts >> Albireo Spotlights Global Patient Communities on Rare Disease Day >> Albireo Pharma Inc ALBO Q4 2020 Earnings Call Transcript >> Albireo Reports Q4 and Year End 2020 Financial Results and Business Update >> Albireo to Participate in Cowen and H C Wainwright Global Investor Conferences |
Aldeyra Therapeutics Inc …Aldeyra Therapeutics Inc |
ALDX (552.75, 38.28, 4.71 %) | 11.61 | Aldeyra Therapeutics ALDX Q4 2020 Earnings Call Transcript …>> Aldeyra Therapeutics ALDX Q4 2020 Earnings Call Transcript >> Aldeyra Therapeutics Reports Full Year 2020 Financial Results and Recent Business Highlights >> Aldeyra Therapeutics Inc to Host Earnings Call >> Aldeyra Therapeutics to Present at the OIS Dry Eye Innovation Showcase on March 11 2021 >> Why Earnings Season Could Be Great for Aldeyra Therapeutics ALDX |
Alimera Sciences Inc. …Alimera Sciences Inc. |
ALIM (63.12, 5.31, 2.56 %) | 10.8 | Alimera Sciences to Participate in Benzinga Biotech Small Cap Conference …>> Alimera Sciences to Participate in Benzinga Biotech Small Cap Conference >> Alimera Sciences Continues to Execute on Its Expansion Strategy in Denmark and Luxembourg and Achieves Extended Reimbursement in Ireland >> Alimera Sciences to Present at Maxim Groups Inaugural Emerging Growth Virtual Conference >> Alimera Sciences to Present at the H C Wainwright Global Life Sciences Conference >> Alimera Sciences Inc ALIM Q4 2020 Earnings Call Transcript |
Alkermes plc …Alkermes plc |
ALKS (3220, 157.66, 7.2 %) | 19.62 | Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucos …>> Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma >> Alkermes Inc Moody s assigns Ba3 to Alkermes term loan stable outlook >> Alkermes to Hold Virtual Investor Day >> Alkermes to Take Part in SVB Leerink 10th Annual Global Healthcare Conference >> Alkermes ALKS Q4 Earnings and Revenues Beat Estimates |
Alnylam Pharmaceuticals Inc …Alnylam Pharmaceuticals Inc |
ALNY (17080, 116.04, 3.19 %) | 140.04 | Alnylam Vir Biotech Deprioritize COVID 19 Drug Development In Hushed Manner …>> Alnylam Vir Biotech Deprioritize COVID 19 Drug Development In Hushed Manner >> Alnylam Issues Inaugural Corporate Responsibility Summary >> Soleo Health to Administer Alnylam Pharmaceuticals GIVLAARI givosiran for the Treatment of Acute Hepatic Porphyria in Adults >> Alnylam to Webcast Presentations at Upcoming March Investor Conferences >> Alnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare Conference |
Alpine Immune Sciences Inc …Alpine Immune Sciences Inc |
ALPN (324.34, 17.06, 2.26 %) | 13.81 | Alpine Immune Sciences Inc ALPN Q4 2020 Earnings Call Transcript …>> Alpine Immune Sciences Inc ALPN Q4 2020 Earnings Call Transcript >> Alpine Immune Sciences Inc ALPN Reports Q4 Loss Tops Revenue Estimates >> Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results >> Alpine Immune Sciences Inc to Host Earnings Call >> Alpine Immune Sciences to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update |
Aileron Therapeutics Inc …Aileron Therapeutics Inc |
ALRN (126.32, 36.21, 3.11 %) | 1.64 | Aileron Therapeutics to Present at 2021 H C Wainwright Global Life Sciences Conference …>> Aileron Therapeutics to Present at 2021 H C Wainwright Global Life Sciences Conference >> Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN 6924 in Patients with Advanced Non Small Cell Lung Cancer NSCLC >> Aileron Therapeutics Announces Completion of 35 9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures BVF Partners L P and Maven Investment Partners >> Aileron Therapeutics Announces Completion of 35 9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures BVF Partners L P and Maven Investment Partners >> Aileron Therapeutics Announces Completion of 35 9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures BVF Partners L P and Maven Investment Partners |
Altimmune Inc …Altimmune Inc |
ALT (650.36, 30.93, 7.81 %) | 17.27 | AdCOVID Altimmunes Single Dose Intranasal COVID 19 Vaccine Candidate Prevents SARS CoV …>> AdCOVID Altimmunes Single Dose Intranasal COVID 19 Vaccine Candidate Prevents SARS CoV 2 induced Disease and Blocks Viral Replication in Preclinical Studies of SARS CoV 2 Infection >> Altimmune Extends Lonza Partnership To Support Production Of AdCOVID >> Altimmune Expands AdCOVID Manufacturing Collaboration with Lonza >> Altimmune Joins Rank Of Stocks With RS Ratings Over 90 >> Altimmune to Present at Upcoming Conferences |
Alexion Pharmaceuticals Inc. …Alexion Pharmaceuticals Inc. |
ALXN (33660, 218.93, 3.86 %) | 151.27 | SHAREHOLDER ALERT WeissLaw LLP Reminds BFTL ALXN KTYB and GLUU Shareholders About Its …>> SHAREHOLDER ALERT WeissLaw LLP Reminds BFTL ALXN KTYB and GLUU Shareholders About Its Ongoing Investigations >> The FTC Is Taking a More Aggressive Approach Toward Pharmaceutical M amp A What It Means for the Industry >> AstraZeneca Pops On Alexion Buyout Despite Mounting Covid Vaccine Doubt >> AstraZeneca Pops On Alexion Buyout Despite Mounting Covid Vaccine Doubt >> STOCK ALERT Halper Sadeh LLP Investigates MGLN CATM EGOV ALXN Shareholders Are Encouraged to Contact the Firm |
Ampio Pharmaceuticals Inc …Ampio Pharmaceuticals Inc |
AMPE (336.9, 170.94, 12.29 %) | 1.82 | Ampio Pharmaceuticals to Present at Benzinga Biotech Small Cap Conference …>> Ampio Pharmaceuticals to Present at Benzinga Biotech Small Cap Conference >> Ampio Pharmaceuticals Details Early Positive Results for Inhaled Ampion in COVID 19 Respiratory Distress >> Ampio Pharmaceuticals to Participate in the 33rd Annual Virtual ROTH Conference on March 15 17 2021 >> Why Ampio Pharmaceuticals Stock Is Jumping Today >> Ampio Pharmaceuticals AMPE Q4 2020 Earnings Call Transcript |
Amphastar Pharmaceuticals Inc …Amphastar Pharmaceuticals Inc |
AMPH (840.49, 36.41, 7.05 %) | 17.91 | New Strong Sell Stocks for March 18th …>> New Strong Sell Stocks for March 18th >> Amphastar Pharmaceuticals Inc AMPH Q4 2020 Earnings Call Transcript >> Amphastar Pharmaceuticals AMPH Surpasses Q4 Earnings and Revenue Estimates >> Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31 2020 >> Amphastar Pharmaceuticals Inc to Host Earnings Call |
Amneal Pharmaceuticals Inc – Class A …Amneal Pharmaceuticals Inc – Class A |
AMRX (2090, 116.02, 4.7 %) | 6.91 | Top Pharmaceutical Stocks for Q2 2021 …>> Top Pharmaceutical Stocks for Q2 2021 >> 5 Value Stocks In The Healthcare Sector >> Amneal Posts Better Than Expected Q4 Results Upbeat 2021 Revenue Outlook >> Amneal Pharmaceuticals Inc AMRX Q4 2020 Earnings Call Transcript >> Amneal Pharmaceuticals AMRX Surpasses Q4 Earnings and Revenue Estimates |
Applied Molecular Transport Inc …Applied Molecular Transport Inc |
AMTI (2340, 24.54, 6.67 %) | 64.46 | Applied Molecular Transport Reports Fourth Quarter and Full Year 2020 Financial Results an …>> Applied Molecular Transport Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update >> 3 Biotech Stocks That Have Already Rocketed Higher in 2021 >> Applied Molecular Transport to Present at Oppenheimer 31st Annual Healthcare Conference >> Who Has Been Buying Applied Molecular Transport Inc NASDAQ AMTI Shares >> Applied Molecular Transport Expands Clinical Pipeline and Announces First Subject Dosed in Phase 1a Trial of Oral AMT 126 |
AnaptysBio Inc …AnaptysBio Inc |
ANAB (617.21, 25.6, 14.87 %) | 21.46 | Broker Revenue Forecasts For AnaptysBio Inc NASDAQ ANAB Are Surging Higher …>> Broker Revenue Forecasts For AnaptysBio Inc NASDAQ ANAB Are Surging Higher >> Why AnaptysBio Stock Is Attractive After 30 Selloff >> Why AnaptysBio Stock Is Popping Today >> AnaptysBio and Seagate Technology See Activist Action >> Why AnaptysBio Shares Rose Nearly 14 on Thursday |
Annexon Inc …Annexon Inc |
ANNX (1210, 21.19, 3.07 %) | 31.15 | Annexon Shares Gain After Patient Dosing Starts In Mid Stage Study For Vision Loss Disorde …>> Annexon Shares Gain After Patient Dosing Starts In Mid Stage Study For Vision Loss Disorder Therapy >> Annexon Advances Classical Complement Platform with Initiation of Global Phase 2 ARCHER Trial in Patients with Geographic Atrophy >> Annexon Welcomes William H Carson M D to the Board of Directors >> Annexon Highlights Recent Achievements and Outlines Expected Key Milestones in 2021 for Its Broad Portfolio of Complement Therapeutics >> Annexon to Present at the J P Morgan 39th Annual Healthcare Conference |
Annovis Bio Inc …Annovis Bio Inc |
ANVS (258.32, 4.09, 1.9 %) | 36.01 | Annovis Bio Presents Novel Treatment For Alzheimer s And Parkinson s Diseases …>> Annovis Bio Presents Novel Treatment For Alzheimer s And Parkinson s Diseases >> Annovis Bio Presenting at M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference >> Annovis Bio Stock Is Trading Higher After Parkinson s Med Shows Improvement In Speed Coordination >> Annovis Bio Announces Positive Phase 2 Data Interim Data Shows ANVS401 Improves Speed and Coordination in Parkinson s Patients >> Annovis Bio Inc to present at the Q1 Virtual Investor Summit |
Apellis Pharmaceuticals Inc …Apellis Pharmaceuticals Inc |
APLS (3960, 62.92, 12.89 %) | 44 | Apellis and Sobi The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Resu …>> Apellis and Sobi The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH >> Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy >> Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635 c 4 >> Apellis Pharmaceuticals To Stop Testing APL 9 In Severe COVID 19 Patients >> Apellis Provides Update on APL 9 for Severe COVID 19 |
Aprea Therapeutics Inc …Aprea Therapeutics Inc |
APRE (124.59, 18.45, 7.76 %) | 5.8 | Aprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provide …>> Aprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Update on Business Operations >> Is Aprea Therapeutics Inc NASDAQ APRE Popular Amongst Institutions >> What Makes Aprea Therapeutics Inc APRE a New Buy Stock >> What Makes Aprea Therapeutics Inc APRE a New Buy Stock >> What Makes Aprea Therapeutics Inc APRE a New Buy Stock |
Aptinyx Inc …Aptinyx Inc |
APTX (212.51, 30.98, 6.06 %) | 3.11 | Aptinyx Inc APTX May Report Negative Earnings Know the Trend Ahead of Next Week s Rele …>> Aptinyx Inc APTX May Report Negative Earnings Know the Trend Ahead of Next Week s Release >> Aptinyx to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday March 24 2021 >> Aptinyx to Participate in Upcoming Investor Conferences >> Aptinyx to Participate at 10th Annual SVB Leerink Global Healthcare Conference >> Petco Health and Wellness Company Inc to Provide Covid 19 Vaccination Payment for Partners |
Aptevo Therapeutics Inc …Aptevo Therapeutics Inc |
APVO (150.91, 1.73, 11.6 %) | 34.51 | Aptevo Confirms Receipt of Nominations and Proposal Notice …>> Aptevo Confirms Receipt of Nominations and Proposal Notice >> Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial >> Aptevo Therapeutics Inc APVO Upgraded to Buy Here s Why >> Kaskela Law LLC Announces Investigation of Aptevo Therapeutics Inc APVO and Encourages Shareholders to Contact the Firm >> Aptevo Therapeutics Announces the Launch of Its Second Platform Technology ADAPTIR FLEX TM and Introduces the New Bispecific Prostate Cancer Candidate APVO442 |
Aravive Inc …Aravive Inc |
ARAV (152.71, 11.23, 3.96 %) | 8.57 | Aravive Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate …>> Aravive Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates >> Aravive to Present Phase 1b Data Evaluating AVB 500 in Platinum Resistant Ovarian Cancer at 2021 Society of Gynecologic Oncology Annual Meeting >> Aravive Announces First Patient Dosed in Phase 1b 2 Clinical Trial of AVB 500 in Patients with Clear Cell Renal Cell Carcinoma >> Aravive to Participate in Upcoming Virtual Investor Conferences in March >> Aravive Announces 21 0 Million Registered Direct Offering with Eshelman Ventures LLC Priced At The Market |
Arcturus Therapeutics Holdings Inc …Arcturus Therapeutics Holdings Inc |
ARCT (1390, 21.45, 14.87 %) | 48.34 | FDA Approves New Drug Application For Ultragenyxs mRNA Therapy Shares Drop …>> FDA Approves New Drug Application For Ultragenyxs mRNA Therapy Shares Drop >> Arcturus Therapeutics Q4 Earnings Insights >> Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates >> Arcturus Therapeutics Holdings Inc to Host Earnings Call >> Have Insiders Been Buying Arcturus Therapeutics Holdings Inc NASDAQ ARCT Shares This Year |
Ardelyx Inc …Ardelyx Inc |
ARDX (700.63, 88.91, 5.22 %) | 6.72 | Ardelyx Appoints Muna Bhanji R Ph to its Board of Directors …>> Ardelyx Appoints Muna Bhanji R Ph to its Board of Directors >> Ardelyx ARDX Reports Q4 Loss Misses Revenue Estimates >> Ardelyx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights >> Ardelyx Inc NASDAQ ARDX When Will It Breakeven >> Knight Therapeutics Announces Canadian Commercial Launch of IBSRELA New Innovative Treatment for Irritable Bowel Syndrome with Constipation |
Arena Pharmaceuticals Inc …Arena Pharmaceuticals Inc |
ARNA (4580, 57.42, 6.06 %) | 72.88 | Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 c 4 …>> Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 c 4 >> 3 Reasons to Avoid Arena Pharmaceuticals and 1 Reason to Buy >> Arena ARNA Tumbles as Mid Stage Gastrointestinal Study Fails >> Return On Capital Employed Overview Arena Pharmaceuticals >> Arena Pharmaceuticals Reports Topline Results from Phase 2b CAPTIVATE Clinical Trial |
Arcutis Biotherapeutics Inc …Arcutis Biotherapeutics Inc |
ARQT (1630, 27.21, 5.22 %) | 30.29 | Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ 252 as …>> Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ 252 as a Potential Treatment for Vitiligo >> Arcutis Biotherapeutics to Showcase Long term Safety Efficacy and Patient Reported Outcomes of Roflumilast Cream for Chronic Plaque Psoriasis at Innovations in Dermatology Virtual Spring Conference 2021 >> Arcutis to Present at the Cowen 41st Annual Health Care Conference >> Courtney Barton Joins Arcutis as Chief Compliance Officer and Chief of Staff >> Arcutis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update |
Arrowhead Pharmaceuticals Inc. …Arrowhead Pharmaceuticals Inc. |
ARWR (7580, 100.47, 5.12 %) | 67.84 | Biotech stocks are a buy especially these 18 picks …>> Biotech stocks are a buy especially these 18 picks >> Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO APOC3 in Patients with Severe Hypertriglyceridemia >> Is Arrowhead Pharmaceuticals ARWR Stock a Buy For 2021 >> Is Arrowhead Pharmaceuticals Inc NASDAQ ARWR Popular Amongst Institutions >> ARWR Multiple Data Readouts in 2021 |
Assembly Biosciences Inc …Assembly Biosciences Inc |
ASMB (193.16, 31.49, 12.28 %) | 4.84 | Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 c 4 …>> Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 c 4 >> Arbutus Biopharma ABUS Q4 2020 Earnings Call Transcript >> Assembly Bio Arbutus Bio Start Testing Vebicorvir AB 729 Triplet Therapy In HBV Infection >> Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus >> Assembly Biosciences Foregoes Vebicorvir Registration Studies For Chronic Suppressive Therapy |
Athersys Inc …Athersys Inc |
ATHX (395.4, 178.83, 12.3 %) | 1.81 | Athersys to Host Year End 2020 Financial Results Call …>> Athersys to Host Year End 2020 Financial Results Call >> Athersys Announces Cooperation Agreement With HEALIOS K K >> Athersys Announces CEO Transition >> UTHealth in Houston and Athersys Announce Commencement of Patient Enrollment in a Phase 2 Trial Evaluating MultiStem Cell Therapy in Trauma >> UTHealth in Houston and Athersys Announce Commencement of Patient Enrollment in a Phase 2 Trial Evaluating MultiStem Cell Therapy in Trauma |
Actinium Pharmaceuticals Inc …Actinium Pharmaceuticals Inc |
ATNM (115.13, 13.38, 6 %) | 8.96 | Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next Gener …>> Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next Generation Actinium 225 Based CD45 Targeting ARC >> Actinium Announces Appointment of Mark Kubik MBA as Chief Business Officer >> Actinium Announces Participation in H C Wainwright Global Life Sciences Conference >> Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation amp Cellular Therapy Annual Meeting >> Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation amp Cellular Therapy Annual Meeting |
Athenex Inc …Athenex Inc |
ATNX (456.41, 61.59, 11.18 %) | 4.85 | ROSEN A TOP RANKED LAW FIRM Encourages Athenex Inc Investors to Secure Counsel Before …>> ROSEN A TOP RANKED LAW FIRM Encourages Athenex Inc Investors to Secure Counsel Before Important Deadline in Securities Class Action ATNX >> The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of REGI ATNX and NEPT >> SHAREHOLDER ACTION REMINDER The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athenex Inc and Encourages Investors with Losses in Excess of 100 000 to Contact the Firm >> CLASS ACTION UPDATE for BLU ATNX and NEPT Levi amp Korsinsky LLP Reminds Investors of Class Actions on Behalf of Shareholders >> DEADLINE ALERT for OTRK ATNX LDOS RRC Law Offices of Howard G Smith Reminds Investors of Class Actions on Behalf of Shareholders |
Avenue Therapeutics Inc …Avenue Therapeutics Inc |
ATXI (110.03, 6.65, 5.37 %) | 6.1 | Avenue Therapeutics Announces Publication of Real World Data on Nonmedical Use of Tramadol …>> Avenue Therapeutics Announces Publication of Real World Data on Nonmedical Use of Tramadol in ASI MV Network >> Avenue Therapeutics Announces Publication of Real World Data on Nonmedical Use of Tramadol in ASI MV Network >> Avenue Therapeutics Announces Publication of Real World Data on Nonmedical Use of Tramadol in ASI MV Network >> Avenue Therapeutics Announces Publication of Real World Data on Nonmedical Use of Tramadol in ASI MV Network >> How Much Of Avenue Therapeutics Inc NASDAQ ATXI Do Institutions Own |
Aurinia Pharmaceuticals Inc …Aurinia Pharmaceuticals Inc |
AUPH (1790, 116.02, 5.13 %) | 13.56 | 3 Favorite Names With Exciting Potential …>> 3 Favorite Names With Exciting Potential >> Aurinia Announces Positive Cost Effectiveness Assessment of LUPKYNIS voclosporin in Latest ICER Draft Evidence Report >> Aurinia Pharmaceuticals Short Term Trading of a Long Term Favorite >> Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences >> Aurinia Pharmaceuticals Inc AUPH Q4 2020 Earnings Call Transcript |
AVEO Pharmaceuticals Inc …AVEO Pharmaceuticals Inc |
AVEO (305.69, 24.78, 4.68 %) | 10.18 | Can AVEO AVEO Run Higher on Strong Earnings Estimate Revisions …>> Can AVEO AVEO Run Higher on Strong Earnings Estimate Revisions >> AVEO Pharmaceuticals AVEO Reports Q4 Loss Lags Revenue Estimates >> AVEO Oncology Reports Full Year 2020 Financial Results and Provides Business Update >> AVEO Pharmaceuticals CANbridge AV 203 Licensing Deal Axed AVEO Regains Ex North American Rights >> AVEO Oncology to Regain Ex North American Rights to AV 203 |
Anavex Life Sciences Corporation …Anavex Life Sciences Corporation |
AVXL (1050, 67.14, 5.9 %) | 14.84 | Anavex Life Sciences Reports ANAVEX 2 73 blarcamesine featured as a Disease Modifying S …>> Anavex Life Sciences Reports ANAVEX 2 73 blarcamesine featured as a Disease Modifying Small Molecule in Phase 3 Clinical Trials in a New Publication in Medical Journal titled Future Avenues for Alzheimers Disease Detection and Therapy >> Gene editing will boost intelligence within a few decades >> Influencers with Andy Serwer Walter Isaacson >> Anavex Life Sciences to Present at the H C Wainwright Global Life Sciences Conference >> Here s Why We re Not At All Concerned With Anavex Life Sciences NASDAQ AVXL Cash Burn Situation |
Axsome Therapeutics Inc …Axsome Therapeutics Inc |
AXSM (2580, 29.5, 10.89 %) | 63.02 | 1 Green Flag for Axsome Therapeutics …>> 1 Green Flag for Axsome Therapeutics >> Axsome s AXSM Q4 Earnings Miss Estimates Pipeline in Focus >> Axsome Therapeutics Inc AXSM Q4 2020 Earnings Call Transcript >> Axsome Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update >> Axsome Therapeutics Inc to Host Earnings Call |
Aytu BioScience Inc …Aytu BioScience Inc |
AYTU (173.95, 14.74, 2.53 %) | 9.88 | Why Did Aytu Biosciences Gap Up Today Technical Levels To Watch …>> Why Did Aytu Biosciences Gap Up Today Technical Levels To Watch >> Why Are Neos Therapeutics Aytu BioScience Stocks Soaring Today >> Aytu Bioscience Inc AYTU Moves 9 2 Higher Will This Strength Last >> The Daily Biotech Pulse Regulatory Setback For Acadia Lilly Forges Diabetes Antibody Treatment Collaboration Aytu s Positive COVID 19 Data >> Aytu BioScience Announces Positive Clinical Results from Healight TM Pilot Study in SARS CoV 2 Patients |
AzurRx BioPharma Inc …AzurRx BioPharma Inc |
AZRX (101.14, 29.48, 2.19 %) | 1.48 | AzurRx BioPharma Announces Completion of Enrollment in Phase 2b OPTION 2 Clinical Trial of …>> AzurRx BioPharma Announces Completion of Enrollment in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis >> AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference March 17 18 >> AzurRx BioPharma Announces 10 Million Registered Direct Offering Priced At the Market Under Nasdaq Rules >> AzurRx BioPharma to Participate in the 33rd Annual Roth Conference >> AzurRx BioPharma to Participate in Fireside Chat at the H C Wainwright Global Life Sciences Conference |
Bioanalytical Systems Inc. …Bioanalytical Systems Inc. |
BASI (160.6, 6.04, 0.95 %) | 15.02 | Bioanalytical Systems Inc Announces Corporate Name Change to Inotiv Inc …>> Bioanalytical Systems Inc Announces Corporate Name Change to Inotiv Inc >> Fed Eyes Faster Recovery in 2021 3 MedTech Stocks to Buy >> Bioanalytical Systems Inc doing business as Inotiv Announces Plan to Expand Service Offerings to Include Cardiovascular Safety Pharmacology >> Here s Why You Should Add IDEXX IDXX to Your Portfolio Now >> Integra IART Neurosurgery Grows Sequentially Amid Supply Woe |
BridgeBio Pharma Inc …BridgeBio Pharma Inc |
BBIO (10260, 96.67, 11.63 %) | 63.47 | 10 Best Hong Kong Stocks To Buy For 2021 …>> 10 Best Hong Kong Stocks To Buy For 2021 >> BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635 c 4 >> BridgeBio Jumps 6 Pre Market On FDA Approval For Nulibry >> BridgeBio Pharma Gets First FDA Approval For Rare Genetic Metabolic Disorder >> BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY fosdenopterin the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A |
Atreca Inc – Class A …Atreca Inc – Class A |
BCEL (551.33, 21.9, 15.58 %) | 15.15 | Atreca Announces Poster Presentation at the Virtual American Association for Cancer Resear …>> Atreca Announces Poster Presentation at the Virtual American Association for Cancer Research AACR Annual Meeting >> Atreca Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments >> Atreca to Participate at Upcoming Virtual Investor Conferences >> Need To Know Atreca Inc NASDAQ BCEL Insiders Have Been Buying Shares >> Is BCEL A Good Stock To Buy Now |
Biodelivery Sciences International …Biodelivery Sciences International |
BDSI (377.32, 98.56, 3.08 %) | 3.65 | Top Biotech Stocks for Q2 2021 …>> Top Biotech Stocks for Q2 2021 >> Biodelivery Sciences International Inc BDSI Q4 2020 Earnings Call Transcript >> BioDelivery BDSI Beats Q4 Earnings Estimates Stock Up >> Recap BioDelivery Sciences Q4 Earnings >> BioDelivery Sciences Reports Strong Q4 and Record Full Year 2020 Results |
Bausch Health Companies Inc …Bausch Health Companies Inc |
BHC (12220, 347.91, 3.88 %) | 32.84 | Bausch Health names new CFO says eye care unit spinoff on track …>> Bausch Health names new CFO says eye care unit spinoff on track >> Bausch Health Announces CFO Succession Plan >> Return On Capital Employed Overview Bausch Health Companies >> Bausch Health Publishes Pipeline Update For The Barclays Global Healthcare Conference >> Solta Medical Announces the U S Launch of The Clear Brilliant Touch Laser |
Biohaven Pharmaceutical Holding Company …Biohaven Pharmaceutical Holding Company Ltd |
BHVN (4680, 49.54, 11.62 %) | 71.35 | Biohaven Announces Pricing Of 200 Million Public Offering Of Common Shares …>> Biohaven Announces Pricing Of 200 Million Public Offering Of Common Shares >> Biohaven Announces Proposed Public Offering Of Common Shares >> 7 Pharmaceutical Stocks Working on Their Next Blockbuster >> ROCE Insights For Biohaven Pharmaceutical >> Biohaven s NURTEC ODT Approved In United Arab Emirates For Acute Treatment Of Migraine |
Bellicum Pharmaceuticals Inc …Bellicum Pharmaceuticals Inc |
BLCM (21.62, 5.04, 13.66 %) | 4.11 | Bellicum Shares Are Trading Higher On First Reported Positive Clinical Use Of iC9 Safety S …>> Bellicum Shares Are Trading Higher On First Reported Positive Clinical Use Of iC9 Safety Switch >> Bellicum Announces First Reported Use of CaspaCIDe Safety Switch to Mitigate CAR T Cell Toxicity >> Ponce Therapeutics Inc Commences First R amp D Program in Anti Aging Products for Skin >> Ponce Therapeutics Inc Commences First R amp D Program in Anti Aging Products for Skin >> Ponce Therapeutics Inc Commences First R amp D Program in Anti Aging Products for Skin |
Bellerophon Therapeutics Inc …Bellerophon Therapeutics Inc |
BLPH (63.29, 7.76, 3.85 %) | 6.45 | Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full Year 2020 …>> Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full Year 2020 Financial Results >> Bellerophon to Present at the H C Wainwright Global Life Sciences Conference >> Bellerophon to Present at the H C Wainwright Virtual BioConnect 2021 Conference >> Bellerophon to Present at the H C Wainwright Virtual BioConnect 2021 Conference >> Bellerophon to Present at the H C Wainwright Virtual BioConnect 2021 Conference |
Bellus Health Inc …Bellus Health Inc |
BLU (316.71, 61.15, 3.51 %) | 4.06 | BLU INVESTOR ALERT Bernstein Liebhard LLP Announces that a Securities Class Action Lawsui …>> BLU INVESTOR ALERT Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against BELLUS Health Inc >> LAWSUITS FILED AGAINST BLU APA and CYDY Jakubowitz Law Pursues Shareholders Claims >> Gainey McKenna amp Egleston Announces A Class Action Lawsuit Has Been Filed Against BELLUS Health Inc BLU >> CLASS ACTION UPDATE for BLU ATNX and NEPT Levi amp Korsinsky LLP Reminds Investors of Class Actions on Behalf of Shareholders >> INVESTOR ALERT Law Offices of Howard G Smith Announces the Filing of a Securities Class Action on Behalf of BELLUS Health Inc BLU Investors |
Biomarin Pharmaceutical Inc. – Registere …Biomarin Pharmaceutical Inc. – Registered Shares |
BMRN (14340, 180.42, 6.32 %) | 77.39 | 7 Pharmaceutical Stocks Working on Their Next Blockbuster …>> 7 Pharmaceutical Stocks Working on Their Next Blockbuster >> BioMarin BMRN Hemophilia Gene Therapy Gets FDA s RMAT Tag >> BioMarin s Hemophilia Gene Therapy Scores RMAT Designation In US >> BioMarin Announces FDA Regenerative Medicine Advanced Therapy RMAT Designation Granted to Valoctocogene Roxaparvovec Investigational Gene Therapy for Hemophilia A >> BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia |
Bristol-Myers Squibb Co. …Bristol-Myers Squibb Co. |
BMY (138650, 2220, 1.27 %) | 62.33 | Is Bristol Myers Stock A Buy As Opdivo Faces An FDA Hurdle In April …>> Is Bristol Myers Stock A Buy As Opdivo Faces An FDA Hurdle In April >> 3 Great Income Stocks to Buy Right Now >> U S Food and Drug Administration FDA Accepts Bristol Myers Squibbs Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy oHCM >> 4 Value Stocks Billionaires Can t Stop Buying >> The FTC Is Taking a More Aggressive Approach Toward Pharmaceutical M amp A What It Means for the Industry |
Blueprint Medicines Corp …Blueprint Medicines Corp |
BPMC (5990, 54.61, 5.5 %) | 98.79 | Blueprint Medicines BPMC Up 2 1 Since Last Earnings Report Can It Continue …>> Blueprint Medicines BPMC Up 2 1 Since Last Earnings Report Can It Continue >> Blueprint Medicines to Showcase Scientific Leadership in Precision Oncology and Hematology at AACR Annual Meeting 2021 >> Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635 c 4 >> Blueprint Medicines BPMC Gets EMA Validation for Ayvakyt in SM >> Blueprint Medicines Announces EMA Validation of Type II Variation Marketing Authorization Application for AYVAKYT avapritinib for the Treatment of Advanced Systemic Mastocytosis |
Biospecifics Technologies Corp. …Biospecifics Technologies Corp. |
BSTC (0, 0, 0 %) | 88.53 | … |
BioXcel Therapeutics Inc …BioXcel Therapeutics Inc |
BTAI (1150, 14.67, 24.6 %) | 43.77 | BTAI NDA Submitted for BXCL501 for Treatment of Schizophrenia and Biopolar Disorder Relat …>> BTAI NDA Submitted for BXCL501 for Treatment of Schizophrenia and Biopolar Disorder Related Agitation >> BioXcel Therapeutics Receives FDA Breakthrough Therapy Designation for BXCL501 for the Acute Treatment of Agitation Associated with Dementia >> The Daily Biotech Pulse Contrasting COVID 19 Treatment Readouts From Roche Vir Delay In Kadmon s FDA Review Alzheimer s Data From Prothena >> BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update >> BioXcel Therapeutics Submits New Drug Application to U S Food and Drug Administration for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders |
BeyondSpring Inc …BeyondSpring Inc |
BYSI (483.58, 11.14, 10.77 %) | 12.14 | BeyondSpring Hosting Key Opinion Leader Webinar on Plinabulin for the Prevention of Chemot …>> BeyondSpring Hosting Key Opinion Leader Webinar on Plinabulin for the Prevention of Chemotherapy Induced Neutropenia >> Benzinga s Top Upgrades Downgrades For January 11 2021 >> Tuesdays 10 Notable Market Movers in the Limelight >> UPDATE BeyondSpring to Present at the J P Morgan Healthcare Conference on January 14 2021 >> BeyondSpring to Present at the J P Morgan Healthcare Conference on January 14 2021 |
Calithera Biosciences Inc …Calithera Biosciences Inc |
CALA (205.32, 69.84, 3.63 %) | 2.74 | Calithera Biosciences Inc CALA Q4 2020 Earnings Call Transcript …>> Calithera Biosciences Inc CALA Q4 2020 Earnings Call Transcript >> Calithera Biosciences Reports Fourth Quarter 2020 Financial Results and Recent Highlights >> Calithera Biosciences Inc to Host Earnings Call >> UPDATE Calithera Biosciences to Report Fourth Quarter 2020 Financial Results on Tuesday March 16 2021 >> Calithera Biosciences to Report Fourth Quarter 2021 Financial Results on Tuesday March 16 2021 |
Capricor Therapeutics Inc …Capricor Therapeutics Inc |
CAPR (115.69, 0, 0 %) | 5.21 | Breakeven On The Horizon For Capricor Therapeutics Inc NASDAQ CAPR …>> Breakeven On The Horizon For Capricor Therapeutics Inc NASDAQ CAPR >> Capricor Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update >> Capricor Therapeutics Inc to Host Earnings Call >> Capricor Therapeutics Announces New Advances in Exosome Mediated mRNA Delivery Platform >> Capricor Therapeutics to Present Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Update on March 11 |
Cara Therapeutics Inc …Cara Therapeutics Inc |
CARA (982.08, 41.82, 7.34 %) | 19.12 | Cara Therapeutics CARA Korsuva NDA Gets FDA Priority Review …>> Cara Therapeutics CARA Korsuva NDA Gets FDA Priority Review >> Vifor Pharma and Cara Therapeutics announce U S FDA acceptance and Priority Review of NDA for KORSUVA injection in hemodialysis patients with moderate to severe pruritus >> Cara Therapeutics and Vifor Pharma announce U S FDA acceptance and Priority Review of NDA for KORSUVA injection in hemodialysis patients with moderate to severe pruritus >> Cara Therapeutics Inc CARA Q4 2020 Earnings Call Transcript >> Cara Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results |
Catabasis Pharmaceuticals Inc …Catabasis Pharmaceuticals Inc |
CATB (73.82, 20.06, 12.89 %) | 3.36 | Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and …>> Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update >> Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences >> Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc >> Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc >> Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc |
Cymabay Therapeutics Inc …Cymabay Therapeutics Inc |
CBAY (357.5, 65.19, 12.8 %) | 4.77 | CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thur …>> CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday March 25 2021 >> CymaBay Therapeutics to Present at the 2021 NASH TAG Conference >> CymaBay Therapeutics to Present at Upcoming Investor Conferences >> CymaBay Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference >> CymaBay Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference |
Catalyst Biosciences Inc …Catalyst Biosciences Inc |
CBIO (192.96, 26.29, 2.79 %) | 5.83 | Catalyst Biosciences Reports Fourth Quarter and Full Year 2020 Operating amp Financial R …>> Catalyst Biosciences Reports Fourth Quarter and Full Year 2020 Operating amp Financial Results and Provides a Corporate Update >> Catalyst Biosciences to Present at the 42nd Annual Raymond James Institutional Investors Conference >> Catalyst Biosciences Announces Partial Exercise and Closing of Over Allotment Option in Public Offering of Common Stock >> Benzinga s Top Ratings Upgrades Downgrades For February 10 2021 >> Benzinga s Top Ratings Upgrades Downgrades For February 10 2021 |
ChemoCentryx Inc …ChemoCentryx Inc |
CCXI (3960, 52.93, 6.9 %) | 53.52 | ChemoCentryx Announces Appointment of Susan M Kanaya to Board of Directors …>> ChemoCentryx Announces Appointment of Susan M Kanaya to Board of Directors >> ChemoCentryx Inc s NASDAQ CCXI Profit Outlook >> ChemoCentryx CCXI Q4 Loss Wider Than Expected Sales Miss >> ChemoCentryx Inc CCXI Q4 2020 Earnings Call Transcript >> ChemoCentryx CCXI Reports Q4 Loss Misses Revenue Estimates |
Avid Bioservices Inc …Avid Bioservices Inc |
CDMO (1070, 55.74, 3.75 %) | 17.95 | Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences amp MedTech Inv …>> Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences amp MedTech Investor Forum >> Avid Bioservices CDMO Sees Hammer Chart Pattern Time to Buy >> Avid Bioservices Inc Announces Pricing of 125 Million Offering of Exchangeable Senior Notes >> Avid Bioservices Inc CDMO Q3 2021 Earnings Call Transcript >> Avid Bioservices CDMO Surpasses Q3 Earnings and Revenue Estimates |
Chembio Diagnostics Inc. …Chembio Diagnostics Inc. |
CEMI (100.38, 17.37, 12.59 %) | 4.21 | Chembio Diagnostics Reports Fourth Quarter and Full Year 2020 Financial Results …>> Chembio Diagnostics Reports Fourth Quarter and Full Year 2020 Financial Results >> Chembio Diagnostics Inc to Host Earnings Call >> Chembio Diagnostics s Earnings Outlook >> Chembio Diagnostics Appoints Industry Leader David Bespalko to its Board of Directors >> Chembio Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on March 11 2021 |
Cerecor Inc …Cerecor Inc |
CERC (295.81, 42.93, 3.41 %) | 3.23 | Cerecor Reports 2020 Financial Results and Provides Business Updates …>> Cerecor Reports 2020 Financial Results and Provides Business Updates >> Cerecor to Present at Upcoming Investor Conferences >> Cerecor Shares Are Trading Higher On Positive CERC 002 Efficacy Data In COVID 19 Study >> The Daily Biotech Pulse Roxadustat Delay For FibroGen AstraZeneca Decision Day For KemPharm NanoViricides Jumps On COVID 19 Drug Data >> Cerecor Announces CERC 002 Significantly Reduced Respiratory Failure and Mortality in Phase 2 Clinical Trial in Patients Hospitalized with COVID 19 ARDS |
ContraFect Corp …ContraFect Corp |
CFRX (166.45, 24.7, 10.86 %) | 5.13 | ContraFect Corporation Announces Proposed Public Offering of Common Stock …>> ContraFect Corporation Announces Proposed Public Offering of Common Stock >> CFRX 86 8 Million BARDA Contract to Support Phase 3 Trial of Exebacase >> The Daily Biotech Pulse Novavax Vaccine Data ContraFect Secures BARDA Funding 2 IPOs >> ContraFect Announces BARDA Contract Award for Up to 86 8 Million and Provides Business Outlook >> ContraFect Announces Appointment of Dr Jane F Barlow to Board of Directors |
Chiasma Inc …Chiasma Inc |
CHMA (189.14, 57.42, 4.76 %) | 3.34 | Chiasma NASDAQ CHMA Shareholders Have Enjoyed An Impressive 117 Share Price Gain …>> Chiasma NASDAQ CHMA Shareholders Have Enjoyed An Impressive 117 Share Price Gain >> Chiasma to Present New Data from Two Phase 3 Trials CHIASMA OPTIMAL and MPOWERED at ENDO 2021 >> Chiasma CHMA Q4 2020 Earnings Call Transcript >> Chiasma CHMA Reports Q4 Loss Lags Revenue Estimates >> Chiasma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update |
Cellectar Biosciences Inc …Cellectar Biosciences Inc |
CLRB (99.47, 40.7, 5.83 %) | 1.92 | Cellectar to Participate at Upcoming Institutional Investor Conferences …>> Cellectar to Participate at Upcoming Institutional Investor Conferences >> Cellectar Granted Japanese Composition of Matter Patent for its Phospholipid Ether Drug Conjugates >> Cellectar to Participate at Upcoming Institutional Investor Conferences >> Cellectar Reports Financial Results for Year Ended December 31 2020 and Provides a Corporate Update >> Cellectar Initiates Pivotal Trial of CLR 131 in Waldenstroms Macroglobulinemia |
Clearside Biomedical Inc …Clearside Biomedical Inc |
CLSD (152.5, 44.95, 0.95 %) | 2.82 | Could The Clearside Biomedical Inc NASDAQ CLSD Ownership Structure Tell Us Something U …>> Could The Clearside Biomedical Inc NASDAQ CLSD Ownership Structure Tell Us Something Useful >> Clearside Biomedical Inc CLSD Reports Q4 Loss Lags Revenue Estimates >> Clearside Biomedical Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update >> Clearside Biomedical Inc to Host Earnings Call >> The Daily Biotech Pulse MediciNova Bags BARDA Contract Lilly s COVID 19 Antibody Cocktail Data Bluebird Bio Refutes Blood Cancer Link |
Celsion Corp …Celsion Corp |
CLSN (133.9, 30.5, 12.16 %) | 2.27 | Celsion Corp to Host Earnings Call …>> Celsion Corp to Host Earnings Call >> Celsion Corporation Reports 2020 Financial Results and Provides Business Update >> Celsion Corporation to Hold Year End 2020 Financial Results and Business Update Conference Call on Friday March 19 2021 >> NeoPhotonics to Host Call to Discuss Optical Communications Trends and Technologies on March 10 2021 >> Do Options Traders Know Something About Celsion CLSN Stock We Don t |
Clovis Oncology Inc …Clovis Oncology Inc |
CLVS (629.09, 86.43, 41.88 %) | 5.32 | Why Clovis Oncology Stock Skyrocketed Today …>> Why Clovis Oncology Stock Skyrocketed Today >> Return On Capital Employed Overview Clovis Oncology >> 5 Top Stock Gainers for Friday FedEx Dollar General Clovis >> Clovis Oncology stock soars after ovarian cancer treatment meets primary endpoint >> Clovis Oncologys Rubraca rucaparib Significantly Improves Progression Free Survival versus Chemotherapy in Patients with Later line Ovarian Cancer Associated with a BRCA Mutation |
Chimerix Inc …Chimerix Inc |
CMRX (893.95, 74.24, 1.31 %) | 9.56 | Chimerix to Present at Virtual H C Wainwright Global Life Sciences Conference …>> Chimerix to Present at Virtual H C Wainwright Global Life Sciences Conference >> Chimerix Exclusive Worldwide Licensee of Cantex s Investigational Product DSTAT Has Announced Promising Topline Results from the First Cohort of a Randomized COVID 19 Clinical Trial >> Chimerix CMRX Q4 2020 Earnings Call Transcript >> Chimerix s DSTAT Shows Promising Results In First Cohort Of COVID 19 Study >> The Daily Biotech Pulse Merck Goes Shopping Decision Day For Sarepta Pfizer Moderna Unveil Vaccine Strategies For Coronavirus Variants |
Concert Pharmaceuticals Inc …Concert Pharmaceuticals Inc |
CNCE (204.29, 25.2, 2.77 %) | 6.1 | Concert Pharmaceuticals to Present at Upcoming Investor Conferences …>> Concert Pharmaceuticals to Present at Upcoming Investor Conferences >> Concert Pharmaceuticals Inc CNCE Q4 2020 Earnings Call Transcript >> Concert Pharmaceuticals Reports 2020 Financial Results and Provides Update on Clinical Programs >> Concert Pharmaceuticals Inc to Host Earnings Call >> We Think Concert Pharmaceuticals NASDAQ CNCE Needs To Drive Business Growth Carefully |
Cns Pharmaceuticals Inc …Cns Pharmaceuticals Inc |
CNSP (72.39, 15.23, 3.45 %) | 2.99 | CNS Pharmaceuticals to Participate in Inaugural Emerging Growth Virtual Conference …>> CNS Pharmaceuticals to Participate in Inaugural Emerging Growth Virtual Conference >> CNS Pharmaceuticals to Present at the H C Wainwright Global Life Sciences Conference >> CNS Pharmaceuticals Berubicin Trial is On Schedule to Commence in March 2021 >> WPD Pharmaceuticals Announces Berubicin Supply Agreement for the Upcoming Clinical Trials >> Polish Regulatory Authority Issues Positive Opinion For CNS Pharma s Brain Cancer Candidate |
Cocrystal Pharma Inc …Cocrystal Pharma Inc |
COCP (118.13, 48.65, 4.55 %) | 1.51 | Cocrystal Pharma Reports 2020 Financial Results Provides Business Update Including Antivi …>> Cocrystal Pharma Reports 2020 Financial Results Provides Business Update Including Antiviral Program Milestones >> Cocrystal Pharma Extends Drug Discovery Collaboration with HitGen and InterX >> Cocrystal Pharma to Participate in the Virtual 33rd Annual Roth Conference >> Cocrystal Pharma to Present at the H C Wainwright Global Life Sciences Virtual Conference UPDATED >> Cocrystal Pharma to Present at the H C Wainwright Global Life Sciences Virtual Conference |
Cogent Biosciences Inc …Cogent Biosciences Inc |
COGT (575.33, 0, 0 %) | 8.14 | Do Institutions Own Cogent Biosciences Inc NASDAQ COGT Shares …>> Do Institutions Own Cogent Biosciences Inc NASDAQ COGT Shares >> Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial Results >> Cogent Biosciences Appoints Accomplished Finance Executive Todd E Shegog to its Board of Directors >> Cogent Biosciences to Present at Virtual 10th Annual SVB Leerlink Global Healthcare Conference 2021 >> Cogent Biosciences to Present at LifeSci Partners Virtual Precision Oncology Day 2021 |
Collegium Pharmaceutical Inc …Collegium Pharmaceutical Inc |
COLL (857.08, 31.88, 14.22 %) | 24.93 | Collegium Pharmaceutical Inc COLL Q4 2020 Earnings Call Transcript …>> Collegium Pharmaceutical Inc COLL Q4 2020 Earnings Call Transcript >> Collegium Reports Record Full Year 2020 Revenue of 310 0 Million >> Collegium Pharmaceutical Inc to Host Earnings Call >> Collegium Pharmaceutical s Earnings Outlook >> Collegium to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and Provide Corporate Update |
Corcept Therapeutics Inc …Corcept Therapeutics Inc |
CORT (2990, 100.45, 10.75 %) | 24.95 | Corcept CORT Begins Adrenal Cancer Study on Relacorilant …>> Corcept CORT Begins Adrenal Cancer Study on Relacorilant >> Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab Keytruda in Patients with Adrenal Cancer with Cortisol Excess >> Corcept Therapeutics Expands Executive Team Atabak Mokari Joins As Chief Financial Officer Charles Robb Named Chief Business Officer >> Corcept Therapeutics Announces Fourth Quarter and Full Year 2020 Audited Financial Results >> Corcept Therapeutics Incorporated s NASDAQ CORT Stock Is Going Strong Is the Market Following Fundamentals |
China Pharma Holdings Inc. …China Pharma Holdings Inc. |
CPHI (44.85, 19.94, 0 %) | 0.9686 | China Pharma Holdings Inc Reports Third Quarter 2020 Financial Results …>> China Pharma Holdings Inc Reports Third Quarter 2020 Financial Results >> China Pharma Holdings Inc Reports Third Quarter 2020 Financial Results >> China Pharma Holdings Inc Reports Third Quarter 2020 Financial Results >> China Pharma Holdings Inc Reports Third Quarter 2020 Financial Results >> A Quick Analysis On China Pharma Holdings NYSEMKT CPHI CEO Salary |
Cumberland Pharmaceuticals Inc. …Cumberland Pharmaceuticals Inc. |
CPIX (46.98, 8.59, 1.2 %) | 3.23 | Cumberland Pharmaceuticals CPIX Beats Q4 Earnings and Revenue Estimates …>> Cumberland Pharmaceuticals CPIX Beats Q4 Earnings and Revenue Estimates >> Recap Cumberland Q4 Earnings >> Cumberland Pharmaceuticals Reports 9 Revenue Growth In 2020 >> Cumberland Pharmaceuticals Inc to Host Earnings Call >> Cumberland Earnings Preview |
Catalyst Pharmaceuticals Inc …Catalyst Pharmaceuticals Inc |
CPRX (424.95, 96.41, 8.71 %) | 4.21 | Top Biotech Stocks for Q2 2021 …>> Top Biotech Stocks for Q2 2021 >> Catalyst Pharma 4Q Revenue Earnings Outperform Estimates >> Catalyst Pharmaceuticals Inc to Host Earnings Call >> Catalyst Pharmaceutical CPRX Beats Q4 Earnings and Revenue Estimates >> Catalyst Pharmaceuticals Announces Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update |
Corbus Pharmaceuticals Holdings Inc …Corbus Pharmaceuticals Holdings Inc |
CRBP (185.79, 77.54, 17.51 %) | 2.16 | Corbus Pharmaceuticals CRBP Moves to Buy Rationale Behind the Upgrade …>> Corbus Pharmaceuticals CRBP Moves to Buy Rationale Behind the Upgrade >> Corbus Pharmaceuticals Holdings Inc CRBP Q4 2020 Earnings Call Transcript >> Recap Corbus Pharmaceuticals Q4 Earnings >> Corbus Pharmaceuticals Reports Fourth Quarter and Year End 2020 Financial Results >> Corbus Pharmaceuticals Holdings Inc to Host Earnings Call |
CorMedix Inc …CorMedix Inc |
CRMD (316.06, 31.66, 8.35 %) | 9.59 | SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of CorMed …>> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of CorMedix Inc CRMD >> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of CorMedix Inc CRMD >> CorMedix Approved to Sell 1 3 Million of NOL Tax Benefits Through The New Jersey Economic Development Authority Program >> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of CorMedix Inc CRMD >> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of CorMedix Inc CRMD |
Corvus Pharmaceuticals Inc …Corvus Pharmaceuticals Inc |
CRVS (121.27, 17.12, 7.44 %) | 3.18 | Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences …>> Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences >> Co Founder Richard Miller Just Bought 8 5 More Shares In Corvus Pharmaceuticals Inc NASDAQ CRVS >> Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock >> Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock >> Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock |
CTI BioPharma Corp …CTI BioPharma Corp |
CTIC (244.89, 52.46, 0.93 %) | 3.27 | CTI BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results …>> CTI BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results >> CTI BioPharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 17 2021 >> CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635 c 4 >> CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635 c 4 >> CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635 c 4 |
Catalent Inc. …Catalent Inc. |
CTLT (18140, 169.45, 1.33 %) | 104 | Estimating The Intrinsic Value Of Catalent Inc NYSE CTLT …>> Estimating The Intrinsic Value Of Catalent Inc NYSE CTLT >> Spacs vs short sellers the great money grab of 2021 >> UPDATE 2 Catalent to ramp up J amp J vaccine production at Italian plant >> Catalent CTLT Sees Hammer Chart Pattern Time to Buy >> Profire Energy Sets Fourth Quarter and Full Year 2020 Conference Call for Thursday March 11 2021 at 1 00 p m ET |
CytomX Therapeutics Inc …CytomX Therapeutics Inc |
CTMX (556.5, 54.81, 6.07 %) | 8.04 | CytomX Therapeutics CTMX Upgraded to Buy What Does It Mean for the Stock …>> CytomX Therapeutics CTMX Upgraded to Buy What Does It Mean for the Stock >> Moving Average Crossover Alert CytomX Therapeutics CTMX >> CytomX Therapeutics Inc CTMX Q4 2020 Earnings Call Transcript >> CytomX Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update >> A Preview Of CytomX Therapeutics s Earnings |
CureVac N.V. …CureVac N.V. |
CVAC (17850, 87.57, 1.17 %) | 89.52 | Sanofi and Translate Bio Begin Clinical Trials of mRNA Based Covid 19 Vaccine …>> Sanofi and Translate Bio Begin Clinical Trials of mRNA Based Covid 19 Vaccine >> Novartis NVS amp CureVac Collaborate for COVID 19 Vaccine >> U S COVID death toll above 518 000 as Biden adds voice to outrage at Texas and Mississippi for reopening >> Novartis Will Help Manufacture CureVacs Covid 19 Vaccine >> UPDATE 1 Novartis deal bolsters CureVac s vaccine contractor line up |
Cyclacel Pharmaceuticals Inc …Cyclacel Pharmaceuticals Inc |
CYCC (61.72, 5.6, 18.75 %) | 8.15 | Cyclacel Pharmaceuticals Announces Closing of 14 5 Million Underwritten Public Offering a …>> Cyclacel Pharmaceuticals Announces Closing of 14 5 Million Underwritten Public Offering and Full Exercise of Over Allotment Option >> Cyclacel to Present at the Oppenheimer 31st Annual Healthcare Conference >> Cyclacel Pharmaceuticals Prices 12 65 Million Underwritten Public Offering of Common Stock >> Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock >> Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results |
Cytokinetics Inc …Cytokinetics Inc |
CYTK (1620, 63.82, 14.45 %) | 24.33 | Cytokinetics Announces Secondary Analysis From GALACTIC HF to Be Presented in Late Breakin …>> Cytokinetics Announces Secondary Analysis From GALACTIC HF to Be Presented in Late Breaking Clinical Trial Session at American College of Cardiology 70th Annual Scientific Session amp Expo ACC 21 >> Cytokinetics CYTK is Overbought Is A Drop Coming >> Cytokinetics to Participate in Upcoming Investor Conferences >> Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 c 4 >> Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day |
Dare Bioscience Inc …Dare Bioscience Inc |
DARE (85.32, 35.47, 3.39 %) | 1.99 | Dar Bioscience to Participate in Upcoming Virtual Conferences …>> Dar Bioscience to Participate in Upcoming Virtual Conferences >> Dar Bioscience to Participate at the 33rd Annual Roth Conference >> Dar Bioscience to Present at the H C Wainwright Global Life Sciences Conference >> Dar Bioscience to Participate in Maxim Groups Late Stage Innovations in Womens Health Virtual Event >> Dar Bioscience to Participate at the Womens Health Innovation Series Contraception Innovation Summit to be held Virtually on February 23 2021 |
Deciphera Pharmaceuticals Inc …Deciphera Pharmaceuticals Inc |
DCPH (2550, 41, 8.03 %) | 42.49 | Deciphera Pharmaceuticals Inc to Present at the Barclays Global Healthcare Conference …>> Deciphera Pharmaceuticals Inc to Present at the Barclays Global Healthcare Conference >> Deciphera Pharmaceuticals Inc to Present at the SVB Leerink 10th Annual Global Healthcare Conference >> Broker Revenue Forecasts For Deciphera Pharmaceuticals Inc NASDAQ DCPH Are Surging Higher >> Deciphera DCPH Reports Narrower Than Expected Q4 Loss >> Benzinga s Top Ratings Upgrades Downgrades For February 10 2021 |
Diffusion Pharmaceuticals Inc …Diffusion Pharmaceuticals Inc |
DFFN (110.88, 63.9, 2.84 %) | 1.07 | Diffusion Pharmaceuticals Doses First Participants in TCOM Study …>> Diffusion Pharmaceuticals Doses First Participants in TCOM Study >> Diffusion Pharmaceuticals Reports 2020 Financial Results and Provides Business Update >> We re Not Very Worried About Diffusion Pharmaceuticals NASDAQ DFFN Cash Burn Rate >> Diffusion Pharmaceuticals Inc to Present at the H C Wainwright Global Life Sciences Conference >> Diffusion Pharmaceuticals Announces Full Exercise of Underwriters Option to Purchase Additional Shares of Common Stock |
DiaMedica Therapeutics Inc …DiaMedica Therapeutics Inc |
DMAC (177.38, 17.46, 0.67 %) | 9.63 | DiaMedica Therapeutics Inc to Host Earnings Call …>> DiaMedica Therapeutics Inc to Host Earnings Call >> DiaMedica Therapeutics Announces 2020 Financial Results and Provides a Business Update >> DiaMedica Therapeutics to Present Research at International Stroke Virtual Conference >> DiaMedica Therapeutics Hosting Key Opinion Leader Webinar on DM199 for Treatment of Acute Ischemic Stroke >> DiaMedica Therapeutics to Participate at Upcoming Investor Conferences |
Dicerna Pharmaceuticals Inc …Dicerna Pharmaceuticals Inc |
DRNA (2140, 68.74, 7.23 %) | 26.51 | Dicerna to Host Webinar on DCR AUD Alcohol Use Disorder Candidate on March 18 2021 …>> Dicerna to Host Webinar on DCR AUD Alcohol Use Disorder Candidate on March 18 2021 >> What You Need To Know About Dicerna Pharmaceuticals Inc s NASDAQ DRNA Investor Composition >> Dicerna Announces Roches Initiation of GalXC RNAi Candidate RG6346 in Phase 2 Combination Trial for Treatment of Chronic Hepatitis B Virus Infection >> Billionaire Steven Cohen Picks Up These 3 Strong Buy Stocks >> Dicerna Pharmaceuticals Inc DRNA Q4 2020 Earnings Call Transcript |
Durect Corp …Durect Corp |
DRRX (524.71, 206.09, 4.28 %) | 2.21 | DURECT Corporation Announces Publication of DUR 928 s Mechanism of Action …>> DURECT Corporation Announces Publication of DUR 928 s Mechanism of Action >> Durect Q4 Earnings Insights >> Durect DRRX Reports Q4 Loss Misses Revenue Estimates >> DURECT Corp to Host Earnings Call >> DURECT Corporation to Participate in Three Investor Conferences in March 2021 |
Dynavax Technologies Corp. …Dynavax Technologies Corp. |
DVAX (1180, 109.38, 18.61 %) | 9.75 | Breakeven Is Near for Dynavax Technologies Corporation NASDAQ DVAX …>> Breakeven Is Near for Dynavax Technologies Corporation NASDAQ DVAX >> Dynavax to Present at the H C Wainwright Virtual 2021 Global Life Sciences Conference >> Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635 c 4 >> Why Dynavax Stock Is Crushing It Today >> Dynavax s Q4 Results Show It s Not Just About Heplisav B Anymore |
Dyne Therapeutics Inc …Dyne Therapeutics Inc |
DYN (829.33, 21.21, 8.14 %) | 16.11 | Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent H …>> Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights >> Dyne Therapeutics Appoints Wildon Farwell M D MPH as Chief Medical Officer >> Dyne Therapeutics Appoints Ashish Dugar Ph D MBA Senior Vice President Global Head of Medical Affairs >> Here s What Dyne Therapeutics Inc s NASDAQ DYN Shareholder Ownership Structure Looks Like >> Dyne Therapeutics Announces Pricing of 168 Million Public Offering |
Auris Medical Holding Ltd …Auris Medical Holding Ltd |
EARS (49.6, 6.74, 1.65 %) | 3.96 | Auris Medical Announces Initiation of Clinical Investigation of AM 301 in Allergic Rhiniti …>> Auris Medical Announces Initiation of Clinical Investigation of AM 301 in Allergic Rhinitis >> Auris Medical Announces Initiation of Clinical Investigation of AM 301 in Allergic Rhinitis >> Auris Medical Announces Initiation of Clinical Investigation of AM 301 in Allergic Rhinitis >> Auris Medical Announces Initiation of Clinical Investigation of AM 301 in Allergic Rhinitis >> Auris Medical Provides Business Update |
Emergent Biosolutions Inc …Emergent Biosolutions Inc |
EBS (4980, 45.5, 5.46 %) | 88.29 | Top Pharmaceutical Stocks for Q2 2021 …>> Top Pharmaceutical Stocks for Q2 2021 >> J amp J to make up to 3 bln COVID 19 vaccines in 2022 chief scientist >> New York Times Credits Report On Emergent BioSolutions For Biden s Canceled Vaccine Plant Visit >> OPNT NDA Filing on Track for 4Q21 >> White House Moves Event from Emergent Facility |
Edesa Biotech Inc …Edesa Biotech Inc |
EDSA (80.71, 6.46, 4.16 %) | 5.68 | Edesa Biotech Reaches Enrollment Milestone in COVID Study …>> Edesa Biotech Reaches Enrollment Milestone in COVID Study >> Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone >> Edesa Biotech Announces Closing of 10 Million Bought Deal Offering of Common Shares >> Edesa Biotech Increases Previously Announced Bought Deal Offering of Common Shares to 10 0 Million >> Edesa Biotech Announces 3 5 Million Bought Deal Offering of Common Shares |
Eagle Pharmaceuticals Inc …Eagle Pharmaceuticals Inc |
EGRX (603.2, 10.12, 13.87 %) | 45.07 | Top Pharmaceutical Stocks for Q2 2021 …>> Top Pharmaceutical Stocks for Q2 2021 >> Is Eagle Pharmaceuticals Inc NASDAQ EGRX Trading At A 21 Discount >> Eagle Pharmaceuticals Inc EGRX Q4 2020 Earnings Call Transcript >> Eagle Pharmaceuticals EGRX Beats Q4 Earnings Estimates >> Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results and Provides Pipeline Review |
Eidos Therapeutics Inc …Eidos Therapeutics Inc |
EIDX (0, 0, 0 %) | 122.21 | … |
Elanco Animal Health Inc …Elanco Animal Health Inc |
ELAN (15970, 452.25, 2.16 %) | 33.75 | Understanding Elanco Animal Health s Unusual Options Activity …>> Understanding Elanco Animal Health s Unusual Options Activity >> UPDATE 2 Elanco says flea tick collars safe amid pressure to recall product >> Elanco stands by safety of Seresto collars which remain available despite calls for removal from market >> Elanco Stands Behind Seresto and its Safety Profile >> Morris Animal Foundation Partners with Elanco to Improve Understanding of Canine Osteoarthritis |
Eledon Pharmaceuticals Inc …Eledon Pharmaceuticals Inc |
ELDN (197.26, 1.03, 13.47 %) | 14.53 | Eledon Pharmaceuticals Strengthens Leadership Team with Chief Medical Officer and Chief Fi …>> Eledon Pharmaceuticals Strengthens Leadership Team with Chief Medical Officer and Chief Financial Officer Hires >> Eledon Pharmaceuticals to Present at H C Wainwright Global Life Sciences Conference >> Eledon Pharmaceuticals to Present at 10th Annual SVB Leerink Global Healthcare Conference >> Eledon Pharmaceuticals to Participate in the Virtual Noble Capital Markets Seventeenth Annual Investor Equity Conference |
Endo International plc …Endo International plc |
ENDP (1850, 227.03, 8.67 %) | 8.105 | Billionaire John Paulsons Top 10 Stock Picks …>> Billionaire John Paulsons Top 10 Stock Picks >> Top Pharmaceutical Stocks for Q2 2021 >> Waterous Energy Fund Successfully Completes Take Over Bid for 57 Million Shares of Osum Oil Sands Corp >> Agiomix Receives the First ISO 15189 Accreditation for Next Generation Sequencing in the Region >> Endo International plc Announces Pricing of Private Offering Of Senior Secured Notes |
Enlivex Therapeutics Ltd …Enlivex Therapeutics Ltd |
ENLV (213.09, 9.83, 0.97 %) | 12.94 | Enlivex Announces Upcoming Virtual Investor Conference Participations …>> Enlivex Announces Upcoming Virtual Investor Conference Participations >> Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the use of Allocetra in Combination with CAR T Therapies >> Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors >> Enlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy >> Enlivex Announces Exercise of Underwriters Option to Purchase Additional Shares |
Enochian Biosciences Inc …Enochian Biosciences Inc |
ENOB (181.38, 14.64, 4.44 %) | 3.7 | Enochian BioSciences to Present to Investors at the H C Wainwright Global Life Sciences C …>> Enochian BioSciences to Present to Investors at the H C Wainwright Global Life Sciences Conference >> What You Need To Know About Enochian Biosciences Inc s NASDAQ ENOB Investor Composition >> What You Need To Know About Enochian Biosciences Inc s NASDAQ ENOB Investor Composition >> What You Need To Know About Enochian Biosciences Inc s NASDAQ ENOB Investor Composition >> What You Need To Know About Enochian Biosciences Inc s NASDAQ ENOB Investor Composition |
Enanta Pharmaceuticals Inc …Enanta Pharmaceuticals Inc |
ENTA (1060, 17.86, 12.12 %) | 51.2 | Enanta Pharmaceuticals to Present at Upcoming Investor Conferences …>> Enanta Pharmaceuticals to Present at Upcoming Investor Conferences >> Enanta Pharmaceuticals to Present at SVB Leerink 10th Annual Global Healthcare Conference >> Enanta Pharmaceuticals Inc ENTA Q1 2021 Earnings Call Transcript >> Enanta Pharmaceuticals ENTA Reports Q1 Loss Tops Revenue Estimates >> Recap Enanta Pharmaceuticals Q1 Earnings |
Essa Pharma Inc …Essa Pharma Inc |
EPIX (1210, 32.73, 0.19 %) | 30.56 | ESSA Pharma Announces Exercise of Option in Connection with Recently Completed 130 Millio …>> ESSA Pharma Announces Exercise of Option in Connection with Recently Completed 130 Million Financing >> LAWSUIT FILED Ebix Inc Sued for Violations of the Federal Securities Laws Investors Should Contact Block amp Leviton LLP >> ESSA Pharma Inc Reports Results of Annual General and Special Meeting of Shareholders >> ESSA Pharma to Present at Upcoming March Investor Conferences >> ESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI 7386 and Enzalutamide for Patients with Metastatic Castration Resistant Prostate Cancer |
Epizyme Inc …Epizyme Inc |
EPZM (930.29, 82.71, 14.75 %) | 8.88 | Epizyme Outlines Clinical Progress TAZVERIK Development Strategy and Pipeline Priorities …>> Epizyme Outlines Clinical Progress TAZVERIK Development Strategy and Pipeline Priorities During Companys Strategic Vision Call >> The Epizyme Inc NASDAQ EPZM Analysts Have Been Trimming Their Sales Forecasts >> Benzinga s Top Ratings Upgrades Downgrades For February 25 2021 >> Epizyme to Host Strategic Vision Call on March 2 2021 >> Epizyme Inc EPZM Q4 2020 Earnings Call Transcript |
Equillium Inc …Equillium Inc |
EQ (234.91, 18.11, 5.85 %) | 7.83 | Equillium Announces Positive Data for Itolizumab in Acute Graft Versus Host Disease in Two …>> Equillium Announces Positive Data for Itolizumab in Acute Graft Versus Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation >> Benzinga s Top Ratings Upgrades Downgrades For March 3 2021 >> Equillium to Present at the H C Wainwright Global Life Sciences Conference >> Equillium to Present at the SVB Leerink 10th Annual Global Healthcare Conference >> Equillium Presents Positive Interim Clinical Data of Itolizumab in First line Treatment of Acute Graft Versus Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience |
Esperion Therapeutics Inc. …Esperion Therapeutics Inc. |
ESPR (814.81, 26.11, 38.72 %) | 28.33 | NEXLETOL bempedoic acid Tablet ezetimibe and atorvastatin combination lowered bad cho …>> NEXLETOL bempedoic acid Tablet ezetimibe and atorvastatin combination lowered bad cholesterol by 60 5 vs placebo in Phase 2 study >> Is Esperion Therapeutics ESPR a Smart Long term Buy >> Esperion Therapeutics Inc ESPR Q4 2020 Earnings Call Transcript >> Recap Esperion Therapeutics Q4 Earnings >> ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update |
89bio Inc …89bio Inc |
ETNB (461.09, 8.42, 13.81 %) | 24.4 | 89bio to Present at the Oppenheimer 31st Annual Healthcare Conference …>> 89bio to Present at the Oppenheimer 31st Annual Healthcare Conference >> 89bio to Participate in the H C Wainwright Global Life Sciences Conference >> 89bio to Present at the 42nd Annual Raymond James Institutional Investors Conference >> 89bio to Present at the SVB Leerink 10 Annual Global Healthcare Conference >> New Strong Sell Stocks for January 21st |
Entasis Therapeutics Holdings Inc …Entasis Therapeutics Holdings Inc |
ETTX (95.87, 13.35, 1.36 %) | 2.82 | Are Institutions Heavily Invested In Entasis Therapeutics Holdings Inc s NASDAQ ETTX Sh …>> Are Institutions Heavily Invested In Entasis Therapeutics Holdings Inc s NASDAQ ETTX Shares >> Entasis Therapeutics Announces Sulbactam Durlobactam Expanded Access Program for Patients in the U S >> Entasis Therapeutics Announces Sulbactam Durlobactam Expanded Access Program for Patients in the U S >> Entasis Therapeutics Announces Sulbactam Durlobactam Expanded Access Program for Patients in the U S >> Entasis Therapeutics Announces Sulbactam Durlobactam Expanded Access Program for Patients in the U S |
Evofem Biosciences Inc …Evofem Biosciences Inc |
EVFM (240.28, 78.84, 11.93 %) | 2.72 | Evofem Biosciences DTC Campaign Get Phexxi Delivers Strong Initial Impact …>> Evofem Biosciences DTC Campaign Get Phexxi Delivers Strong Initial Impact >> Evofem Biosciences Announces Publication in American Journal of Obstetrics and Gynecology of AMPREVENCE Study of EVO100 for Chlamydia and Gonorrhea Prevention >> What Type Of Shareholders Make Up Evofem Biosciences Inc s NASDAQ EVFM Share Registry >> Why Evofem Biosciences Stock Is Falling Today >> ROCE Insights For Evofem Biosciences |
Evoke Pharma Inc …Evoke Pharma Inc |
EVOK (94.32, 22.43, 3.26 %) | 2.34 | Evoke Pharma Inc NASDAQ EVOK Is Expected To Breakeven In The Near Future …>> Evoke Pharma Inc NASDAQ EVOK Is Expected To Breakeven In The Near Future >> Evoke Pharma Inc EVOK Reports Q4 Loss Misses Revenue Estimates >> Evoke Pharma Reports Fourth Quarter and Full Year 2020 Financial Results >> Evoke Pharma Inc to Host Earnings Call >> Evoke Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 11 2021 |
Eyegate Pharmaceuticals Inc …Eyegate Pharmaceuticals Inc |
EYEG (25.87, 4.35, 0.56 %) | 5.59 | EyeGate Pharmaceuticals Announces Management Transition In Support of Strategic Transforma …>> EyeGate Pharmaceuticals Announces Management Transition In Support of Strategic Transformation >> EyeGate Pharmaceuticals Announces Management Transition In Support of Strategic Transformation >> EyeGate Pharmaceuticals Announces Management Transition In Support of Strategic Transformation >> EyeGate Pharmaceuticals Announces Management Transition In Support of Strategic Transformation >> EyeGate Enters Into Agreement for 8 0 Million Private Placement |
Fortress Biotech Inc …Fortress Biotech Inc |
FBIO (399.64, 66.45, 1.97 %) | 4.02 | Is Fortress Biotech Inc NASDAQ FBIO Popular Amongst Insiders …>> Is Fortress Biotech Inc NASDAQ FBIO Popular Amongst Insiders >> Checkpoint Therapeutics Reports Full Year 2020 Financial Results and Recent Corporate Highlights >> NASDAQ FBIO Investor Notice Lawsuit against Fortress Biotech Inc announced by Shareholders Foundation >> Will Fortress Biotech FBIO Report Negative Q4 Earnings What You Should Know >> Mustang Bio to Participate in Three March 2021 Virtual Investor Conferences |
Forte Biosciences Inc …Forte Biosciences Inc |
FBRX (349.6, 9.92, 3.12 %) | 26.3 | Forte Biosciences Inc to Announce 4Q and Full Year 2020 Results and Provide a General Bu …>> Forte Biosciences Inc to Announce 4Q and Full Year 2020 Results and Provide a General Business Update >> Forte Biosciences Inc to Present at the Chardan Annual Microbiome Medicines Summit on March 8th >> Forte Biosciences Inc to Present at the Cowen Annual Health Care Conference on March 1st >> What Kind Of Investors Own Most Of Forte Biosciences Inc NASDAQ FBRX >> Forte Biosciences Inc Reports Inducement Grants Under Nasdaq Listing Rules |
FibroGen Inc …FibroGen Inc |
FGEN (3080, 83.64, 11.18 %) | 32.67 | SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroG …>> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen Inc FGEN >> 3 Biotech Stocks That Could Double In 12 Months >> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen Inc FGEN >> FibroGen Initiates LELANTOS 2 Second Phase 3 Clinical Study of Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy >> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen Inc FGEN |
Homology Medicines Inc …Homology Medicines Inc |
FIXX (478.98, 32.84, 6.19 %) | 10.1 | Homology Medicines FIXX Reports Q4 Loss Tops Revenue Estimates …>> Homology Medicines FIXX Reports Q4 Loss Tops Revenue Estimates >> Homology Medicines Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights >> Earnings Preview Homology Medicines FIXX Q4 Earnings Expected to Decline >> Homology Medicines Regains Global Rights To Novartis Ophthalmology Program >> Homology Medicines Regains Worldwide Rights to Ophthalmology Program Based on its In Vivo Nuclease Free Gene Editing Platform |
Flexion Therapeutics Inc …Flexion Therapeutics Inc |
FLXN (555.17, 46.06, 17.72 %) | 10.5 | Flexion Therapeutics to Present at the Oppenheimer 31st Annual Virtual Healthcare Conferen …>> Flexion Therapeutics to Present at the Oppenheimer 31st Annual Virtual Healthcare Conference >> Flexion Therapeutics Inc FLXN Q4 2020 Earnings Call Transcript >> Flexion Therapeutics FLXN Reports Q4 Loss Misses Revenue Estimates >> Flexion Therapeutics Q4 Earnings Insights >> Flexion Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results |
Amicus Therapeutics Inc …Amicus Therapeutics Inc |
FOLD (2790, 234.32, 13.68 %) | 10.16 | Amicus Therapeutics Announces Presentation and Posters at the 2021 MDA Clinical amp Scie …>> Amicus Therapeutics Announces Presentation and Posters at the 2021 MDA Clinical amp Scientific Conference >> Amicus FOLD Q4 Earnings Miss Estimates Sales Beat on Galafold >> Amicus Therapeutics Inc FOLD Q4 2020 Earnings Call Transcript >> Amicus Therapeutics FOLD Reports Q4 Loss Tops Revenue Estimates >> Amicus Therapeutics Q4 Earnings Insights |
Five Prime Therapeutics Inc …Five Prime Therapeutics Inc |
FPRX (1670, 22.8, 12.49 %) | 37.66 | SHAREHOLDER ALERT Rigrodsky Law P A Reminds Investors of Investigations of FRTA AEGN …>> SHAREHOLDER ALERT Rigrodsky Law P A Reminds Investors of Investigations of FRTA AEGN FPRX and MIK Buyouts >> SHAREHOLDER ALERT WeissLaw LLP Reminds FI SVBI FRPX and PAND Shareholders About Its Ongoing Investigations >> INVESTIGATION ALERT Halper Sadeh LLP Investigates WIFI FFG FPRX PTVCA Shareholders Are Encouraged to Contact the Firm >> Lifshitz Law Firm P C Announces Investigation of MDCA FPRX PAND and PRSP >> INVESTIGATION ALERT Halper Sadeh LLP Investigates MGLN FPRX FLIR WDR HMSY SNCA Shareholders are Encouraged to Contact the Firm |
Frequency Therapeutics Inc …Frequency Therapeutics Inc |
FREQ (1310, 26.29, 20.22 %) | 35.1 | What Is The Ownership Structure Like For Frequency Therapeutics Inc NASDAQ FREQ …>> What Is The Ownership Structure Like For Frequency Therapeutics Inc NASDAQ FREQ >> Earnings Preview Frequency Therapeutics Inc FREQ Q4 Earnings Expected to Decline >> The Daily Biotech Pulse Aridis To Study Antibody Cocktail For Coronavirus Variants Revance amp Protalix Data Readouts >> Frequency Therapeutics FX 322 Data Published In Peer Reviewed Journal >> Frequency Therapeutics Announces Publication of Phase 1 2 Data Showing Hearing Improvements in Acquired Sensorineural Hearing Loss Patients Receiving FX 322 |
F-star Therapeutics Inc …F-star Therapeutics Inc |
FSTX (99.98, 1.41, 1.32 %) | 11.49 | Do Institutions Own F star Therapeutics Inc NASDAQ FSTX Shares …>> Do Institutions Own F star Therapeutics Inc NASDAQ FSTX Shares >> F star Therapeutics to Host Full Year 2020 Investor Call and Provide Corporate Update on March 29 2021 >> F star Therapeutics to Present at Upcoming Investor Conferences >> F star Granted Composition of Matter Patent for FS118 a Bispecific Antibody Targeting LAG 3 and PD L1 >> F star Therapeutics to Participate in Upcoming Conferences |
Galectin Therapeutics Inc …Galectin Therapeutics Inc |
GALT (135.92, 40.56, 11.4 %) | 2.31 | OncoImmunology Publishes Pre clinical Research Showing Galectin Therapeutics Belapectin Ga …>> OncoImmunology Publishes Pre clinical Research Showing Galectin Therapeutics Belapectin Galectin 3 Inhibitor Reduces Tumor Progression in Combination with Anti OX40 Therapy >> Galectin Therapeutics to Present at H C Wainwright Global Life Sciences Conference >> What Kind Of Investors Own Most Of Galectin Therapeutics Inc NASDAQ GALT >> What Kind Of Investors Own Most Of Galectin Therapeutics Inc NASDAQ GALT >> What Kind Of Investors Own Most Of Galectin Therapeutics Inc NASDAQ GALT |
Generation Bio Co …Generation Bio Co |
GBIO (1890, 27.41, 5.75 %) | 33.5 | Generation Bio Reports Fourth Quarter and Full Year 2020 Financial Results …>> Generation Bio Reports Fourth Quarter and Full Year 2020 Financial Results >> Why Earnings Season Could Be Great for Generation Bio GBIO >> Benzinga s Top Ratings Upgrades Downgrades For February 18 2021 >> Generation Bio Appoints Ron Cooper to Its Board of Directors >> Trade Alert The Independent Director Of Generation Bio Co NASDAQ GBIO Charles Rowland Has Just Spent US 500k Buying 25 More Shares |
Global Blood Therapeutics Inc. …Global Blood Therapeutics Inc. |
GBT (2680, 54.84, 21.63 %) | 42.7 | GBT Appoints Alexis A Thompson M D M P H to Board of Directors …>> GBT Appoints Alexis A Thompson M D M P H to Board of Directors >> GBT Expands Sickle Cell Disease Pipeline with Exclusive In license of Two Novel Small Molecule Programs from Sanofi S A >> GBT Announces New Employment Inducement Grants >> Top Growth Stocks for March 2021 >> GBT Opens 2021 ACCEL Grant Program Providing up to 500 000 in Support to the Sickle Cell Disease Community |
Geron Corp. …Geron Corp. |
GERN (617.5, 296.5, 12.29 %) | 1.75 | Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635 c 4 …>> Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635 c 4 >> Why Geron Corporation Stock Is Falling Today >> Gene editing will boost intelligence within a few decades >> Geron GERN Q4 2020 Earnings Call Transcript >> Geron Corporation Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights |
Guardion Health Sciences Inc …Guardion Health Sciences Inc |
GHSI (50.1, 13.52, 0.55 %) | 2.59 | Guardion Health Sciences Regains Compliance with Nasdaq Minimum Bid Price Rule …>> Guardion Health Sciences Regains Compliance with Nasdaq Minimum Bid Price Rule >> Guardion Health Sciences to Participate in Maxim Groups Inaugural Emerging Growth Virtual Conference >> Guardion Health stock tumbles after reverse stock split announcement >> Guardion Health Sciences Announces 1 for 6 Reverse Stock Split Effective Pre Market Opening on Monday March 1 2021 >> Malaysias Ho Wah Genting Berhad Advises Guardion Health Sciences That It Has received Regulatory Product Registration Approval for Second Immune Support Dietary Supplement Designed and Produced by Guardion Health Sciences |
Galmed Pharmaceuticals Ltd …Galmed Pharmaceuticals Ltd |
GLMD (81.88, 17.77, 1.09 %) | 3.42 | Galmed Dips 2 On Larger Than Expected Quarterly Loss …>> Galmed Dips 2 On Larger Than Expected Quarterly Loss >> Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2020 Financial Results >> Galmed Pharmaceuticals Ltd to Host Earnings Call >> Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo 5MER >> Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2020 Financial Results and Provide Business Update on Thursday March 18 |
GlycoMimetics Inc …GlycoMimetics Inc |
GLYC (179.78, 46.6, 2.3 %) | 3.33 | GlycoMimetics to Share GMI 1359 and Galectin 3 Antagonist Program Data at AACR 2021 Meetin …>> GlycoMimetics to Share GMI 1359 and Galectin 3 Antagonist Program Data at AACR 2021 Meeting >> Apollomics Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics Uproleselan for the Treatment of AML >> GlycoMimetics Inc GLYC Q4 2020 Earnings Call Transcript >> GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2020 >> GlycoMimetics Inc to Host Earnings Call |
Esports Entertainment Group Inc …Esports Entertainment Group Inc |
GMBL (294.49, 7.33, 5.08 %) | 16.5 | Implied Volatility Surging for Esports Entertainment Group GMBL Stock Options …>> Implied Volatility Surging for Esports Entertainment Group GMBL Stock Options >> Esports Entertainment Group Interview to Air on Bloomberg TV in the U S on the RedChip Money Report R >> Esports Entertainment Group Expands its VIE bet Esports Betting Brand into Latin America with Two New Marketing Partnerships >> Esports Entertainment Group to Present at LD Micro Zoom Edition >> Esports Entertainment Group Varney amp Co Interview Postponed |
Genprex Inc …Genprex Inc |
GNPX (246.79, 30.84, 10.33 %) | 5.06 | Genprex to Participate in Upcoming March Investor Conferences …>> Genprex to Participate in Upcoming March Investor Conferences >> Small and Microcap Company Investor Presentations Now Available for On Demand Viewing >> Small and Microcap Company Investor Presentations Now Available for On Demand Viewing >> Small and Microcap Company Investor Presentations Now Available for On Demand Viewing >> Small and Microcap Company Investor Presentations Now Available for On Demand Viewing |
Gossamer Bio Inc …Gossamer Bio Inc |
GOSS (739.64, 67.54, 11.67 %) | 9.51 | Gossamer Bio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Bu …>> Gossamer Bio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update >> Gossamer Bio to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on February 25 2021 >> Gossamer Bio to Host Webcast Focused on its Inflammatory Bowel Disease Program GB004 on February 18 2021 >> Have Insiders Been Buying Gossamer Bio Inc NASDAQ GOSS Shares This Year >> Is GOSS A Good Stock To Buy Now According To Hedge Funds |
Graybug Vision Inc …Graybug Vision Inc |
GRAY (159.61, 19.84, 2.93 %) | 7.47 | Is Graybug Vision Stock a Buy Right Now This Is What You Need to Know …>> Is Graybug Vision Stock a Buy Right Now This Is What You Need to Know >> Why Is Graybug Vision Stock Plunging Today >> Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trial >> Graybug Vision Announces Full Year 2020 Financial Results and Recent Corporate Developments >> Graybug Vision to Participate in SVB Leerink Global Healthcare Conference |
Galera Therapeutics Inc …Galera Therapeutics Inc |
GRTX (290.64, 21.96, 0.67 %) | 11.27 | Galera Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent …>> Galera Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Accomplishments >> Galera Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference >> We Think Galera Therapeutics NASDAQ GRTX Needs To Drive Business Growth Carefully >> Is GRTX A Good Stock To Buy Now >> Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference |
GT Biopharma Inc …GT Biopharma Inc |
GTBP (166.19, 3.94, 7.25 %) | 6.13 | GT Biopharma Announces Updated Interim GTB 3550 Trike Clinical Trial Results …>> GT Biopharma Announces Updated Interim GTB 3550 Trike Clinical Trial Results >> GT Biopharma to Present at The Virtual 33rd Annual Roth Conference >> GT Biopharma Announces Preclinical Results For Its ROR1 TriKE As A Treatment For Prostate Cancer >> GT Biopharma Adds University of Wisconsin Madison Carbone Cancer Center as Second Site in Ongoing Phase 1 2 Clinical Trial of GTB 3550 TriKE a Novel NK Cell Therapeutic Cancer Treatment >> Psyched Wellness Provides Update on Pre Clinical Trial of Its Muscimol Extract AME 1 |
G1 Therapeutics Inc …G1 Therapeutics Inc |
GTHX (967.99, 33.81, 18.73 %) | 21.74 | G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 c 4 …>> G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 c 4 >> G1 Therapeutics to Participate in Two Investor Conferences in March >> G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA trilaciclib the Only FDA Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy Induced Myelosuppression >> G1 Therapeutics Inc GTHX Q4 2020 Earnings Call Transcript >> Recap G1 Therapeutics Q4 Earnings |
Hepion Pharmaceuticals Inc …Hepion Pharmaceuticals Inc |
HEPA (160.14, 7.41, 35.09 %) | 2.1 | Hepion Pharmaceuticals to Present on CRV431 and AI POWR at NASH TAG 2021 …>> Hepion Pharmaceuticals to Present on CRV431 and AI POWR at NASH TAG 2021 >> Hepion Pharmaceuticals to Present on CRV431 and AI POW TM at NASH TAG 2021 >> Hepion Pharmaceuticals to Present on CRV431 and AI POWR TM at NASH TAG 2021 >> Hepion Pharmaceuticals Inc Announces Closing of Public Offering >> Hepion Pharmaceuticals Announces Pricing of Public Offering |
HEXO Corp …HEXO Corp |
HEXO (949.18, 115.82, 8.27 %) | 7.23 | HEXO Corp announces positive adjusted EBITDA and 94 increase in net revenue from prior ye …>> HEXO Corp announces positive adjusted EBITDA and 94 increase in net revenue from prior year >> Why HEXO Corp HEXO Might Surprise This Earnings Season >> CGC Stock A Buy Canopy Growth Slumps After February Rally But Profit Outlook Improves >> HEXO HEXO Expected to Beat Earnings Estimates What to Know Ahead of Q2 Release >> HEXO Corp wins complete dismissal of US federal shareholder class action |
Humanigen Inc …Humanigen Inc |
HGEN (959.35, 30.82, 7.53 %) | 16.32 | Humanigen Sets Date for Virtual Annual Shareholders Meeting …>> Humanigen Sets Date for Virtual Annual Shareholders Meeting >> Humanigen Inc NASDAQ HGEN On The Verge Of Breaking Even >> Humanigen Announces 80 Million Loan Facility from Hercules Capital >> Humanigen Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update >> Do Options Traders Know Something About Humanigen HGEN Stock We Don t |
Harmony Biosciences Holdings Inc …Harmony Biosciences Holdings Inc |
HRMY (1880, 46.16, 1.27 %) | 30.94 | Harmony Biosciences Hosts Summit Which Sheds Light on Impact of Sleep Disruption in Rare D …>> Harmony Biosciences Hosts Summit Which Sheds Light on Impact of Sleep Disruption in Rare Diseases >> Harmony Biosciences Highlights Publication of WAKIX pitolisant Efficacy Data in Sleep Medicine >> Harmony Biosciences Appoints Sandip Kapadia as Chief Financial Officer >> Harmony Biosciences Announces Date Of Fourth Quarter And Full Year 2020 Financial Results >> Harmony Biosciences Certified As A Great Place To Work For The Third Year In A Row |
Harrow Health Inc …Harrow Health Inc |
HROW (197.35, 23.81, 4.83 %) | 7.64 | HealthEquity HQY Enhances Commuter Offering With New Buyout …>> HealthEquity HQY Enhances Commuter Offering With New Buyout >> Harrow Health HROW Lags Q4 Earnings Estimates >> Harrow Health Announces Fourth Quarter and Year End 2020 Financial Results >> Harrow Health Inc to Host Earnings Call >> Harrow Health to Participate in H C Wainwright Global Life Sciences Conference |
Heron Therapeutics Inc …Heron Therapeutics Inc |
HRTX (1520, 90.59, 22.24 %) | 15.62 | Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended Decem …>> Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31 2020 and Highlights Recent Corporate Updates >> How Much Did Heron Therapeutics NASDAQ HRTX Shareholders Earn From Share Price Movements Over The Last Three Years >> Heron Therapeutics to Present at Several Upcoming Virtual Investor Conferences >> Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow On Study of HTX 011 in Patients Undergoing Bunionectomy Surgery >> Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program |
Histogen Inc …Histogen Inc |
HSTO (41.81, 9.98, 17.15 %) | 1.34 | Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study of Emricasan in Symp …>> Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study of Emricasan in Symptomatic COVID 19 Patients >> Histogen Announces Removal of Clinical Hold by FDA for HST 003 IND to Initiate a Phase 1 2 Trial for Knee Cartilage Regeneration >> Histogen Reports Fourth Quarter and Year End 2020 Financial Results and Provides Business Update >> Histogen Strengthens Board of Directors with Appointment of Industry Leader Susan Windham Bannister Ph D >> Histogen to Report Fourth Quarter and Year End 2020 Financial Results and Provide Business Update |
Heat Biologics Inc …Heat Biologics Inc |
HTBX (201.75, 21.75, 9.3 %) | 8.26 | Heat Biologics to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth …>> Heat Biologics to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference >> HTBX HS 110 Phase 2 Interim Data >> Heat Biologics to Present at 2021 BIO CEO amp Investor Digital Conference >> Heat Biologics Stock Notches Scorching RS Rating >> Heat Biologics Stock Notches Scorching RS Rating |
Horizon Therapeutics Plc …Horizon Therapeutics Plc |
HZNP (20110, 217.89, 3.13 %) | 88.15 | Halozyme Stock Joins The 80 Plus RS Rating Club …>> Halozyme Stock Joins The 80 Plus RS Rating Club >> AstraZeneca to supply U S with extra 500 000 doses of COVID 19 antibody based cocktail >> Few Top Global Growth Stocks To Buy And Watch On IBD s Screen Of The Day >> Stocks Showing Leadership Covid Recovery Play Ligand Earns Key Rating Jump >> Horizon Therapeutics plc Completes Acquisition of Viela Bio Inc |
iBio Inc …iBio Inc |
IBIO (365.59, 215.41, 4.75 %) | 1.7 | iBio Stock Is Not Likely To Move Higher Given Its Huge Dilution …>> iBio Stock Is Not Likely To Move Higher Given Its Huge Dilution >> iBio to Participate in the 33rd Annual Roth Conference >> iBio IBIO Q2 2021 Earnings Call Transcript >> iBio Reports Fiscal Second Quarter 2021 Financial Results and Provides Corporate Update >> iBio Inc to Host Earnings Call |
Immucell Corp. …Immucell Corp. |
ICCC (71.93, 5.13, 0.12 %) | 10.43 | ImmuCell Corp to Host Earnings Call …>> ImmuCell Corp to Host Earnings Call >> ImmuCell Makes Important Regulatory Submission and Announces Unaudited Financial Results for the Year Ended December 31 2020 >> ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31 2020 >> ImmuCell Announces Preliminary Unaudited Sales Results for the Year Ended December 31 2020 >> ImmuCell Announces Restructuring of its Bank Debt |
Intercept Pharmaceuticals Inc …Intercept Pharmaceuticals Inc |
ICPT (762.14, 27.64, 23.17 %) | 22.2 | 3 Under the Radar Growth Stocks With 55 to 106 Upside According to Wall Street …>> 3 Under the Radar Growth Stocks With 55 to 106 Upside According to Wall Street >> Intercept Announces Departure of Chief Financial Officer >> Intercept s ICPT Q4 Loss Wider than Expected Sales Miss >> Intercept Pharmaceuticals Inc ICPT Q4 2020 Earnings Call Transcript >> Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results Issues 2021 Financial Guidance and Provides Business Update |
InflaRx N.V. …InflaRx N.V. |
IFRX (201.07, 19.45, 2.21 %) | 4.47 | InflaRx to Present at Upcoming Investor Conferences …>> InflaRx to Present at Upcoming Investor Conferences >> InflaRx Announces Closing of 75 Million Public Offering of Common Shares and One Year Warrants >> What Kind Of Investors Own Most Of InflaRx N V NASDAQ IFRX >> InflaRx Announces Pricing of 75 Million Public Offering of Common Shares and One Year Warrants >> InflaRx Announces Proposed Offering of Common Shares and One Year Warrants |
IGM Biosciences Inc …IGM Biosciences Inc |
IGMS (2840, 15.66, 13.68 %) | 83.13 | IGM Biosciences Appoints Lisa Decker Ph D as Chief Business Officer …>> IGM Biosciences Appoints Lisa Decker Ph D as Chief Business Officer >> IGM Biosciences NASDAQ IGMS Is In A Good Position To Deliver On Growth Plans >> 5 Value Stocks In The Healthcare Sector >> IGM Biosciences to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day >> The Daily Biotech Pulse GSK Vir To Start COVID 19 Antibody Study Novartis In Licenses BeiGene s Cancer Drug Earnings Preannouncements Continue |
Immunogen, Inc. …Immunogen, Inc. |
IMGN (1790, 169.83, 13.48 %) | 8.28 | Why Is ImmunoGen IMGN Up 9 2 Since Last Earnings Report …>> Why Is ImmunoGen IMGN Up 9 2 Since Last Earnings Report >> ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635 c 4 >> ImmunoGen Announces Webcast of Presentation at Upcoming H C Wainwright Virtual Global Life Sciences Conference >> News Flash Analysts Just Made An Incredible Upgrade To Their ImmunoGen Inc NASDAQ IMGN Forecasts >> We Think ImmunoGen NASDAQ IMGN Can Afford To Drive Business Growth |
Immunome Inc …Immunome Inc |
IMNM (327.13, 7.07, 3.04 %) | 33.2 | Why Immunome Stock Skyrocketed Today …>> Why Immunome Stock Skyrocketed Today >> Immunome stock more than triples after isolating antibodies in treatment of COVID 19 variants >> Immunome Discovers Antibodies Capable of Neutralizing Multiple SARS CoV 2 Variants Including the South African Variant in Pseudovirus Testing >> Immunome Skyrockets on Isolation of COVID Antibodies >> Abzena Selected by Immunome to Develop and Manufacture Antibody Cocktail for Immunomes COVID 19 Antibody Based Treatment |
Imara Inc …Imara Inc |
IMRA (180.13, 14.95, 4.79 %) | 10.2 | Imara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR 687 …>> Imara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR 687 for Sickle Cell Disease and Beta Thalassemia >> Bronstein Gewirtz amp Grossman LLC Announces Investigation of IMARA Inc IMRA and Encourages Investors to Contact the Firm >> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA Inc IMRA >> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA Inc IMRA >> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA Inc IMRA |
Immunic Inc …Immunic Inc |
IMUX (324.93, 14.93, 8.8 %) | 14.95 | Should You Take Comfort From Insider Transactions At Immunic Inc NASDAQ IMUX …>> Should You Take Comfort From Insider Transactions At Immunic Inc NASDAQ IMUX >> Immunic Inc to Participate in Industry and Investor Conferences in March >> Immunic s IMU 838 Shows Promising Clinical Effect In Mid Stage Liver Disease Study >> The Daily Biotech Pulse Lily Rigel Licensing Deal vTv Starts Early Stage Psoriasis Study Immunic Data Readout >> Immunic Inc Announces Positive Top Line Data From Investigator Sponsored Phase 2 Proof of Concept Clinical Trial of IMU 838 in Primary Sclerosing Cholangitis |
IMV Inc …IMV Inc |
IMV (220.07, 61.35, 1.04 %) | 3.13 | IMV Inc IMV Q4 2020 Earnings Call Transcript …>> IMV Inc IMV Q4 2020 Earnings Call Transcript >> IMV Inc Announces Fourth Quarter and Full Year 2020 Financial and Operational Results >> IMV Inc to Host Earnings Call >> IMV INC IMV Reports Next Week What to Expect >> IMV to Announce Fourth Quarter and Fiscal 2020 Financial and Operational Results and Host Conference Call and Webcast on March 17 2021 |
Infinity Pharmaceuticals Inc. …Infinity Pharmaceuticals Inc. |
INFI (262.37, 56.63, 2.19 %) | 3.36 | Is the Options Market Predicting a Spike in Infinity INFI Stock …>> Is the Options Market Predicting a Spike in Infinity INFI Stock >> Infinity Pharmaceuticals INFI Reports Q4 Loss Tops Revenue Estimates >> Infinity Pharmaceuticals Q4 Earnings Insights >> Infinity Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Update on Eganelisib Development >> Infinity Pharmaceuticals Inc to Host Earnings Call |
InMed Pharmaceuticals Inc …InMed Pharmaceuticals Inc |
INM (34.05, 6.96, 5.91 %) | 4.11 | Ontario Lottery and Gaming Corporation MidDay lottery winning numbers March 17 2021 …>> Ontario Lottery and Gaming Corporation MidDay lottery winning numbers March 17 2021 >> InMed to Present at Virtual Conferences in March 2021 >> IIROC Trading Halt TTO H >> InMed Announces Closing of US 4 5 Million Private Placement >> InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results |
Insmed Inc …Insmed Inc |
INSM (3980, 100.76, 7.98 %) | 36.43 | Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635 c 4 …>> Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635 c 4 >> Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update >> Insmed Inc to Host Earnings Call >> Insmed to Present at Two March Conferences >> Insmed s Inhaled Treprostinil Palmitil Is Safe Healthy Volunteers Study Show |
Innoviva Inc …Innoviva Inc |
INVA (1220, 68.98, 14.45 %) | 11.84 | Top Biotech Stocks for Q2 2021 …>> Top Biotech Stocks for Q2 2021 >> Armata Pharmaceuticals Announces Closing of Second and Final Tranche of 20 Million Private Placement with Innoviva >> Moving Average Crossover Alert Innoviva >> Innoviva Inc s NASDAQ INVA Stock Has Been Sliding But Fundamentals Look Strong Is The Market Wrong >> Innoviva Q4 Earnings Insights |
Inozyme Pharma Inc …Inozyme Pharma Inc |
INZY (509.44, 7.69, 14.36 %) | 21.8 | The Balancing Act on Lifetime to Feature ENPP1 Deficiency …>> The Balancing Act on Lifetime to Feature ENPP1 Deficiency >> Inozyme Pharma Appoints Deborah Wenkert M D as Senior Vice President and Chief Medical Officer >> Inozyme Pharma Announces Authorization to Proceed in U S and U K with Phase 1 2 Clinical Trial of INZ 701 for the Treatment of ENPP1 Deficiency >> Is INZY A Good Stock To Buy Now >> Inozyme Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights |
Ionis Pharmaceuticals Inc …Ionis Pharmaceuticals Inc |
IONS (7570, 132.81, 6.4 %) | 52.8 | TRACON Pharmaceuticals Announces Appointment of Lisa Johnson Pratt M D to its Board of …>> TRACON Pharmaceuticals Announces Appointment of Lisa Johnson Pratt M D to its Board of Directors >> Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis >> Ionis Pharmaceuticals Inc IONS Q4 2020 Earnings Call Transcript >> Ionis reports fourth quarter and full year 2020 financial results and recent business achievements >> Ionis to present at upcoming investor conferences |
Ironwood Pharmaceuticals Inc – Class A …Ironwood Pharmaceuticals Inc – Class A |
IRWD (1850, 155.36, 11.53 %) | 11.22 | Ironwood IRWD Up 20 4 Since Last Earnings Report Can It Continue …>> Ironwood IRWD Up 20 4 Since Last Earnings Report Can It Continue >> Edward Owens Is The Independent Director of Ironwood Pharmaceuticals Inc NASDAQ IRWD And They Just Picked Up 5 9 More Shares >> 3 Undervalued Biotechs Worth Adding to Your Watch List >> Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences >> Ironwood Pharmaceuticals Inc IRWD Q4 2020 Earnings Call Transcript |
IVERIC bio Inc …IVERIC bio Inc |
ISEE (583.38, 84.38, 5.46 %) | 6.08 | Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635 c 4 …>> Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635 c 4 >> New Strong Sell Stocks for March 11th >> IVERIC bio Inc ISEE Q4 2020 Earnings Call Transcript >> Iveric Bio Reports Fourth Quarter and Year End 2020 Operational Highlights and Financial Results >> IVERIC bio Inc to Host Earnings Call |
Intra-Cellular Therapies Inc …Intra-Cellular Therapies Inc |
ITCI (2900, 76.11, 8.45 %) | 35.04 | Intra Cellular Therapies Inc ITCI Q4 2020 Earnings Call Transcript …>> Intra Cellular Therapies Inc ITCI Q4 2020 Earnings Call Transcript >> Intra Cellular Therapies Reports Fourth Quarter and Full Year 2020 Financial Results And Provides Corporate Update >> Intra Cellular Therapies Inc to Host Earnings Call >> Intra Cellular Therapies Discloses New Drug Candidate For Dementia Related Episodes >> Intra Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity ITI 1284 |
Iterum Therapeutics Plc …Iterum Therapeutics Plc |
ITRM (267.61, 40.04, 9.06 %) | 1.65 | Iterum Therapeutics Appoints Beth P Hecht to Board of Directors …>> Iterum Therapeutics Appoints Beth P Hecht to Board of Directors >> Iterum Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results >> Iterum Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 12 2021 >> Iterum Therapeutics to Present in Upcoming Investor Conferences >> UTILITY Therapeutics Joins Antimicrobials Working Group |
Jaguar Health Inc …Jaguar Health Inc |
JAGX (268.96, 65.17, 5.21 %) | 2.07 | Jaguar Health Announces Incorporation of Napo EU Subsidiary in Italy …>> Jaguar Health Announces Incorporation of Napo EU Subsidiary in Italy >> Jaguar Health Signs Definitive Agreement for 5 Million Non dilutive Financing Transaction Involving Sale of Royalty Rights Related to Future Potential Crofelemer Mytesi COVID related Indication Revenue Stream >> Is the Parabolic Rise of JAGX Stock Too Good to Be True >> Jaguar Health Enters Binding Term Sheet for 5 Million Non dilutive Financing Transaction Involving Sale of Royalty Rights Related to Future Potential Crofelemer Mytesi COVID related Indication Revenue Stream >> Monteverde amp Associates PC Announces Proposed Class Action Settlement On Behalf Of Holders Of Jaguar Animal Health Common Stock |
Jazz Pharmaceuticals plc …Jazz Pharmaceuticals plc |
JAZZ (9610, 54.14, 8.02 %) | 169.63 | New Strong Sell Stocks for March 18th …>> New Strong Sell Stocks for March 18th >> Jazz Pharmaceuticals and Hypersomnia Foundation Launch Campaign to Increase Understanding and Awareness of Idiopathic Hypersomnia >> Update Jazz Pharmaceuticals NASDAQ JAZZ Stock Gained 62 In The Last Year >> These 3 Value Stocks Are Absurdly Cheap Right Now >> Why GW Pharmaceuticals Stock Rocketed 40 5 in February |
Johnson & Johnson …Johnson & Johnson |
JNJ (422040, 2610, 0.58 %) | 160.47 | Bidens vaccine goal was not a moonshot challenge Analyst …>> Bidens vaccine goal was not a moonshot challenge Analyst >> Janssen s Ponvory Wins FDA Nod For Relapsing Multiple Sclerosis >> UPDATE 2 U S FDA approves J amp J s multiple sclerosis treatment launch in April >> Biden Administration Nears Goal of Administering 100 Million Vaccines >> Could a Supply Glut Sink COVID Vaccine Stocks |
KalVista Pharmaceuticals Inc …KalVista Pharmaceuticals Inc |
KALV (795.78, 21.14, 3.7 %) | 34.27 | KalVista Pharmaceuticals Appoints Nancy Stuart to Board of Directors …>> KalVista Pharmaceuticals Appoints Nancy Stuart to Board of Directors >> KalVista Pharmaceuticals Inc KALV Moves to Buy Rationale Behind the Upgrade >> KalVista Pharmaceuticals Inc KALV Reports Q3 Loss Misses Revenue Estimates >> KalVista Pharmaceuticals Reports Third Fiscal Quarter Results >> KalVista Pharmaceuticals Inc KALV Expected to Beat Earnings Estimates Should You Buy |
Kadmon Holdings Inc …Kadmon Holdings Inc |
KDMN (735.57, 155.55, 21.69 %) | 4.09 | Bronstein Gewirtz amp Grossman LLC Announces Investigation of Kadmon Holdings Inc K …>> Bronstein Gewirtz amp Grossman LLC Announces Investigation of Kadmon Holdings Inc KDMN and Encourages Investors to Contact the Firm >> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kadmon Holdings Inc KDMN >> Gene editing will boost intelligence within a few decades >> The Daily Biotech Pulse Contrasting COVID 19 Treatment Readouts From Roche Vir Delay In Kadmon s FDA Review Alzheimer s Data From Prothena >> Influencers with Andy Serwer Walter Isaacson |
Chinook Therapeutics Inc …Chinook Therapeutics Inc |
KDNY (728.36, 4.76, 16.07 %) | 17.47 | Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of At …>> Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of Atrasentan for Patients with IgA Nephropathy >> Chinook Therapeutics to Present at Upcoming Investor Conferences >> Chinook Therapeutics and Evotec Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases >> Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development CKD3 Summit >> Chinook Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference |
Kindred Biosciences Inc …Kindred Biosciences Inc |
KIN (195.8, 37.08, 2.97 %) | 4.77 | Kindred Biosciences KIN Reports Q4 Loss Lags Revenue Estimates …>> Kindred Biosciences KIN Reports Q4 Loss Lags Revenue Estimates >> Kindred Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results >> Kindred Biosciences Inc to Host Earnings Call >> Will Kindred Biosciences KIN Report Negative Earnings Next Week What You Should Know >> Kindred Biosciences KIN May Report Negative Earnings Know the Trend Ahead of Q4 Release |
Kamada Ltd …Kamada Ltd |
KMDA (280.55, 28.55, 3.51 %) | 6.21 | Kamada to Present at the Jefferies Global Plasma Summit …>> Kamada to Present at the Jefferies Global Plasma Summit >> Kamada Announces the Closing of the Acquisition of the FDA Licensed Plasma Collection Center from Blood and Plasma Research Inc in the U S >> Kamada Files Annual Report for the Year Ended December 31 2020 >> Recap Kamada Q4 Earnings >> Recap Kamada Q4 Earnings |
KemPharm Inc …KemPharm Inc |
KMPH (228.74, 4.19, 71.13 %) | 10.84 | Are Options Traders Betting on a Big Move in KemPharm KMPH Stock …>> Are Options Traders Betting on a Big Move in KemPharm KMPH Stock >> KemPharm Reports Fourth Quarter and Full Year 2020 Financial Results >> KemPharm Inc to Host Earnings Call >> KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results >> KemPharm Won FDA Approval But This Analyst Isnt Happy |
Kiniksa Pharmaceuticals Ltd – Class A …Kiniksa Pharmaceuticals Ltd – Class A |
KNSA (1580, 29.38, 13.17 %) | 21.72 | Kiniksa Wins FDA Nod For ARCALYST Injection therapy Shares Pop After Hours …>> Kiniksa Wins FDA Nod For ARCALYST Injection therapy Shares Pop After Hours >> The Daily Biotech Pulse Sarepta Gene Therapy Data Idera Plunges On Failed Skin Cancer Study 3 IPOs >> Kiniksa Announces FDA Approval of ARCALYST rilonacept for Recurrent Pericarditis >> The Daily Biotech Pulse FDA Nod For Pfizer Kiniksa Rises On Commercialization Pact With Regeneron Bio Techne To Buy Diagnostic Company >> Kiniksa Launches Patient Registry RESONANCE for Recurrent Pericarditis |
Kinnate Biopharma Inc …Kinnate Biopharma Inc |
KNTE (1620, 37.27, 2.49 %) | 35.37 | Kinnate Biopharma Inc Announces Its Addition to the Russell 2000 Index …>> Kinnate Biopharma Inc Announces Its Addition to the Russell 2000 Index >> We re Hopeful That Kinnate Biopharma NASDAQ KNTE Will Use Its Cash Wisely >> Kinnate Biopharma Inc to Participate in Upcoming Investor Conferences >> Biotech IPO Frenzy Brings in 3 Stocks to Buy >> Benzinga s Top Upgrades Downgrades For December 28 2020 |
Karyopharm Therapeutics Inc …Karyopharm Therapeutics Inc |
KPTI (951.92, 66.49, 25.21 %) | 12.04 | Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 c 4 …>> Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 c 4 >> Karyopharm Announces Upcoming Virtual Investor Conference Participation >> Analysts Have Lowered Expectations For Karyopharm Therapeutics Inc NASDAQ KPTI After Its Latest Results >> KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General Kahn Swick amp Foti LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc KPTI >> Is Karyopharm Therapeutics NASDAQ KPTI Weighed On By Its Debt Load |
Kronos Bio Inc …Kronos Bio Inc |
KRON (1570, 48.58, 4.58 %) | 28.13 | Kronos Bio to Present Pre Clinical Data at the AACR Virtual Annual Meeting 2021 for KB 074 …>> Kronos Bio to Present Pre Clinical Data at the AACR Virtual Annual Meeting 2021 for KB 0742 an Oral CDK9 Inhibitor Targeting MYC amplified Cancers >> The Daily Biotech Pulse FDA Nod For Pfizer Kiniksa Rises On Commercialization Pact With Regeneron Bio Techne To Buy Diagnostic Company >> Kronos Bio Announces Positive End of Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1 mutated Acute Myeloid Leukemia AML >> Kronos Bio Announces First Patient Dosed in Phase 1 2 Clinical Trial of KB 0742 an Oral CDK9 Inhibitor Targeting MYC amplified Cancers >> Kronos Bio Announces Participation in the Cowen 41st Annual Health Care Conference |
Keros Therapeutics Inc …Keros Therapeutics Inc |
KROS (1400, 18.31, 3.76 %) | 55 | Keros Therapeutics Presents Results from Preclinical Studies of KER 050 and ALK2 Inhibitor …>> Keros Therapeutics Presents Results from Preclinical Studies of KER 050 and ALK2 Inhibitors at the European School of Haematology ESH 2nd Translational Research E Conference >> Keros Therapeutics to Present at the H C Wainwright Global Life Sciences 2021 Virtual Conference >> Keros Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference >> Companies Like Keros Therapeutics NASDAQ KROS Are In A Position To Invest In Growth >> Keros Therapeutics Announces Addition to NASDAQ Biotechnology Index |
Karuna Therapeutics Inc …Karuna Therapeutics Inc |
KRTX (3490, 23.89, 6.41 %) | 116.89 | Karuna Therapeutics to Present at Upcoming Investor Conferences …>> Karuna Therapeutics to Present at Upcoming Investor Conferences >> Karuna Therapeutics Announces Pricing of Public Offering of Common Stock >> Karuna Therapeutics Announces Proposed Public Offering of Common Stock >> Karuna Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides General Business Update >> Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT 1 Phase 2 Trial Evaluating KarXT in Schizophrenia |
Kura Oncology Inc …Kura Oncology Inc |
KURA (1890, 60.18, 11.8 %) | 25.94 | Kura Oncology Inc KURA Q4 2020 Earnings Call Transcript …>> Kura Oncology Inc KURA Q4 2020 Earnings Call Transcript >> Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results >> Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma >> Kura Oncology Inc to Host Earnings Call >> Kura Oncology to Participate in Four Upcoming Investor Conferences |
Kymera Therapeutics Inc …Kymera Therapeutics Inc |
KYMR (2700, 40.06, 2.61 %) | 49.42 | Kymera Therapeutics Appoints Elena Ridloff CFA to Board of Directors …>> Kymera Therapeutics Appoints Elena Ridloff CFA to Board of Directors >> Kymera Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update >> Kymera Therapeutics Announces First in Human Dose in Phase 1 Trial of KT 474 a First in Class IRAK4 Protein Degrader to Treat Immune Inflammatory Diseases >> Kymera Therapeutics to Present at Upcoming March Investor Conferences >> Kymera Therapeutics to Present at Upcoming February Investor Conferences |
Lannett Co., Inc. …Lannett Co., Inc. |
LCI (282.14, 32.6, 24.31 %) | 6.35 | SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lannet …>> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lannett Company Inc LCI >> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lannett Company Inc LCI >> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lannett Company Inc LCI >> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lannett Company Inc LCI >> Lannett plans to file experimental insulin product with FDA sometime this year |
Lifevantage Corporation …Lifevantage Corporation |
LFVN (132.77, 12.96, 6.25 %) | 9.37 | LifeVantage Corporation NASDAQ LFVN Stock Has Shown Weakness Lately But Financials Look …>> LifeVantage Corporation NASDAQ LFVN Stock Has Shown Weakness Lately But Financials Look Strong Should Prospective Shareholders Make The Leap >> LifeVantage Announces Appointment of Chief Executive Officer >> LifeVantage Announces Appointment of Chief Executive Officer >> LifeVantage Announces Appointment of Chief Executive Officer >> LifeVantage Announces Appointment of Chief Executive Officer |
Ligand Pharmaceuticals, Inc. – Class B …Ligand Pharmaceuticals, Inc. – Class B |
LGND (2620, 15.28, 14.48 %) | 154.9 | GameStop s Get Rich Fast Trick Is Running Out …>> GameStop s Get Rich Fast Trick Is Running Out >> Stocks Showing Leadership Covid Recovery Play Ligand Earns Key Rating Jump >> Ligand Pharmaceuticals Gets A Composite Rating Upgrade >> Crispr Therapeutics Hits 80 Plus Relative Strength Rating Benchmark >> Altimmune Joins Rank Of Stocks With RS Ratings Over 90 |
Lixte Biotechnology Holdings Inc …Lixte Biotechnology Holdings Inc |
LIXT (44.48, 3.23, 0.58 %) | 3.95 | Lixte Biotechnology to Present Its Novel Product Candidate for Targeted Cancer Therapy at …>> Lixte Biotechnology to Present Its Novel Product Candidate for Targeted Cancer Therapy at the Benzinga Biotech Small Cap Conference on March 24 >> Lixte Biotechnology to Showcase Its Anti Cancer Therapy Enhancer LB 100 at the Virtual 33rd Annual ROTH Capital Conference >> WestPark Capital Announces Completion of 4 19 Million Registered Direct Offering for Lixte Biotechnology Holdings Inc Nasdaq LIXT >> WallachBeth Capital Announces Completion of 4 19 Million Registered Direct Offering for Lixte Biotechnology Holdings Inc >> Lixte Biotechnology Announces the Closing of 4 19 Million Registered Direct Offering |
Lilly(Eli) & Co …Lilly(Eli) & Co |
LLY (176500, 856.57, 0.66 %) | 183.93 | Vaccines are here Thats no reason to call off the hunt for effective COVID 19 treatments …>> Vaccines are here Thats no reason to call off the hunt for effective COVID 19 treatments >> Dont Lose Sight of Biogens Depression Drug How It Could Send the Stock Much Higher >> Lilly says its monoclonal antibody is no longer being ordered in 3 states due to variant concerns >> Lilly LLY Mirikizumab Meets Ulcerative Colitis Study Goal >> Lilly Presents Patient Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio at St Gallen Virtual Congress 2021 |
Lipocine Inc …Lipocine Inc |
LPCN (157.75, 86.07, 4.61 %) | 1.7 | Lipocine To Present At M Vest Maxim Conference And At The Lytham Partners Conference …>> Lipocine To Present At M Vest Maxim Conference And At The Lytham Partners Conference >> Lipocine Announces Financial Results For The Year Ended December 31 2020 >> Lipocine Announces Publication in Journal of Endocrinological Investigation Highlighting the Potential of LPCN 1144 in the Treatment of NASH and Hepatic Fibrosis >> Lipocine Announces Presentations on TLANDO at ENDO 2021 Conference >> Lipocine to Present at Two Upcoming Investor Conferences |
Leap Therapeutics Inc …Leap Therapeutics Inc |
LPTX (137.7, 44, 2.78 %) | 2.38 | Introducing Leap Therapeutics NASDAQ LPTX A Stock That Climbed 80 In The Last Year …>> Introducing Leap Therapeutics NASDAQ LPTX A Stock That Climbed 80 In The Last Year >> Leap Therapeutics Inc LPTX Reports Q4 Loss Lags Revenue Estimates >> Leap Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results >> Leap Therapeutics to Present at Upcoming Virtual Investor Conferences >> What You Need To Know About Leap Therapeutics Inc s NASDAQ LPTX Investor Composition |
Liquidia Corp …Liquidia Corp |
LQDA (126.44, 28.44, 4.39 %) | 2.77 | What Kind Of Investors Own Most Of Liquidia Corporation NASDAQ LQDA …>> What Kind Of Investors Own Most Of Liquidia Corporation NASDAQ LQDA >> Liquidia Corporation to Host 2020 Financial Results Conference Call on March 23 2021 >> Liquidia Corporation Secures 20 5 Million Debt Facility with Silicon Valley Bank >> EQUITY ALERT ROSEN A TOP RANKED LAW FIRM Announces Investigation of Securities Claims Against Liquidia Corporation LQDA >> EQUITY ALERT ROSEN A TOP RANKED LAW FIRM Announces Investigation of Securities Claims Against Liquidia Corporation LQDA |
Larimar Therapeutics Inc …Larimar Therapeutics Inc |
LRMR (275.67, 15.02, 1.65 %) | 17.27 | Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Res …>> Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results >> Here s Why We re Not Too Worried About Larimar Therapeutics NASDAQ LRMR Cash Burn Situation >> Larimar Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference >> Is LRMR A Good Stock To Buy Now >> Larimar Therapeutics Added to NASDAQ Biotechnology Index |
Lantern Pharma Inc …Lantern Pharma Inc |
LTRN (236.08, 1.59, 7.04 %) | 19.75 | Lantern Pharma Announces Filing of Seven Patent Applications Globally on Novel DNA Damagin …>> Lantern Pharma Announces Filing of Seven Patent Applications Globally on Novel DNA Damaging Agent with Anticancer Properties >> Lantern Pharma Interview to Air on Bloomberg TV in the US on the RedChip Money Report >> How Much Are Lantern Pharma Inc NASDAQ LTRN Insiders Spending On Buying Shares >> Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and Operational Highlights >> Lantern Pharma Inc to Host Earnings Call |
Lumos Pharma Inc …Lumos Pharma Inc |
LUMO (110.47, 6.23, 0.69 %) | 12.69 | Lumos Pharma to Participate in March 2021 Investor Conferences …>> Lumos Pharma to Participate in March 2021 Investor Conferences >> Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD >> Lumos Pharma Inc to Host Earnings Call >> Data Supporting Use of Predictive Enrichment Markers for Lumos Pharmas LUM 201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society >> Lumos Pharma to Present Poster Demonstrating Greater GH Response to LUM 201 than to Standard GH Secretagogues in PGHD at the Endocrine Society ENDO 2021 Annual Meeting |
Lexicon Pharmaceuticals Inc …Lexicon Pharmaceuticals Inc |
LXRX (943.29, 45.65, 7.86 %) | 6.355 | Implied Volatility Surging for Lexicon Pharmaceuticals LXRX Stock Options …>> Implied Volatility Surging for Lexicon Pharmaceuticals LXRX Stock Options >> Lexicon Pharmaceuticals LXRX Reports Q4 Loss Tops Revenue Estimates >> Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Update >> Lexicon Pharmaceuticals Inc to Host Earnings Call >> Lexicon Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on March 10 2021 |
Merrimack Pharmaceuticals Inc …Merrimack Pharmaceuticals Inc |
MACK (86.82, 12.95, 4.45 %) | 6.78 | Merrimack Reports Full Year 2020 Financial Results …>> Merrimack Reports Full Year 2020 Financial Results >> How Much Of Merrimack Pharmaceuticals Inc NASDAQ MACK Do Institutions Own >> How Much Of Merrimack Pharmaceuticals Inc NASDAQ MACK Do Institutions Own >> How Much Of Merrimack Pharmaceuticals Inc NASDAQ MACK Do Institutions Own >> How Much Of Merrimack Pharmaceuticals Inc NASDAQ MACK Do Institutions Own |
Mustang Bio Inc …Mustang Bio Inc |
MBIO (236.29, 50.58, 5.32 %) | 3.42 | Mustang Bio to Participate in Three March 2021 Virtual Investor Conferences …>> Mustang Bio to Participate in Three March 2021 Virtual Investor Conferences >> Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day >> Mustang Bio Inc s NASDAQ MBIO Intrinsic Value Is Potentially 25 Below Its Share Price >> Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X linked Severe Combined Immunodeficiency XSCID >> Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X linked Severe Combined Immunodeficiency XSCID |
Moleculin Biotech Inc …Moleculin Biotech Inc |
MBRX (109.72, 9.99, 6.03 %) | 4.22 | Moleculin to Participate in Four Upcoming Healthcare Conferences …>> Moleculin to Participate in Four Upcoming Healthcare Conferences >> Moleculin Announces Full Exercise of Over Allotment Option >> Moleculin Announces Full Exercise of Over Allotment Option >> Moleculin Announces Full Exercise of Over Allotment Option >> Moleculin Announces Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin in Sarcoma Lung Metastases |
Seres Therapeutics Inc …Seres Therapeutics Inc |
MCRB (2100, 82.8, 7.93 %) | 20.02 | Seres Therapeutics to Present at the 31st Annual Oppenheimer Healthcare Conference …>> Seres Therapeutics to Present at the 31st Annual Oppenheimer Healthcare Conference >> Seres Therapeutics Announces Discontinuation of Enrollment in SER 401 Study in Metastatic Melanoma >> Benzinga s Top Ratings Upgrades Downgrades For March 5 2021 >> Seres Therapeutics MCRB Reports Q4 Loss Tops Revenue Estimates >> Seres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updates |
Madrigal Pharmaceuticals Inc …Madrigal Pharmaceuticals Inc |
MDGL (1910, 12.46, 21.39 %) | 112.33 | Billionaire Nicholas Pritzkers Tao Capitals Best Stock Ideas and Portfolio …>> Billionaire Nicholas Pritzkers Tao Capitals Best Stock Ideas and Portfolio >> Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights >> Is MDGL A Good Stock To Buy Now >> Here s Why We re Not Too Worried About Madrigal Pharmaceuticals NASDAQ MDGL Cash Burn Situation >> Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience The American Association for the Study of Liver Diseases Meeting November 13 2020 Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52 Week Phase 3 MAESTRO NAFLD 1 Trial |
Medifast Inc …Medifast Inc |
MED (2980, 11.21, 4.11 %) | 234.74 | IBD 50 Stocks To Watch Medifast Seeks Support Amid Strong Momentum …>> IBD 50 Stocks To Watch Medifast Seeks Support Amid Strong Momentum >> Medifast Inc Announces Quarterly Dividend >> IBD 50 Stocks To Watch Medifast Looks To Rebound Amid Strong Momentum >> Zacks com featured highlights include Crocs MEDIFAST Sprouts Farmers Market Meridian Bioscience and iRobot >> 5 Must Buy Efficient Stocks to Make Your Portfolio Stand Out |
MEI Pharma Inc …MEI Pharma Inc |
MEIP (402.98, 109.33, 8.91 %) | 3.62 | MEI PHARMA INVESTIGATION CONTINUED by Former Louisiana Attorney General Kahn Swick amp …>> MEI PHARMA INVESTIGATION CONTINUED by Former Louisiana Attorney General Kahn Swick amp Foti LLC Continues to Investigate the Officers and Directors of MEI Pharma Inc MEIP >> MEI Pharma to Present Study at the American Association for Cancer Research AACR Annual Meeting 2021 Demonstrating that Voruciclib Inhibits KRAS Mutant Cancers in Pre Clinical Models >> MEI Pharma to present at the virtual H C Wainwright Global Life Sciences Conference 2021 >> MEI Pharma Reports Second Quarter Fiscal Year 2021 Results and Operational Highlights >> MEI Pharma Reports Second Quarter Fiscal Year 2021 Results and Operational Highlights |
Macrogenics Inc …Macrogenics Inc |
MGNX (1650, 53.31, 7.61 %) | 29.21 | MacroGenics MGNX Stock Jumps 6 6 Will It Continue to Soar …>> MacroGenics MGNX Stock Jumps 6 6 Will It Continue to Soar >> Forecast Analysts Think MacroGenics Inc s NASDAQ MGNX Business Prospects Have Improved Drastically >> MacroGenics to Participate in Upcoming Investor Conferences >> MacroGenics MGNX Q4 2020 Earnings Call Transcript >> MacroGenics Provides Update on Corporate Progress and 2020 Financial Results |
Millendo Therapeutics Inc …Millendo Therapeutics Inc |
MLND (43.53, 17.8, 1.76 %) | 2.25 | Millendo Therapeutics Provides Pipeline and Business Update …>> Millendo Therapeutics Provides Pipeline and Business Update >> Millendo Therapeutics Provides Pipeline and Business Update >> Millendo Therapeutics Provides Pipeline and Business Update >> Millendo Therapeutics Provides Pipeline and Business Update >> Is MLND A Good Stock To Buy Now |
Mannkind Corp …Mannkind Corp |
MNKD (963.92, 236.34, 7.24 %) | 3.63 | MannKind Announces Closing of Initial Purchasers Option to Purchase Additional Convertible …>> MannKind Announces Closing of Initial Purchasers Option to Purchase Additional Convertible Senior Notes >> MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors >> MannKind Corporation to Participate in Oppenheimer s 31st Annual Healthcare Conference >> MannKind Corporation to Participate in H C Wainwright Global Life Sciences Conference >> MannKind Corporation Prices Upsized 200 0 Million Convertible Senior Notes Offering |
Medicinova Inc …Medicinova Inc |
MNOV (337.75, 40.37, 5.72 %) | 5.63 | MNOV BARDA Contract to Support Development of MN 166 in ARDS …>> MNOV BARDA Contract to Support Development of MN 166 in ARDS >> Why MediciNova Stock Skyrocketed Today >> Benzinga s Top Ratings Upgrades Downgrades For March 10 2021 >> The Daily Biotech Pulse MediciNova Bags BARDA Contract Lilly s COVID 19 Antibody Cocktail Data Bluebird Bio Refutes Blood Cancer Link >> MediciNova Announces Partnership with BARDA to Develop MN 166 ibudilast as a Medical Countermeasure Against Chlorine Gas induced Lung Injury |
Morphic Holding Inc …Morphic Holding Inc |
MORF (2310, 19.65, 7.82 %) | 64.26 | Morphic Therapeutic Announces Pricing of Upsized 245 0 Million Public Offering …>> Morphic Therapeutic Announces Pricing of Upsized 245 0 Million Public Offering >> Why Morphic Holding Stock Is Falling Today >> The Daily Biotech Pulse Roxadustat Delay For FibroGen AstraZeneca Decision Day For KemPharm NanoViricides Jumps On COVID 19 Drug Data >> Morphic Therapeutic Announces Proposed Public Offering >> Why Morphic Holding Stock Is Skyrocketing Today |
Merck & Co Inc …Merck & Co Inc |
MRK (195670, 2530, 0.81 %) | 77.27 | KEYTRUDA pembrolizumab Plus LENVIMA lenvatinib Significantly Improved Progression …>> KEYTRUDA pembrolizumab Plus LENVIMA lenvatinib Significantly Improved Progression Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Platinum Based Chemotherapy in Phase 3 Study >> U S set to reach 100M vaccinations six weeks early >> AstraZeneca benefits outweigh risks UK drugs regulator >> Merck MRK Outpaces Stock Market Gains What You Should Know >> Merck Announces Filing of Form 10 Registration Statement in Connection with Planned Spinoff of Organon amp Co |
Marker Therapeutics Inc …Marker Therapeutics Inc |
MRKR (124.32, 33.67, 9.65 %) | 1.8 | Marker Therapeutics Inc Announces Closing of Public Offering of Common Stock …>> Marker Therapeutics Inc Announces Closing of Public Offering of Common Stock >> Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference >> Marker Therapeutics Inc Announces Pricing of Public Offering of Common Stock >> Marker Therapeutics Inc Announces Proposed Public Offering of Common Stock >> Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results |
Marinus Pharmaceuticals Inc …Marinus Pharmaceuticals Inc |
MRNS (642.4, 24.6, 17.2 %) | 15.91 | Marinus Pharmaceuticals MRNS Reports Q4 Loss Lags Revenue Estimates …>> Marinus Pharmaceuticals MRNS Reports Q4 Loss Lags Revenue Estimates >> Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter 2020 Financial Results >> Marinus Pharmaceuticals Inc to Host Earnings Call >> Marinus Pharmaceuticals Unveils New Brand as the Company Prepares for Commercialization >> Marinus Pharmaceuticals to Participate in Multiple Investor Healthcare and Life Sciences Conferences |
Mersana Therapeutics Inc …Mersana Therapeutics Inc |
MRSN (1300, 66.83, 13.16 %) | 17.11 | Mersana Therapeutics Announces Publication of Two Manuscripts Detailing Preclinical Studie …>> Mersana Therapeutics Announces Publication of Two Manuscripts Detailing Preclinical Studies of the Dolaflexin Platform and Upifitamab Rilsodotin XMT 1536 in AACR Journal Molecular Cancer Therapeutics >> Moving Average Crossover Alert Mersana Therapeutics MRSN >> Mersana Therapeutics Announces Appointment of Allene Diaz to Board of Directors >> Mersana Therapeutics to Present Three Posters at Upcoming Virtual 2021 American Association for Cancer Research Annual Meeting >> Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates |
Mirati Therapeutics Inc …Mirati Therapeutics Inc |
MRTX (9740, 45.89, 7.97 %) | 177.8 | Analyst Forecasts Just Became More Bearish On Mirati Therapeutics Inc NASDAQ MRTX …>> Analyst Forecasts Just Became More Bearish On Mirati Therapeutics Inc NASDAQ MRTX >> 7 Biotech Stocks With Catalysts That Go Far Beyond Covid 19 Vaccines >> 7 Pharmaceutical Stocks Working on Their Next Blockbuster >> Mirati Therapeutics to Present Late Breaking Data That Advance the Understanding of Synthetic Lethal PRMT5 Inhibitors in MTAP Deleted Cancers at AACR 2021 >> 15 Fastest Growing Biotech Companies in the US |
Merus N.V …Merus N.V |
MRUS (865.26, 17.76, 3.83 %) | 21.99 | Merus N V MRUS Reports Q4 Loss Tops Revenue Estimates …>> Merus N V MRUS Reports Q4 Loss Tops Revenue Estimates >> Merus Announces Financial Results for the Fourth Quarter and Full Year 2020 and Provides Business Update >> Merus Announces Poster Presentations for Zenocutuzumab and MCLA 129 at the American Association for Cancer Research 2021 Annual Meeting >> Merus to Participate in a Fireside Chat at the 33rd Annual Roth Conference >> Merus N V MRUS May Report Negative Earnings Know the Trend Ahead of Q4 Release |
Maravai LifeSciences Holdings Inc – Clas …Maravai LifeSciences Holdings Inc – Class A |
MRVI (10070, 95.76, 2.87 %) | 35.15 | Maravai LifeSciences Offers End to End mRNA Production with the Launch of TriLink BioTechn …>> Maravai LifeSciences Offers End to End mRNA Production with the Launch of TriLink BioTechnologies Plasmid DNA Manufacturing Services >> Analysts Just Made A Dazzling Upgrade To Their Maravai LifeSciences Holdings Inc NASDAQ MRVI Forecasts >> Maravai LifeSciences Holdings Inc Class A Common Stock MRVI Q4 2020 Earnings Call Transcript >> Dow Jones Futures Signal Stock Market Rally Rebound Vaccine Play Soars >> Dow Jones Futures Signal Stock Market Rally Rebound Vaccine Play Soars |
Metacrine Inc …Metacrine Inc |
MTCR (212.01, 20.34, 0.6 %) | 7.8 | Metacrine Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financia …>> Metacrine Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results >> Metacrine Inc to Host Earnings Call >> Metacrine to Present Final Results from Phase 1 Trial of MET642 an Optimized FXR Agonist at the 2021 NASH TAG Conference >> Metacrine Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call >> Metacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASH |
Molecular Templates Inc …Molecular Templates Inc |
MTEM (663.63, 35.63, 2.94 %) | 11.4 | Molecular Templates Inc Reports Fourth Quarter 2020 Financial Results …>> Molecular Templates Inc Reports Fourth Quarter 2020 Financial Results >> Molecular Templates to Participate in Upcoming Virtual Investor Conferences >> Newsflash Molecular Templates Inc NASDAQ MTEM Analysts Have Been Trimming Their Revenue Forecasts >> Molecular Templates Inc Announces Pricing of 75 9 Million Public Equity Offering >> Molecular Templates Inc Announces Proposed Public Offering of Common Stock |
Matinas Biopharma Holdings Inc …Matinas Biopharma Holdings Inc |
MTNB (229.39, 184.06, 8.43 %) | 1.15 | Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 …>> Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on March 29 2021 >> Matinas BioPharma to Present at the Barclays Global Healthcare Conference >> Matinas BioPharma Announces Topline Results from ENHANCE IT Study of LYPDISO Against Vascepa >> Matinas BioPharma Announces Topline Results from ENHANCE IT Study of LYPDISO Against Vascepa >> Matinas BioPharma Announces Topline Results from ENHANCE IT Study of LYPDISO Against Vascepa |
Myriad Genetics, Inc. …Myriad Genetics, Inc. |
MYGN (2350, 73.21, 6.87 %) | 29.53 | Myriad Genetics MYGN Collaborates to Advance Oncology Care …>> Myriad Genetics MYGN Collaborates to Advance Oncology Care >> Myriad Genetics Joins Forces with Intermountain Precision Genomics for a Comprehensive Offering of Germline and Somatic Tumor Testing Services >> Myriad Genetics Inc MYGN Q2 2021 Earnings Call Transcript >> Recap Myriad Genetics Q2 Earnings >> Myriad Genetics Delivers 6 Sequential Revenue Growth Company Continues to Execute Strategic Transformation Plan |
Myovant Sciences Ltd …Myovant Sciences Ltd |
MYOV (2230, 32.77, 12.27 %) | 24.14 | Why A Controversial Biogen Drug Could Become A Major Blockbuster …>> Why A Controversial Biogen Drug Could Become A Major Blockbuster >> Myovant Sciences to Present at Upcoming Investor Conferences >> The Daily Biotech Pulse Lily Rigel Licensing Deal vTv Starts Early Stage Psoriasis Study Immunic Data Readout >> Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids >> Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A 08 |
Nature`s Sunshine Products, Inc. …Nature`s Sunshine Products, Inc. |
NATR (402.96, 18.48, 0.68 %) | 19.83 | Nu Skin Enterprises Races Higher From Coronavirus Crash Falls Rises Again …>> Nu Skin Enterprises Races Higher From Coronavirus Crash Falls Rises Again >> What Kind Of Investors Own Most Of Nature s Sunshine Products Inc NASDAQ NATR >> Nature s Sunshine Reports Historic Fourth Quarter and Full Year 2020 Results Introduces Capital Allocation Strategy >> Nature s Sunshine Products Inc to Host Earnings Call >> Natures Sunshine Sets Fourth Quarter and Full Year 2020 Conference Call for Wednesday March 10 2021 at 5 00 p m ET |
Navidea Biopharmaceuticals Inc …Navidea Biopharmaceuticals Inc |
NAVB (61.13, 18.43, 1.03 %) | 2.25 | Navidea Biopharmaceuticals to Host Fourth Quarter 2020 Earnings Conference Call and Corpor …>> Navidea Biopharmaceuticals to Host Fourth Quarter 2020 Earnings Conference Call and Corporate Update >> Navidea Biopharmaceuticals to Present at the H C Wainwright Global Life Sciences Virtual Conference >> Navidea Biopharmaceuticals Announces 5 Million Private Placement with Existing Investor >> The Daily Biotech Pulse Dynavax Poaches GSK Vaccine Exec KalVista Jumps On Data Readout Corcept Issues Negative Preannouncement >> The Daily Biotech Pulse Dynavax Poaches GSK Vaccine Exec KalVista Jumps On Data Readout Corcept Issues Negative Preannouncement |
NeuBase Therapeutics Inc …NeuBase Therapeutics Inc |
NBSE (206.65, 19.22, 4.59 %) | 8.42 | Here s What NeuBase Therapeutics Inc s NASDAQ NBSE Shareholder Ownership Structure Loo …>> Here s What NeuBase Therapeutics Inc s NASDAQ NBSE Shareholder Ownership Structure Looks Like >> NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical amp Scientific Conference >> NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021 >> NeuBase Therapeutics Reports Financial Results for the First Quarter of Fiscal Year 2021 >> NeuBase Therapeutics Announces Acquisition of Gene Modulating Technology from Vera Therapeutics |
Novabay Pharmaceuticals Inc …Novabay Pharmaceuticals Inc |
NBY (43.1, 31.25, 2.13 %) | 1.02 | NovaBay Pharmaceuticals to Hold 2020 Fourth Quarter and Full Year Conference Call on March …>> NovaBay Pharmaceuticals to Hold 2020 Fourth Quarter and Full Year Conference Call on March 25 >> NovaBay Pharmaceuticals to Participate in Virtual 33rd Annual Roth Conference >> NovaBay CEO Issues Letter to Stockholders >> NovaBay CEO Issues Letter to Stockholders >> NovaBay CEO Issues Letter to Stockholders |
Neos Therapeutics Inc …Neos Therapeutics Inc |
NEOS (57.37, 49.22, 2.39 %) | 1.18 | Why Are Neos Therapeutics Aytu BioScience Stocks Soaring Today …>> Why Are Neos Therapeutics Aytu BioScience Stocks Soaring Today >> Glass Lewis a Leading Independent Proxy Advisory Firm Recommends Neos Therapeutics Stockholders Vote FOR the Pending Merger With Aytu BioScience >> Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote FOR the Pending Merger With Aytu BioScience >> Moore Kuehn Encourages MTSC SPRQ NEOS and PRSP Investors to Contact Law Firm >> Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18 2021 |
Minerva Neurosciences Inc …Minerva Neurosciences Inc |
NERV (133.46, 41.13, 5.95 %) | 3.1 | Minerva Neurosciences NERV Q4 2020 Earnings Call Transcript …>> Minerva Neurosciences NERV Q4 2020 Earnings Call Transcript >> Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates >> Minerva Neurosciences Inc to Host Earnings Call >> The Week Ahead In Biotech March 7 13 Conference Presentations And More Earnings >> Minerva Neurosciences to Report Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates on March 8 2021 |
Ngm Biopharmaceuticals Inc …Ngm Biopharmaceuticals Inc |
NGM (2340, 50.63, 3.39 %) | 30.34 | Companies Like NGM Biopharmaceuticals NASDAQ NGM Are In A Position To Invest In Growth …>> Companies Like NGM Biopharmaceuticals NASDAQ NGM Are In A Position To Invest In Growth >> NGM Biopharmaceuticals NGM Reports Q4 Loss Lags Revenue Estimates >> NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results >> NGM Bio Initiates Expansion of Ongoing Phase 1b Proof of Concept Study of NGM120 in Patients with Metastatic Pancreatic Cancer >> NGM Bio to Present at the Cowen 41st Annual Health Care Conference |
Nektar Therapeutics …Nektar Therapeutics |
NKTR (4160, 177.86, 11.95 %) | 22.1 | Nektar NKTR Q4 Earnings and Revenues Top Pipeline On Track …>> Nektar NKTR Q4 Earnings and Revenues Top Pipeline On Track >> Need To Know The Consensus Just Cut Its Nektar Therapeutics NASDAQ NKTR Estimates For 2021 >> Nektar Posts Better Than Feared Quarterly Loss Misses On Revenues >> Nektar Therapeutics NKTR Q4 2020 Earnings Call Transcript >> Nektar Therapeutics Q4 Earnings Insights |
Nkarta Inc …Nkarta Inc |
NKTX (1480, 27.72, 5.12 %) | 41.75 | Nkarta Announces February and March 2021 Investor Conference Schedule …>> Nkarta Announces February and March 2021 Investor Conference Schedule >> Is NKTX A Good Stock To Buy Now >> Fate Stock Soars After Novel Natural Killer Treatment for Cancers Makes a Splash >> Nkarta Reports Third Quarter 2020 Financial Results >> Nkarta Announces Treatment of First Patient in First in Human Clinical Trial of Engineered NKG2D Based NK Cell Cancer Immunotherapy NKX101 |
Neoleukin Therapeutics Inc …Neoleukin Therapeutics Inc |
NLTX (495.44, 32.01, 9.3 %) | 11.47 | Neoleukin Therapeutics to Host 2020 Financial Results Conference Call and Webcast on March …>> Neoleukin Therapeutics to Host 2020 Financial Results Conference Call and Webcast on March 25 2021 >> Neoleukin Therapeutics to Present at H C Wainwright Global Life Sciences Conference >> Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days >> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neoleukin Therapeutics Inc NLTX >> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neoleukin Therapeutics Inc NLTX |
Novan Inc …Novan Inc |
NOVN (260.9, 130.56, 4.07 %) | 1.56 | NOVN B SIMPLE4 Enrollment Complete …>> NOVN B SIMPLE4 Enrollment Complete >> Novan to Present at the H C Wainwright Global Life Sciences Conference >> Novan Bolsters Commercialization Expertise with Election of Steven D Skolsky to Board of Directors >> Novan Reports Full Year 2020 Financial Results and Provides Corporate Update >> Novan Completes Enrollment in B SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum |
NeuroBo Pharmaceuticals Inc …NeuroBo Pharmaceuticals Inc |
NRBO (81.19, 15.78, 0.89 %) | 4.74 | NeuroBo Pharmaceuticals to Participate in H C Wainwright Global Life Sciences Conference …>> NeuroBo Pharmaceuticals to Participate in H C Wainwright Global Life Sciences Conference >> NeuroBo Pharmaceuticals Closes 10 0 Million Private Placement >> NeuroBo Pharmaceuticals Closes 10 0 Million Private Placement >> NeuroBo Pharmaceuticals Closes 10 0 Million Private Placement >> NeuroBo Pharmaceuticals Announces 10 0 Million Private Placement |
Nurix Therapeutics Inc …Nurix Therapeutics Inc |
NRIX (1840, 19.83, 12.76 %) | 38.12 | Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pedia …>> Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers >> Nurix Therapeutics Announces Presentation of NX 1607 Preclinical Data at AACR >> Nurix Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares >> Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences >> Nurix Therapeutics Announces Pricing of Upsized Public Offering of Common Stock |
Intec Pharma Ltd …Intec Pharma Ltd |
NTEC (19.5, 3.82, 14.29 %) | 4.43 | INTEC PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick amp …>> INTEC PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick amp Foti LLC Investigates Merger of Intec Pharma Ltd NTEC >> Intec Pharma Announces Filing of 2020 Annual Report on Form 10 K >> INVESTIGATION ALERT Halper Sadeh LLP Investigates STAY GNMK RMBL FI NTEC Shareholders are Encouraged to Contact the Firm >> Intec Pharma and Decoy Biosystems Announce Merger Agreement >> Here s Why We re Watching Intec Pharma s NASDAQ NTEC Cash Burn Situation |
Intellia Therapeutics Inc …Intellia Therapeutics Inc |
NTLA (4570, 52.88, 15.29 %) | 62.08 | Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR based In Vivo Editi …>> Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR based In Vivo Editing of Bone Marrow at Keystone eSymposium >> The Intellia Therapeutics NASDAQ NTLA Share Price Is Up 360 And Shareholders Are Delighted >> 15 Fastest Growing Biotech Companies in the US >> Intellia NTLA Miss Earnings amp Revenues Estimates in Q4 >> Intellia Therapeutics Inc NTLA Q4 2020 Earnings Call Transcript |
Novus Therapeutics Inc …Novus Therapeutics Inc |
NVUS (0, 0, 0 %) | 14.6 | … |
Nymox Pharmaceutical Corp …Nymox Pharmaceutical Corp |
NYMX (204.7, 42.18, 8.99 %) | 2.65 | Nymox Provides Update on Regulatory Filing Activities …>> Nymox Provides Update on Regulatory Filing Activities >> Nymox Provides Update on Regulatory Filing Activities >> Nymox Provides Update on Regulatory Filing Activities >> What You Need To Know About Nymox Pharmaceutical Corporation s NASDAQ NYMX Investor Composition >> What You Need To Know About Nymox Pharmaceutical Corporation s NASDAQ NYMX Investor Composition |
Ocular Therapeutix Inc …Ocular Therapeutix Inc |
OCUL (1490, 66.76, 7.6 %) | 19.71 | Ocular Therapeutix OCUL Reports Q4 Loss Lags Revenue Estimates …>> Ocular Therapeutix OCUL Reports Q4 Loss Lags Revenue Estimates >> Ocular Therapeutix Reports Fourth Quarter and Year End 2020 Financial Results and Business Update >> Ocular Therapeutix Inc to Host Earnings Call >> The Daily Biotech Pulse Fulgent s Big Quarter Gilead Awaits FDA Decision Apellis Winds Up COVID 19 Study >> Ocular Therapeutix Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA dexamethasone ophthalmic insert for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis |
Ocuphire Pharma Inc …Ocuphire Pharma Inc |
OCUP (81.85, 10.42, 0.17 %) | 6.92 | Ocuphire Announces MIRA 2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets P …>> Ocuphire Announces MIRA 2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint >> Ocuphire Announces Financial Results for the Full Year 2020 and Provides Corporate Update >> Ocuphire Announces Publication of MIRA 1 Phase 2b Results in Optometry and Visual Science Demonstrating Reduction of Pharmacologically Induced Mydriasis by Nyxol >> Ocuphire to Participate in March Investor Conferences >> Ocuphire Initiates Enrollment in VEGA 1 Phase 2 Trial Investigating Nyxol in Presbyopia |
Oragenics Inc …Oragenics Inc |
OGEN (118.4, 108.01, 2.36 %) | 0.9975 | Oragenics COVID 19 Related Deal Pushes The Stock Higher …>> Oragenics COVID 19 Related Deal Pushes The Stock Higher >> Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID 19 Vaccine >> Oragenics to Participate in Two Investment Conferences During March >> Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling 21 9 Million and the Redemption of Its Series C Preferred Stock >> SARS CoV 2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice |
Olema Pharmaceuticals Inc …Olema Pharmaceuticals Inc |
OLMA (1740, 34.65, 1.34 %) | 44.59 | Olema Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Co …>> Olema Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates >> Olema Oncology Announces Late Breaking Poster Presentation at the American Association for Cancer Research AACR Annual Meeting 2021 >> Olema Oncology to Participate at Upcoming Virtual Investor Conferences >> We re Hopeful That Olema Pharmaceuticals NASDAQ OLMA Will Use Its Cash Wisely >> Biotech IPO Frenzy Brings in 3 Stocks to Buy |
Omeros Corporation …Omeros Corporation |
OMER (1220, 58.93, 21.3 %) | 18.94 | Omeros OMER Reports Q4 Loss Misses Revenue Estimates …>> Omeros OMER Reports Q4 Loss Misses Revenue Estimates >> Recap Omeros Q4 Earnings >> Omeros Corporation Reports Fourth Quarter and Year End 2020 Financial Results >> Omeros Corp to Host Earnings Call >> Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 1 2021 |
Oncorus Inc …Oncorus Inc |
ONCR (412.28, 12.19, 1.88 %) | 15.68 | Oncorus Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business …>> Oncorus Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights >> Oncorus Secures 57M Via Equity At 9 Discount >> Oncorus Announces Pricing of Public Offering of Common Stock >> Oncorus Announces Proposed Public Offering of Common Stock >> Oncorus Announces Publication of Preclinical Data Demonstrating Potent Systemic Antitumor Activity of its Clinical Stage Oncolytic Herpes Simplex Viral Immunotherapy Product Candidate ONCR 177 |
OncoSec Medical Inc …OncoSec Medical Inc |
ONCS (205.53, 15.46, 2.54 %) | 5.74 | OncoSec Announces Publication in Clinical Cancer Research of Data Supporting the Therapeut …>> OncoSec Announces Publication in Clinical Cancer Research of Data Supporting the Therapeutic Potential of Lead Product Candidate TAVO in Triple Negative Breast Cancer >> OncoSec Announces Approval of 2 5 Million in NJEDA NOL Program Tax Benefits >> OncoSec Appoints Bridget O Keeffe Ph D as Vice President of Clinical Development >> What Type Of Shareholders Own The Most Number of OncoSec Medical Incorporated NASDAQ ONCS Shares >> What Type Of Shareholders Own The Most Number of OncoSec Medical Incorporated NASDAQ ONCS Shares |
Oncternal Therapeutics Inc …Oncternal Therapeutics Inc |
ONCT (368.81, 19.69, 0.45 %) | 8.36 | Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5 …>> Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635 c 4 >> We re Not Very Worried About Oncternal Therapeutics NASDAQ ONCT Cash Burn Rate >> Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2020 Financial Results >> Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update >> Oncternal Therapeutics to Participate in March Investor Conferences |
Onconova Therapeutics Inc …Onconova Therapeutics Inc |
ONTX (262.4, 173.37, 10.52 %) | 1.12 | Onconova Therapeutics Reports Full Year 2020 Financial Results Provides Business Update …>> Onconova Therapeutics Reports Full Year 2020 Financial Results Provides Business Update >> Onconova Therapeutics Inc to Host Earnings Call >> Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results >> Onconova Therapeutics to Participate in Three Investment Conferences During the Month of March >> Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement |
Opko Health Inc …Opko Health Inc |
OPK (3280, 401.33, 24.07 %) | 4.63 | Insider Buys OPKO Health s Stock …>> Insider Buys OPKO Health s Stock >> Insider Buys OPKO Health s Shares >> ROCE Insights For OPKO Health >> Opko Health s Q4 Service Revenues More Than Double Due To COVID 19 Testing Services >> Here s Why OPKO Health s Solid Q4 Results Didn t Send Shares Flying Higher |
OptiNose Inc …OptiNose Inc |
OPTN (200.14, 27.89, 17.13 %) | 3.84 | OptiNose OPTN Reports Q4 Loss Lags Revenue Estimates …>> OptiNose OPTN Reports Q4 Loss Lags Revenue Estimates >> Optinose Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights >> OptiNose Inc to Host Earnings Call >> Earnings Preview for OptiNose >> Optinose Announces Reporting Date for Fourth Quarter 2020 Financial Results |
ORIC Pharmaceuticals Inc …ORIC Pharmaceuticals Inc |
ORIC (1080, 18.62, 18.59 %) | 26.84 | ORIC Pharmaceuticals to Present Posters on Four Programs at the 2021 American Association …>> ORIC Pharmaceuticals to Present Posters on Four Programs at the 2021 American Association for Cancer Research AACR Annual Meeting >> ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences >> Spiking Yields Pierce Bonds amp Growth Stocks >> ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences >> How Much Of ORIC Pharmaceuticals Inc NASDAQ ORIC Do Institutions Own |
Oramed Pharmaceuticals, Inc …Oramed Pharmaceuticals, Inc |
ORMP (250.86, 23.57, 7.38 %) | 9.32 | Premas Biotech and Oramed Announce Oral COVID 19 Vaccine Candidate That Produces Antibodie …>> Premas Biotech and Oramed Announce Oral COVID 19 Vaccine Candidate That Produces Antibodies After a Single Dose >> Oramed Forms a Joint Venture Oravax Medical Inc for the Development of Novel Oral COVID 19 Vaccines >> Oramed Reaches 25 Randomization in World s First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol >> Oramed to Present at H C Wainwright Global Life Sciences Conference 2021 >> Oramed Issues Letter to Shareholders |
Otonomy Inc …Otonomy Inc |
OTIC (143.61, 48.2, 4.19 %) | 2.82 | Are Options Traders Betting on a Big Move in Otonomy OTIC Stock …>> Are Options Traders Betting on a Big Move in Otonomy OTIC Stock >> Otonomy to Participate in Three Upcoming Investor Conferences >> ROCE Insights For Otonomy >> Otonomy stock loses half its value after disappointing trial results of vertigo treatment >> Otonomy s OTIVIDEX Fails To Separate From Placebo In Inner Ear Disorder Study |
Ovid Therapeutics Inc …Ovid Therapeutics Inc |
OVID (282.01, 41.28, 7.81 %) | 4.22 | Ovid Posts Larger Than Feared Quarterly Loss Revenue Beat …>> Ovid Posts Larger Than Feared Quarterly Loss Revenue Beat >> Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results Provides Corporate Update for 2021 >> What Kind Of Investors Own Most Of Ovid Therapeutics Inc NASDAQ OVID >> The Daily Biotech Pulse KemPharm ADHD Drug Gets The Nod MediciNova Shelves Vaccine Study >> Takeda buys epilepsy treatment rights from Ovid for up to 856 mln |
Prestige Consumer Healthcare Inc …Prestige Consumer Healthcare Inc |
PBH (2300, 49.42, 6.8 %) | 45.96 | Prestige Consumer Healthcare Inc Announces Upsize and Pricing of 600 Million Senior Note …>> Prestige Consumer Healthcare Inc Announces Upsize and Pricing of 600 Million Senior Notes >> Prestige Consumer Healthcare Inc Announces Offering of 500 Million Senior Notes >> Prestige Brands Inc Moody s upgrades Prestige Brands CFR to B1 outlook stable >> Update Prestige Consumer Healthcare NYSE PBH Stock Gained 25 In The Last Three Years >> 10 Cheap Healthcare Stocks To Buy Now |
Puma Biotechnology Inc …Puma Biotechnology Inc |
PBYI (436.55, 34.44, 14.17 %) | 10.32 | The wild ride that made Rudy Giuliani Kraken lawyer Sidney Powell and Fox News targets …>> The wild ride that made Rudy Giuliani Kraken lawyer Sidney Powell and Fox News targets in the mother of all defamation cases >> Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635 c 4 >> Polyphor Announces Financial Results for the Full Year 2020 >> Puma Biotechnology to Present at the Barclays Global Healthcare Conference >> Puma Biotechnology to Present at the H C Wainwright Global Life Sciences Conference |
Pacira BioSciences Inc …Pacira BioSciences Inc |
PCRX (3080, 43.1, 15.66 %) | 69.51 | Halozyme Stock Joins The 80 Plus RS Rating Club …>> Halozyme Stock Joins The 80 Plus RS Rating Club >> Stocks Showing Leadership Covid Recovery Play Ligand Earns Key Rating Jump >> Pacira BioSciences Reports Preliminary Net Product Sales of 36 2 Million for February 2021 >> Pacira BioSciences to Present at the 2021 Barclays Global Healthcare Conference >> Pacira s PCRX Q4 Earnings Top Estimates Revenues Miss |
PDS Biotechnology Corporation …PDS Biotechnology Corporation |
PDSB (109.41, 16.11, 2.92 %) | 4.92 | PDS Biotech Reports Financial Results for the Year Ended December 31 2020 and Provides Bu …>> PDS Biotech Reports Financial Results for the Year Ended December 31 2020 and Provides Business Update >> PDS Biotechnology Corp to Host Earnings Call >> PDS Biotech Announces Presentation and Panel Participation at the Benzinga Biotech Small Cap Conference >> PDS Biotech Announces that its COVID 19 Vaccine Consortium Received a Commitment from The Ministry of Science Technology and Innovation of Brazil MCTI to fund Clinical Development and Commercialization of a Versamune Based COVID 19 Vaccine with an Award of up to Approximately US 60 million >> PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter and Full Year 2020 Financial Results |
Pfizer Inc. …Pfizer Inc. |
PFE (198310, 5570, 1.21 %) | 35.77 | I still have a lot of confidence in the Astrazeneca vaccine Doctor …>> I still have a lot of confidence in the Astrazeneca vaccine Doctor >> Bidens vaccine goal was not a moonshot challenge Analyst >> Supply is soon going to outmatch demand for the vaccine Doctor >> Students can now sit 3 feet apart CDC says >> UPDATE 1 Mexican president thanks Biden for COVID shots to ease shortage |
PhaseBio Pharmaceuticals Inc …PhaseBio Pharmaceuticals Inc |
PHAS (129.82, 26.05, 12.07 %) | 3.875 | PhaseBio Announces Pricing of Public Offering of Common Stock …>> PhaseBio Announces Pricing of Public Offering of Common Stock >> PhaseBio Announces Proposed Public Offering of Common Stock >> PhaseBio Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights >> PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab >> Reflecting on PhaseBio Pharmaceuticals NASDAQ PHAS Share Price Returns Over The Last Year |
Phio Pharmaceuticals Corp …Phio Pharmaceuticals Corp |
PHIO (24.65, 5.76, 5.35 %) | 2.95 | Phio Pharmaceuticals To Present New Data on PD 1 Targeting INTASYL at the 2021 American As …>> Phio Pharmaceuticals To Present New Data on PD 1 Targeting INTASYL at the 2021 American Association for Cancer Research AACR Annual Meeting >> Phio Pharmaceuticals and AgonOx Inc Announce Collaboration on Clinical Development of Novel T Cell based Cancer Immunotherapies >> Phio Pharmaceuticals Announces Closing of 7 7 Million Registered Direct Offering of Common Stock Priced At the Market >> Phio Pharmaceuticals Announces 7 7 Million Registered Direct Offering of Common Stock Priced At the Market >> Phio Pharmaceuticals Announces Closing of 14 0 Million Private Placement Priced At the Market |
PLx Pharma Inc. …PLx Pharma Inc. |
PLXP (219.53, 7.77, 8.6 %) | 10.07 | PLx Pharma Inc Reports Fourth Quarter and Full Year 2020 Results and Provides Business Up …>> PLx Pharma Inc Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update >> PLx Pharma Inc to Host Earnings Call >> PLx Pharma Inc to Present at the Oppenheimer 31st Annual Healthcare Conference >> What Is The Ownership Structure Like For PLx Pharma Inc NASDAQ PLXP >> PLx Pharma Inc to Discuss 2020 Fourth Quarter Financial Results on March 12 2021 Conference Call and Provide Business Update |
PMV Pharmaceuticals Inc …PMV Pharmaceuticals Inc |
PMVP (1770, 36.86, 4.73 %) | 40.29 | PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Ass …>> PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research AACR Annual Meeting 2021 >> PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights >> PMV Pharma Appoints p53 Pioneer Dr Guillermina Lozano to Scientific Advisory Board >> We re Not Worried About PMV Pharmaceuticals NASDAQ PMVP Cash Burn >> Is PMVP A Good Stock To Buy Now |
Praxis Precision Medicines Inc …Praxis Precision Medicines Inc |
PRAX (1660, 37.7, 2.14 %) | 38.64 | Praxis Precision Medicines Inc PRAX Q4 2020 Earnings Call Transcript …>> Praxis Precision Medicines Inc PRAX Q4 2020 Earnings Call Transcript >> Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results >> Praxis Precision Medicines Inc to Host Earnings Call >> Praxis Precision Medicines to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday March 17 2021 >> Praxis Precision Medicines Partners With Ciitizen to Improve Patient Guided Drug Development |
PainReform Ltd …PainReform Ltd |
PRFX (50.52, 0, 0 %) | 5 | PainReform Provides Year End Business Update and Reports Progress Towards Commencing Phase …>> PainReform Provides Year End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF 110 for Non Opiate Post Operative Pain Relief >> PainReform to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference >> PainReform Announces 6 0 Million Private Placement >> PainReform to Present at the H C Wainwright BioConnect 2021 Conference >> PainReform to Present at the H C Wainwright BioConnect 2021 Conference |
Perrigo Company plc …Perrigo Company plc |
PRGO (5560, 131.77, 4.92 %) | 41.8 | Analyzing Perrigo s Ex Dividend Date …>> Analyzing Perrigo s Ex Dividend Date >> Perrigo Company plc s NYSE PRGO Intrinsic Value Is Potentially 54 Above Its Share Price >> Perrigo Company PLC PRGO Q4 2020 Earnings Call Transcript >> Perrigo Stock Is Soaring Because of a Deal Its CEO Says More Good News Is Coming >> Perrigo PRGO Misses on Q4 Earnings to Sell Generic Unit |
Prelude Therapeutics Inc …Prelude Therapeutics Inc |
PRLD (2660, 16.06, 8.85 %) | 52.61 | Prelude Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Pro …>> Prelude Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Update >> Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences >> Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares >> Prelude Therapeutics Announces Pricing of Upsized Public Offering >> Prelude Therapeutics Announces Launch of Proposed Public Offering |
ProPhase Labs Inc …ProPhase Labs Inc |
PRPH (109.54, 9.45, 0.79 %) | 7.39 | ProPhase Labs to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call …>> ProPhase Labs to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Wednesday March 31 2021 at 4 30 p m Eastern Time >> Analysts Expect ProPhase Labs Inc NASDAQ PRPH To Breakeven Soon >> ProPhase Labs Begins Advanced Saliva based Viral PCR Multiplex Testing for COVID 19 Influenza A amp B and Other Viruses After FDA Confirmation of Two Emergency Use Authorizations >> ProPhase Labs Exceeding Initial Goals as Covid 19 Lab Testing Business Ramps up >> ProPhase Labs Announces Opening of Large CLIA Lab Covid Testing Facility in Garden City New York |
ProQR Therapeutics N.V …ProQR Therapeutics N.V |
PRQR (273.84, 44.64, 2.01 %) | 5.51 | Did You Miss ProQR Therapeutics NASDAQ PRQR 75 Share Price Gain …>> Did You Miss ProQR Therapeutics NASDAQ PRQR 75 Share Price Gain >> ProQR to Present Results from Phase 1 2 Trial of QR 421a for Usher Syndrome >> ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference >> ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results >> ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome |
Prothena Corporation plc …Prothena Corporation plc |
PRTA (1020, 39.9, 2.46 %) | 23.9 | Why Is Prothena PRTA Up 46 8 Since Last Earnings Report …>> Why Is Prothena PRTA Up 46 8 Since Last Earnings Report >> Why Is Prothena PRTA Up 46 8 Since Last Earnings Report >> The Daily Biotech Pulse Contrasting COVID 19 Treatment Readouts From Roche Vir Delay In Kadmon s FDA Review Alzheimer s Data From Prothena >> Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD PD 2021 >> Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD PD 2021 |
Paratek Pharmaceuticals Inc. …Paratek Pharmaceuticals Inc. |
PRTK (368.9, 41.56, 10.77 %) | 7.85 | Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635 c 4 …>> Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635 c 4 >> Paratek Pharmaceuticals PRTK Q4 2020 Earnings Call Transcript >> Paratek Pharmaceuticals Announces Full Year 2020 Total Revenue of 46 9 Million including NUZYRA omadacycline Net U S Sales of 38 8 Million >> Paratek Pharmaceuticals Inc to Host Earnings Call >> Paratek Pharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference |
PTC Therapeutics Inc …PTC Therapeutics Inc |
PTCT (3840, 66.17, 7.21 %) | 55.51 | Results from the Second Year of Evrysdi risdiplam Treatment Demonstrated Sustained Impro …>> Results from the Second Year of Evrysdi risdiplam Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients >> PTC Presents Results from a Real World Study of Steroid Switching in the Treatment of Patients with Dystrophinopathies >> Spinal Muscular Atrophy SMA Foundation and PTC Therapeutics Expand Partnership to Advance Drug Discovery and Development Research in Regenerative Medicine >> CHMP Adopts Positive Opinion for Evrysdi for the Treatment of Spinal Muscular Atrophy in Adults and Children Aged Two Months and Older >> PTC Therapeutics Inc to Host Earnings Call |
Protagonist Therapeutics Inc …Protagonist Therapeutics Inc |
PTGX (1360, 27.59, 10.03 %) | 29.41 | Protagonist Therapeutics PTGX Reports Q4 Loss Tops Revenue Estimates …>> Protagonist Therapeutics PTGX Reports Q4 Loss Tops Revenue Estimates >> Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update >> Protagonist Therapeutics Inc to Host Earnings Call >> Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results >> Will Protagonist Therapeutics PTGX Report Negative Q4 Earnings What You Should Know |
Proteostasis Therapeutics Inc …Proteostasis Therapeutics Inc |
PTI (0, 0, 0 %) | 1.11 | … |
Palatin Technologies Inc. …Palatin Technologies Inc. |
PTN (176.35, 221.15, 3.68 %) | 0.7697 | New Strong Sell Stocks for March 11th …>> New Strong Sell Stocks for March 11th >> Palatin Technologies to Participate in H C Wainwright Global Life Sciences Virtual Conference >> Palatin Technologies Inc to Host Earnings Call >> Palatin Technologies Inc Reports Second Quarter Fiscal Year 2021 Financial Results and Recent Business Highlights >> Palatin Technologies Inc to Report Second Quarter Fiscal Year 2021 Results Teleconference and Webcast to be held on February 17 2021 |
Petros Pharmaceuticals Inc …Petros Pharmaceuticals Inc |
PTPI (32.35, 6.11, 1.03 %) | 3.2 | Recently Published Research on Stendra avanafil for Endothelial Function in Men with Er …>> Recently Published Research on Stendra avanafil for Endothelial Function in Men with Erectile Dysfunction to Initiate Petros Pharmaceuticals Plans for Expanded Labeling >> Petros Pharmaceuticals Welcomes Dr Mohit Khera to Steering Committee to Expand into Non Rx Status for Stendra avanafil >> Petros Pharmaceuticals Establishes Steering Committee to Expand into Non Rx Status for Stendra avanafil >> Petros Pharmaceuticals Establishes Steering Committee to Expand into Non Rx Status for Stendra avanafil >> Petros Pharmaceuticals Establishes Steering Committee to Expand into Non Rx Status for Stendra avanafil |
Pulmatrix Inc …Pulmatrix Inc |
PULM (85.87, 32.24, 4.16 %) | 1.45 | Pulmatrix Provides a Pipeline and Business Update …>> Pulmatrix Provides a Pipeline and Business Update >> Pulmatrix Announces Closing of 40 Million Registered Direct Offering >> Pulmatrix Announces 40 Million Registered Direct Offering Priced At the Market under Nasdaq Rules >> Pulmatrix Announces 40 Million Registered Direct Offering Priced At the Market under Nasdaq Rules >> Pulmatrix Reports Third Quarter 2020 Financial Results and Business Updates |
Qualigen Therapeutics Inc …Qualigen Therapeutics Inc |
QLGN (83.88, 21.15, 7.61 %) | 3.05 | Qualigen Therapeutics Inc to present at the Benzinga Biotech Small Cap Conference …>> Qualigen Therapeutics Inc to present at the Benzinga Biotech Small Cap Conference >> Qualigen Therapeutics Inc Promotes Shishir Sinha to Chief Operating Officer Position >> Qualigen Therapeutics Inc to present at the Oppenheimer 31st Annual Healthcare Conference >> Qualigen Therapeutics Secures Option to Negotiate License for G Quadruplex Anti Cancer Technology from UCL >> Qualigen Therapeutics Announces Completion of Milestone Related to the License and Technology Transfer of its FastPack Diagnostics Products in China |
Quotient Ltd …Quotient Ltd |
QTNT (424.61, 75.73, 5.44 %) | 4.04 | Credit Activity of Renters Much Stronger than Macroeconomic Indicators Would Suggest …>> Credit Activity of Renters Much Stronger than Macroeconomic Indicators Would Suggest >> Penny Stocks to Buy Using Technical Analysis for March 2021 >> Quotient Limited Announces Equity Awards >> Quotient Limited to Participate in the Cowen 41st Annual Healthcare Conference >> Quotient Limited Announces Manuel Mendez as Chief Executive Officer |
uniQure N.V. …uniQure N.V. |
QURE (1580, 39.88, 7.62 %) | 32.67 | UniQure QURE Reports Q4 Loss Lags Revenue Estimates …>> UniQure QURE Reports Q4 Loss Lags Revenue Estimates >> uniQure Announces 2020 Financial Results and Highlights Recent Company Progress >> uniQure to Participate in Multiple Upcoming Industry Conferences in March >> Is uniQure NASDAQ QURE Using Debt Sensibly >> The Bullish Piece Of News That Caused This Gene Therapy Stock To Pop |
Ultragenyx Pharmaceutical Inc. …Ultragenyx Pharmaceutical Inc. |
RARE (8620, 63.41, 9.25 %) | 119.99 | Why Is Ultragenyx RARE Down 22 Since Last Earnings Report …>> Why Is Ultragenyx RARE Down 22 Since Last Earnings Report >> Biotech stocks are a buy especially these 18 picks >> Ultragenyx s RARE IND for mRNA Therapy UX053 Cleared by FDA >> FDA Approves New Drug Application For Ultragenyxs mRNA Therapy Shares Drop >> Ultragenyx Announces FDA Clearance of Investigational New Drug IND Application for UX053 an mRNA for the Treatment of Glycogen Storage Disease Type III |
Rocket Pharmaceuticals Inc …Rocket Pharmaceuticals Inc |
RCKT (3690, 55.35, 14.9 %) | 54.59 | New Strong Sell Stocks for March 10th …>> New Strong Sell Stocks for March 10th >> Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP L201 Gene Therapy for Leukocyte Adhesion Deficiency I >> Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results >> Benzinga s Top Ratings Upgrades Downgrades For February 18 2021 >> Rocket Pharmaceuticals Announces Participation at Upcoming Conferences |
Arcus Biosciences Inc …Arcus Biosciences Inc |
RCUS (2800, 37.99, 15.51 %) | 35.3 | Arcus Biosciences Inc RCUS Stock Jumps 9 5 Will It Continue to Soar …>> Arcus Biosciences Inc RCUS Stock Jumps 9 5 Will It Continue to Soar >> Arcus Biosciences Announces New Employment Inducement Grants >> Industry Analysts Just Upgraded Their Arcus Biosciences Inc NYSE RCUS Revenue Forecasts By 10 >> Analysts Are Upgrading Arcus Biosciences Inc NYSE RCUS After Its Latest Results >> Arcus Biosciences Announces New Employment Inducement Grants |
Radius Health Inc. …Radius Health Inc. |
RDUS (1080, 46.45, 12.72 %) | 21.99 | Radius Health Inc Announces 175 Million Financing Transaction …>> Radius Health Inc Announces 175 Million Financing Transaction >> Radius RDUS Q4 Loss Wider Than Expected Revenues Beat >> Pacira s PCRX Q4 Earnings Top Estimates Revenues Miss >> Radius Health RDUS Q4 2020 Earnings Call Transcript >> Radius Health Inc Fourth Quarter and Full Year Results |
Regeneron Pharmaceuticals, Inc. …Regeneron Pharmaceuticals, Inc. |
REGN (52970, 102.23, 2.27 %) | 474.68 | FDA Updates Fact Sheets For Eli Lilly Regeneron s COVID 19 Antibody Therapies Under Emerg …>> FDA Updates Fact Sheets For Eli Lilly Regeneron s COVID 19 Antibody Therapies Under Emergency Use >> Vaccines are here Thats no reason to call off the hunt for effective COVID 19 treatments >> U S set to reach 100M vaccinations six weeks early >> AstraZeneca benefits outweigh risks UK drugs regulator >> 2 Great Stocks You Can Buy on Sale |
Reliv` International, Inc. …Reliv` International, Inc. |
RELV (0, 0, 0 %) | 3.6 | … |
Recro Pharma Inc …Recro Pharma Inc |
REPH (118.15, 22.83, 5.52 %) | 3.65 | Recro to Present at H C Wainwright Global Life Science Conference …>> Recro to Present at H C Wainwright Global Life Science Conference >> Recro Reports Fourth Quarter and Year End 2020 Financial Results >> Recro Pharma Inc to Host Earnings Call >> Earnings Preview for Recro Pharma >> Recro to Report Fourth Quarter and Year End 2020 Financial Results Earlier Than Previously Announced |
Reata Pharmaceuticals Inc – Class A …Reata Pharmaceuticals Inc – Class A |
RETA (4310, 29.61, 11.18 %) | 109.93 | Reata RETA Beats on Q4 Earnings Submits Bardoxolone NDA …>> Reata RETA Beats on Q4 Earnings Submits Bardoxolone NDA >> Reata Pharmaceuticals Inc RETA Q4 2020 Earnings Call Transcript >> Reata Pharma Shares Are Trading Higher After Filing US Application In Alport Syndrome Related Kidney Disease >> Reata Pharmaceuticals Inc Announces Fourth Quarter and Full Year 2020 Financial Results and Provides an Update on Clinical Development Programs >> Reata Pharmaceuticals Inc Submits NDA for Companys Lead Program Bardoxolone in Alport Syndrome |
Regulus Therapeutics Inc …Regulus Therapeutics Inc |
RGLS (114.31, 36.65, 8.58 %) | 1.72 | Investors Who Bought Regulus Therapeutics NASDAQ RGLS Shares A Year Ago Are Now Up 101 …>> Investors Who Bought Regulus Therapeutics NASDAQ RGLS Shares A Year Ago Are Now Up 101 >> Regulus Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Recent Updates >> Regulus Therapeutics to Present at the H C Wainwright Global Life Sciences Conference >> Will Regulus RGLS Report Negative Q4 Earnings What You Should Know >> Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease ADPKD |
Rigel Pharmaceuticals …Rigel Pharmaceuticals |
RIGL (693.8, 168.46, 9.98 %) | 3.975 | Rigel Announces Completion of Patient Enrollment for NIH NHLBI Sponsored Phase 2 Trial of …>> Rigel Announces Completion of Patient Enrollment for NIH NHLBI Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID 19 Patients >> Need To Know Analysts Are Much More Bullish On Rigel Pharmaceuticals Inc NASDAQ RIGL Revenues >> Rigel Pharmaceuticals RIGL Reports Q4 Loss Tops Revenue Estimates >> Rigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update >> Rigel Pharmaceuticals Inc to Host Earnings Call |
Avidity Biosciences Inc …Avidity Biosciences Inc |
RNA (994.5, 32.19, 11.33 %) | 26.21 | Avidity Biosciences Reports Fourth Quarter and Year End 2020 Financial Results and Recent …>> Avidity Biosciences Reports Fourth Quarter and Year End 2020 Financial Results and Recent Highlights >> We Think Avidity Biosciences NASDAQ RNA Can Afford To Drive Business Growth >> Avidity Biosciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference >> Avidity Biosciences Appoints W Michael Flanagan Ph D as Chief Technical Officer >> Avidity Biosciences Announces Changes to its Board of Directors |
Repare Therapeutics Inc …Repare Therapeutics Inc |
RPTX (1100, 36.2, 1.47 %) | 28.62 | Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 …>> Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results >> Benzinga s Top Ratings Upgrades Downgrades For March 1 2021 >> Repare Therapeutics Announces March 2021 Virtual Investor Conference Participation >> Could The Repare Therapeutics Inc NASDAQ RPTX Ownership Structure Tell Us Something Useful >> Repare Therapeutics to Present at Virtual Investor Conferences in January |
Revance Therapeutics Inc …Revance Therapeutics Inc |
RVNC (1970, 65.53, 5.23 %) | 27.8 | Investors Who Bought Revance Therapeutics NASDAQ RVNC Shares A Year Ago Are Now Up 73 …>> Investors Who Bought Revance Therapeutics NASDAQ RVNC Shares A Year Ago Are Now Up 73 >> Revance to Participate in Upcoming Virtual Healthcare Conferences >> Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635 c 4 >> The Daily Biotech Pulse Aridis To Study Antibody Cocktail For Coronavirus Variants Revance amp Protalix Data Readouts >> Revance Therapeutics DaxibotulinumtoxinA For Injection Improves Muscle Tone In Mid Stage Upper Limb Spasticity |
Rhythm Pharmaceuticals Inc. …Rhythm Pharmaceuticals Inc. |
RYTM (1350, 36.87, 7.42 %) | 24.59 | Rhythm Pharmaceuticals Announces Late Breaking Data Presentations at ENDO 2021 …>> Rhythm Pharmaceuticals Announces Late Breaking Data Presentations at ENDO 2021 >> Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results >> Rhythm Pharmaceuticals to Present at Cowen amp Co 41st Annual Health Care Conference >> What Kind Of Investors Own Most Of Rhythm Pharmaceuticals Inc NASDAQ RYTM >> Rhythm Pharmaceuticals Inc Announces Closing of 172 5 Million Public Offering Including Full Exercise of the Underwriters Option to Purchase Additional Shares |
Sage Therapeutics Inc …Sage Therapeutics Inc |
SAGE (4680, 51.11, 10.18 %) | 75.07 | Dont Lose Sight of Biogens Depression Drug How It Could Send the Stock Much Higher …>> Dont Lose Sight of Biogens Depression Drug How It Could Send the Stock Much Higher >> Dont Lose Sight of Biogens Depression Drug Amid Focus on Alzheimers Disease >> Sage Therapeutics Announces Continued Positive Zuranolone Data for Both 30 mg and 50 mg Doses in Open Label SHORELINE Study in Patients with MDD >> Sage Therapeutics Announces Departure of Chief Operating Officer >> Top Growth Stocks for March 2021 |
Cassava Sciences Inc …Cassava Sciences Inc |
SAVA (1880, 23.43, 12.54 %) | 56.25 | 3 Biotech Stocks to Avoid Right Now …>> 3 Biotech Stocks to Avoid Right Now >> Why Cassava Sciences Stock Is Skyrocketing Today >> The Zacks Analyst Blog Highlights Denbury Riot Blockchain Marathon Digital Holdings Silvergate Capital and Cassava Sciences >> A Year Into the COVID 19 Pandemic 5 Stock Winners >> Cassava Sciences SAVA Up More Than 600 YTD Here s Why |
Strongbridge Biopharma plc …Strongbridge Biopharma plc |
SBBP (230.76, 60.04, 0.99 %) | 3.32 | Strongbridge Biopharma plc to Present at Oppenheimers 31st Annual Healthcare Conference …>> Strongbridge Biopharma plc to Present at Oppenheimers 31st Annual Healthcare Conference >> Strongbridge Biopharma plc NASDAQ SBBP Analysts Are Pretty Bullish On The Stock After Recent Results >> Strongbridge Biopharma SBBP Reports Q4 Loss Tops Revenue Estimates >> Strongbridge Biopharma plc Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update >> Strongbridge Biopharma Plc to Host Earnings Call |
Silverback Therapeutics Inc …Silverback Therapeutics Inc |
SBTX (1840, 22.91, 9.49 %) | 59.17 | Silverback Therapeutics Announces the Appointment of Dr Maria Koehler to its Board of Dir …>> Silverback Therapeutics Announces the Appointment of Dr Maria Koehler to its Board of Directors >> How Much Are Silverback Therapeutics Inc NASDAQ SBTX Insiders Spending On Buying Shares >> Silverback Therapeutics to Present at Upcoming Investor Conferences >> SVB Leerink Bullish On Silverback Therapeutics Sees Diverse Pipeline >> Benzinga s Top Upgrades Downgrades For December 29 2020 |
Scynexis Inc …Scynexis Inc |
SCYX (168.69, 7.87, 14.07 %) | 8.35 | SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies FURI …>> SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies FURI and CARES Demonstrating Oral Ibrexafungerp s Ability to Treat Severe Fungal Infections in the Hospital Setting >> SCYNEXIS to Participate in Maxim Groups Late Stage Innovations in Womens Health Virtual Event >> UTILITY Therapeutics Joins Antimicrobials Working Group >> SCYNEXIS Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to Ibrexafungerp in Greater China >> SCYNEXIS and Hansoh Pharma Announce Licensing Agreement and Strategic Partnership for Ibrexafungerp in Greater China |
Schrodinger Inc …Schrodinger Inc |
SDGR (5750, 43.92, 6.6 %) | 76.29 | Schr dinger to Participate in Credit Suisse 2021 Healthcare Innovators Series The Inters …>> Schr dinger to Participate in Credit Suisse 2021 Healthcare Innovators Series The Intersection of Drug Discovery Drug Development and Artificial Intelligence >> Is There Any Hope Left for Schrodinger Stock >> Schr dinger Announces Preclinical Data for CDC7 Program to Be Presented at AACR Virtual Annual Meeting 2021 >> Schrodinger Inc SDGR Q4 2020 Earnings Call Transcript >> Schr dinger Reports Financial Results for the Fourth Quarter and Full Year 2020 and Provides Outlook for 2021 |
Seelos Therapeutics Inc …Seelos Therapeutics Inc |
SEEL (193.75, 49.61, 5.19 %) | 4.09 | Midday Market Update What Stocks Are Up Today …>> Midday Market Update What Stocks Are Up Today >> Why Seelos Therapeutics Stock Is Skyrocketing Today >> Seelos Therapeutics Announces Completion of Open Label Patient Enrollment of Proof of Concept Study of SLS 002 Intranasal Racemic Ketamine for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder >> Seelos Therapeutics Buys Back Portion Of SLS002 Related Royalties >> The Daily Biotech Pulse Lily Rigel Licensing Deal vTv Starts Early Stage Psoriasis Study Immunic Data Readout |
Selecta Biosciences Inc …Selecta Biosciences Inc |
SELB (449.94, 79.81, 8.69 %) | 4.39 | Selecta Biosciences Inc NASDAQ SELB Just Reported And Analysts Have Been Lifting Their …>> Selecta Biosciences Inc NASDAQ SELB Just Reported And Analysts Have Been Lifting Their Price Targets >> Selecta Biosciences Inc SELB Reports Q4 Loss Tops Revenue Estimates >> Selecta Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results >> Selecta Biosciences Inc to Host Earnings Call >> Selecta Biosciences Inc SELB May Report Negative Earnings Know the Trend Ahead of Q4 Release |
Sesen Bio Inc. …Sesen Bio Inc. |
SESN (454.45, 129.27, 1.83 %) | 3.06 | Sesen Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Significant Regu …>> Sesen Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Significant Regulatory and Commercial Readiness Progress for the Companys Lead Product Candidate Vicineum >> Sesen Bio Submits Marketing Authorization Application to the European Medicines Agency for Vicineum >> Sesen Bio Announces Conference Call with Neal Shore M D FACS to Provide Clinical Perspective on the Companys Lead Product Candidate Vicineum >> Why Sesen Bio Stock Is Soaring Today >> Sesen Bio Announces FDA Acceptance and Priority Review of its Biologics License Application for Vicineum |
Sigilon Therapeutics Inc …Sigilon Therapeutics Inc |
SGTX (769.26, 22.93, 0.56 %) | 21.51 | Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Busi …>> Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights >> Sigilons SIG 007 Granted Orphan Drug Designation By FDA Shares Pop 6 >> Sigilon Therapeutics Receives Orphan Drug Designation for SIG 007 for the Treatment of Fabry Disease >> Sigilon Therapeutics to Present at Barclays Global Healthcare Conference >> Sigilon Therapeutics Announces Preclinical Data in Multiple Lysosomal Diseases at the 17th Annual WORLDSymposium |
SIGA Technologies Inc …SIGA Technologies Inc |
SIGA (515.87, 44.91, 4.44 %) | 6.5 | SIGA Reports Financial Results for Three and Twelve Months Ended December 31 2020 …>> SIGA Reports Financial Results for Three and Twelve Months Ended December 31 2020 >> SIGA Technologies Inc to Host Earnings Call >> SIGA Technologies to Host Business Update Call on March 4 2021 Following Release of Year End 2020 Financial Results >> There s No Escaping SIGA Technologies Inc s NASDAQ SIGA Muted Earnings >> There s No Escaping SIGA Technologies Inc s NASDAQ SIGA Muted Earnings |
Sio Gene Therapies Inc …Sio Gene Therapies Inc |
SIOX (161.57, 40.05, 1.07 %) | 2.65 | How Many Sio Gene Therapies Inc NASDAQ SIOX Shares Did Insiders Buy In The Last Year …>> How Many Sio Gene Therapies Inc NASDAQ SIOX Shares Did Insiders Buy In The Last Year >> Sio Gene Therapies Provides Update on Cash Position and Major Upcoming GM1 Gangliosidosis Program Milestones >> Sio Gene Therapies to Participate in Upcoming Investor amp Scientific Conferences >> Sio Gene Therapies to Present at the 10th Annual SVB Leerink Global Healthcare Conference >> Sio Gene Therapies Announces Financial Results for Third Fiscal Quarter Ended December 31 2020 |
Salarius Pharmaceuticals Inc …Salarius Pharmaceuticals Inc |
SLRX (64.65, 19.35, 9.81 %) | 1.5 | Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full Year 202 …>> Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full Year 2020 Financial Results >> Salarius Pharmaceuticals Inc to Host Earnings Call >> Salarius Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results >> Salarius Announces Closing of 23 Million Underwritten Public Offering of Common Stock Following Full Exercise of Over Allotment Option >> Salarius Announces Pricing of 20 Million Underwritten Public Offering of Common Stock |
SELLAS Life Sciences Group Inc …SELLAS Life Sciences Group Inc |
SLS (132.32, 9.22, 8.73 %) | 10.54 | SELLAS Life Sciences to Participate in the M Vest and Maxim Group Inaugural Emerging Growt …>> SELLAS Life Sciences to Participate in the M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference on March 17th >> SELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones >> SELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones >> SELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones >> SELLAS Announces Promising Initial Clinical Data for Galinpepimut S GPS in Combination with Checkpoint Inhibitors in Two Solid Tumor Indications |
Syndax Pharmaceuticals Inc …Syndax Pharmaceuticals Inc |
SNDX (1130, 44.09, 11.18 %) | 23.02 | Is Syndax Pharmaceuticals NASDAQ SNDX Using Debt In A Risky Way …>> Is Syndax Pharmaceuticals NASDAQ SNDX Using Debt In A Risky Way >> Syndax Posts Better Than Feared Quarterly Loss Sales Beat Estimates >> Syndax Pharmaceuticals Q4 Earnings Insights >> Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update >> Syndax Pharmaceuticals Inc to Host Earnings Call |
Soligenix Inc …Soligenix Inc |
SNGX (51.78, 28.7, 7.41 %) | 1.75 | Soligenix Anticipated to Achieve Multiple Milestones in 2021 …>> Soligenix Anticipated to Achieve Multiple Milestones in 2021 >> Soligenix to Receive 865 000 in Non Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program >> The Daily Biotech Pulse FDA Nod For Pfizer Kiniksa Rises On Commercialization Pact With Regeneron Bio Techne To Buy Diagnostic Company >> Soligenix Announces Positive Progress in the Pre clinical Development of its COVID 19 Vaccine >> Soligenix Provides Important Highlights and Upcoming Catalysts in Corporate Update Letter |
Sunesis Pharmaceuticals Inc …Sunesis Pharmaceuticals Inc |
SNSS (0, 0, 0 %) | 13.5 | Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and 65M Pri …>> Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and 65M Private Placement >> Sunesis Pharma Climbs After Viracta Poised To Nab US Patent For Nanatinostat Valganciclovir Regime >> Viracta Therapeutics Announces Notice of Allowance for U S Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein Barr Virus associated Lymphoma >> Viracta Therapeutics to Participate in Upcoming Virtual Investor Conferences >> MERGER INVESTIGATION Halper Sadeh LLP Investigates CPAH HMSY SNSS EIDX Shareholders Are Encouraged to Contact the Firm |
Spectrum Pharmaceuticals, Inc. …Spectrum Pharmaceuticals, Inc. |
SPPI (547.39, 131.9, 8.09 %) | 3.43 | Spectrum Pharmaceuticals Provides Update on ROLONTIS eflapegrastim Pre Approval Inspec …>> Spectrum Pharmaceuticals Provides Update on ROLONTIS eflapegrastim Pre Approval Inspection >> Spectrum s SPPI NSCLC Drug Gets FDA s Fast Track Designation >> The Daily Biotech Pulse Contrasting COVID 19 Treatment Readouts From Roche Vir Delay In Kadmon s FDA Review Alzheimer s Data From Prothena >> FDA Grants Fast Track Designation to Spectrum Pharmaceuticals Poziotinib >> How Much Of Spectrum Pharmaceuticals Inc NASDAQ SPPI Do Institutions Own |
Spruce Biosciences Inc …Spruce Biosciences Inc |
SPRB (393.84, 3.81, 10.22 %) | 17.61 | Spruce Biosciences Presents Phase 1 and 2 Data for Tildacerfont in Adults with Congenital …>> Spruce Biosciences Presents Phase 1 and 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia from Endocrine Societys 2021 Annual Meeting >> Spruce Biosciences to Announce Phase 1 and 2 Data of Tildacerfont at Endocrine Societys 2021 Annual Meeting >> Spruce Biosciences to Participate in Upcoming Investor Conferences >> What Type Of Shareholders Make Up Spruce Biosciences Inc s NASDAQ SPRB Share Registry >> Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021 |
Spero Therapeutics Inc …Spero Therapeutics Inc |
SPRO (490.09, 24.48, 9 %) | 15.74 | Spero Therapeutics Inc SPRO Reports Q4 Loss Lags Revenue Estimates …>> Spero Therapeutics Inc SPRO Reports Q4 Loss Lags Revenue Estimates >> Spero Therapeutics Announces Fourth Quarter and Full Year 2020 Operating Results and Provides Business Update >> Spero Therapeutics Inc to Host Earnings Call >> Is Spero Therapeutics NASDAQ SPRO In A Good Position To Deliver On Growth Plans >> Will Spero Therapeutics Inc SPRO Report Negative Q4 Earnings What You Should Know |
Sarepta Therapeutics Inc …Sarepta Therapeutics Inc |
SRPT (6790, 75.12, 9.74 %) | 83 | Can Sarepta s Remarkable Gene Therapy Pull Shares Out Of The Dumps …>> Can Sarepta s Remarkable Gene Therapy Pull Shares Out Of The Dumps >> Can Sarepta s Remarkable Gene Therapy Pull Shares Out Of The Dumps >> Sarepta Therapeutics Investigational Gene Therapy SRP 9003 for the Treatment of Limb Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration >> Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference >> Sarepta SRPT Q4 Loss Widens Y Y Revenues Beat Estimates |
Sierra Oncology Inc …Sierra Oncology Inc |
SRRA (203.91, 10.23, 0.09 %) | 20.18 | Here s What Sierra Oncology Inc s NASDAQ SRRA Shareholder Ownership Structure Looks Li …>> Here s What Sierra Oncology Inc s NASDAQ SRRA Shareholder Ownership Structure Looks Like >> Sierra Oncology Reports 2020 Year End Results >> R E P E A T Media Advisory Government of Canada to make Housing Related Announcement in Winnipeg >> Sierra Oncology to Present at Three Upcoming Investor Conferences >> Sierra Oncology Announces Presentation at LifeSci Partners Precision Oncology Day |
Stoke Therapeutics Inc …Stoke Therapeutics Inc |
STOK (1950, 34.57, 9.53 %) | 46.68 | We re Not Worried About Stoke Therapeutics NASDAQ STOK Cash Burn …>> We re Not Worried About Stoke Therapeutics NASDAQ STOK Cash Burn >> Ultragenyx s RARE IND for mRNA Therapy UX053 Cleared by FDA >> Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates >> Stoke Therapeutics to Present at the Barclays Global Healthcare Conference >> Mersana Therapeutics Inc to Host Earnings Call |
Satsuma Pharmaceuticals Inc …Satsuma Pharmaceuticals Inc |
STSA (116.18, 13.65, 5.07 %) | 6.06 | Satsuma Pharmaceuticals to Present at the 31st Annual Oppenheimer Healthcare Conference …>> Satsuma Pharmaceuticals to Present at the 31st Annual Oppenheimer Healthcare Conference >> Satsuma Pharma Shares Rise After Raising 80M Via Private Placement Plans New Pivotal Study For Migraine >> Satsuma Pharmaceuticals Announces Updated STS101 Development Plan >> Satsuma Pharmaceuticals Announces 80 Million Private Placement Financing >> 5 Value Stocks In The Healthcare Sector |
Shattuck Labs Inc …Shattuck Labs Inc |
STTK (1620, 27.14, 1.59 %) | 35.04 | Shattuck Labs Posts Narrower Than Estimated 4Q Loss …>> Shattuck Labs Posts Narrower Than Estimated 4Q Loss >> Shattuck Labs Announces Promotion of Andrew R Neill to Chief Financial Officer >> Shattuck Labs Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights >> Shattuck Labs to Present Two Posters at the 2021 American Association for Cancer Research AACR Annual Meeting >> Shattuck Labs Announces Participation in Upcoming March Investor Conferences |
Supernus Pharmaceuticals Inc …Supernus Pharmaceuticals Inc |
SUPN (1400, 50.78, 14.71 %) | 25.57 | 3 Undervalued Biotechs Worth Adding to Your Watch List …>> 3 Undervalued Biotechs Worth Adding to Your Watch List >> Supernus Pharmaceuticals Inc SUPN Q4 2020 Earnings Call Transcript >> Supernus to Present at Cowen Healthcare Conference >> Supernus Pharmaceuticals Q4 Earnings Insights >> Supernus Announces Fourth Quarter and Full Year 2020 Financial Results |
Sinovac Biotech, Ltd. …Sinovac Biotech, Ltd. |
SVA (0, 0, 0 %) | 6.47 | Thailand to start first coronavirus vaccinations this week …>> Thailand to start first coronavirus vaccinations this week >> Sinovac Amends Shareholder Rights Plan >> UPDATE 1 Thailand allows emergency use of Sinovac s COVID 19 vaccine >> Turkey to procure 105 mln doses of COVID 19 vaccines by end April Sabah >> Asian Stocks Down Weighed Down by Higher Bond Yields Disappointing U S Data |
Savara Inc …Savara Inc |
SVRA (127.92, 45.24, 2 %) | 2.13 | Do Options Traders Know Something About Savara SVRA Stock We Don t …>> Do Options Traders Know Something About Savara SVRA Stock We Don t >> Thinking About Buying Stock In AstraZeneca Apple McDonald s Savara Or Jabil >> Savara Announces Closing of 130 Million Public Offering Following Full Exercise of Underwriters Option >> Savara Announces Pricing of Public Offering of Common Stock >> Savara Announces Proposed Public Offering of Common Stock |
Synlogic Inc …Synlogic Inc |
SYBX (165.74, 32.76, 0.98 %) | 4.02 | Synlogic Announces Fourth Quarter and Full Year 2020 Conference Call amp Webcast …>> Synlogic Announces Fourth Quarter and Full Year 2020 Conference Call amp Webcast >> If You Had Bought Synlogic NASDAQ SYBX Shares A Year Ago You d Have Earned 134 Returns >> Synlogic Announces Promotion of Dr Caroline Kurtz to Chief Development Officer and Strengthening of Leadership Team >> Synlogic to Present at Upcoming Virtual Banking and Industry Conferences >> What Type Of Shareholders Make Up Synlogic Inc s NASDAQ SYBX Share Registry |
Synthetic Biologics Inc …Synthetic Biologics Inc |
SYN (106.54, 127.36, 7.64 %) | 0.7901 | Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results …>> Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results >> Synthetic Biologics Inc to Host Earnings Call >> How Many Synthetic Biologics Inc NYSEMKT SYN Shares Did Insiders Buy In The Last Year >> How Many Synthetic Biologics Inc NYSEMKT SYN Shares Did Insiders Buy In The Last Year >> How Many Synthetic Biologics Inc NYSEMKT SYN Shares Did Insiders Buy In The Last Year |
Syros Pharmaceuticals Inc. …Syros Pharmaceuticals Inc. |
SYRS (585.32, 56.72, 7.1 %) | 8.56 | Looking Into Syros Pharmaceuticals s Return On Capital Employed …>> Looking Into Syros Pharmaceuticals s Return On Capital Employed >> Syros Pharmaceuticals Inc SYRS Reports Q4 Loss Tops Revenue Estimates >> Syros Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones >> Syros Pharmaceuticals Inc to Host Earnings Call >> Syros to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday March 4 2021 |
Taro Pharmaceutical Industries …Taro Pharmaceutical Industries |
TARO (3000, 8.76, 1.47 %) | 78.1 | Taro Pharmaceutical Industries NYSE TARO Shareholders Are Down 44 On Their Shares …>> Taro Pharmaceutical Industries NYSE TARO Shareholders Are Down 44 On Their Shares >> Taro Provides Results for December 31 2020 >> Taro to Announce Third Quarter Results on January 27 2021 >> Is TARO A Good Stock To Buy Now >> Taro Pharmaceutical Industries Ltd to Host Earnings Call |
Theravance Biopharma Inc …Theravance Biopharma Inc |
TBPH (1340, 51.21, 6.87 %) | 19.65 | Are Theravance Biopharma Inc NASDAQ TBPH Investors Paying Above The Intrinsic Value …>> Are Theravance Biopharma Inc NASDAQ TBPH Investors Paying Above The Intrinsic Value >> Theravance Biopharma to Participate in an Upcoming Investor Conference >> Theravance Biopharma Inc TBPH Q4 2020 Earnings Call Transcript >> Theravance Biopharma Q4 Earnings Insights >> Theravance Biopharma Inc to Host Earnings Call |
Tricida Inc …Tricida Inc |
TCDA (255.83, 48.88, 9.01 %) | 5.05 | Have Insiders Been Buying Tricida Inc NASDAQ TCDA Shares This Year …>> Have Insiders Been Buying Tricida Inc NASDAQ TCDA Shares This Year >> The Gross Law Firm Announces Class Actions on Behalf of Shareholders of TCDA REGI and ATNX >> FINAL DEADLINE TODAY The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tricida Inc and Encourages Investors with Losses in Excess of 100 000 to Contact the Firm >> The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of QS TCDA and OTRK >> TCDA FILING DEADLINE TODAY Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Tricida Inc |
Tff Pharmaceuticals Inc …Tff Pharmaceuticals Inc |
TFFP (362.5, 17.74, 1.25 %) | 15.53 | TFF Pharmaceuticals Inc Common Stock TFFP Q4 2020 Earnings Call Transcript …>> TFF Pharmaceuticals Inc Common Stock TFFP Q4 2020 Earnings Call Transcript >> TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Business Results >> Tff Pharmaceuticals Inc to Host Earnings Call >> NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration >> NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration |
TG Therapeutics Inc …TG Therapeutics Inc |
TGTX (6840, 120.36, 9.83 %) | 46.04 | TG Therapeutics Announces Publication of Results from the UNITY NHL Phase 2b Trial Evaluat …>> TG Therapeutics Announces Publication of Results from the UNITY NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed or Refractory Indolent non Hodgkin Lymphoma in the Journal of Clinical Oncology >> TG Therapeutics to Present Results from the ULTIMATE I amp II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual Meeting >> TG Therapeutics to Present at the H C Wainwright Global Life Sciences Conference >> Company News for Mar 3 2021 >> Is TG Therapeutics Inc NASDAQ TGTX Popular Amongst Insiders |
Theratechnologies Inc. …Theratechnologies Inc. |
THTX (303.11, 86.84, 0.68 %) | 3.41 | Theratechnologies Announces Two E Posters on TH1902 To Be Presented at American Associatio …>> Theratechnologies Announces Two E Posters on TH1902 To Be Presented at American Association for Cancer Research AACR Annual Meeting 2021 >> Theratechnologies to Present at the H C Wainwright Global Life Sciences Conference >> Theratechnologies Announces Fourth Quarter and Fiscal Year 2020 Financial Results >> Theratechnologies Inc to Host Earnings Call >> Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2020 |
Tonix Pharmaceuticals Holding Corp …Tonix Pharmaceuticals Holding Corp |
TNXP (459.09, 156.47, 1.08 %) | 1.37 | Positive Phase 3 Efficacy Data Bolsters Tonix Pharmaceuticals Expectations For Phase 3 Co …>> Positive Phase 3 Efficacy Data Bolsters Tonix Pharmaceuticals Expectations For Phase 3 Confirmatory Trial In Fibromyalgia >> Tonix Pharmaceuticals Announces Issuance of U S Patent for Compositions and Uses of Tianeptine Oxalate Salt the Active Ingredient of TNX 601 CR >> Why Tonix Pharmaceuticals Stock Is Soaring Today >> The Daily Biotech Pulse Merck s Keytruda Gets Label Expansion In Europe Pfizer To Sell Chinese Biologics Unit Celcuity Spikes >> Tonix Pharmaceuticals Reports Positive COVID 19 Vaccine Efficacy Results in Non Human Primates Vaccinated with TNX 1800 and Challenged with Live SARS CoV 2 |
Turning Point Therapeutics Inc …Turning Point Therapeutics Inc |
TPTX (5370, 45.58, 4.63 %) | 102.71 | Turning Point Therapeutics to Present New Preclinical Data For Three Drug Candidates at Am …>> Turning Point Therapeutics to Present New Preclinical Data For Three Drug Candidates at American Association For Cancer Research Annual Meeting >> Turning Point Therapeutics to Participate in Upcoming Investor Conferences >> Turning Point Therapeutics Reports Fourth Quarter and Full Year Financial Results Provides Operational Updates >> Turning Point Therapeutics Inc to Host Earnings Call >> Why Turning Point Is Turning Heads |
Trevena Inc …Trevena Inc |
TRVN (322.98, 0, 0 %) | 1.97 | Trevena Inc Appoints Marvin H Johnson Jr to Board of Directors …>> Trevena Inc Appoints Marvin H Johnson Jr to Board of Directors >> Trevena Inc Reports Fourth Quarter and Full Year 2020 Results >> Trevena Inc to Host Earnings Call >> Earnings Scheduled For March 9 2021 >> Trevena to Release Fourth Quarter and Full Year 2020 Financial Results on March 9 2021 |
Travere Therapeutics Inc …Travere Therapeutics Inc |
TVTX (1670, 0, 0 %) | 26.81 | Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results …>> Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results >> Travere Therapeutics Inc to Host Earnings Call >> Travere Therapeutics Recognizes Rare Disease Day 2021 and the Importance of Working Together to Innovate and Address Healthcare Disparities in Rare Disease >> Travere Therapeutics to Present at Upcoming Investor Conferences >> Travere Therapeutics Announces European Commission Has Granted Orphan Designation to Sparsentan for the Treatment of IgA Nephropathy |
TherapeuticsMD Inc …TherapeuticsMD Inc |
TXMD (620.48, 266.15, 20.94 %) | 1.5 | Here s What TherapeuticsMD Inc s NASDAQ TXMD Shareholder Ownership Structure Looks Lik …>> Here s What TherapeuticsMD Inc s NASDAQ TXMD Shareholder Ownership Structure Looks Like >> TherapeuticsMD Inc TXMD Q4 2020 Earnings Call Transcript >> TherapeuticsMD TXMD Reports Q4 Loss Tops Revenue Estimates >> Recap TherapeuticsMD Q4 Earnings >> TherapeuticsMD Announces Fourth Quarter and Full Year 2020 Financial Results |
Tyme Technologies Inc …Tyme Technologies Inc |
TYME (378.64, 106.55, 2.85 %) | 2.11 | Is Tyme Technologies Inc s NASDAQ TYME Shareholder Ownership Skewed Towards Insiders …>> Is Tyme Technologies Inc s NASDAQ TYME Shareholder Ownership Skewed Towards Insiders >> TYME Provides Business Update and Announces Third Quarter Fiscal 2021 Financial and Operating Results >> TYME Provides Business Update and Announces Third Quarter Fiscal 2021 Financial and Operating Results >> TYME Provides Business Update and Announces Third Quarter Fiscal 2021 Financial and Operating Results >> Why Tyme Technologies Stock Is Taking Off Today |
UroGen Pharma Ltd …UroGen Pharma Ltd |
URGN (435.04, 19.36, 14.28 %) | 18.05 | UROGEN PHARMA URGN Reports Q4 Loss Tops Revenue Estimates …>> UROGEN PHARMA URGN Reports Q4 Loss Tops Revenue Estimates >> UroGen Pharma Q4 Earnings Insights >> UroGen Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments >> UroGen Pharma Announces 75 Million of Non Dilutive Funding from RTW Investments >> UroGen Pharma Ltd to Host Earnings Call |
United Therapeutics Corp …United Therapeutics Corp |
UTHR (7590, 43.66, 4.39 %) | 170.35 | United Therapeutics Corporation To Present At The Oppenheimer 31st Annual Healthcare Confe …>> United Therapeutics Corporation To Present At The Oppenheimer 31st Annual Healthcare Conference >> Looking Into United Therapeutics s Return On Capital Employed >> United Therapeutics Pulls Plug On Trevyent Development >> United Therapeutics Corporation Just Missed Earnings But Analysts Have Updated Their Models >> United Therapeutics Corp UTHR Q4 2020 Earnings Call Transcript |
Vascular Biogenics Ltd …Vascular Biogenics Ltd |
VBLT (97.8, 37.18, 8.81 %) | 2.03 | Vascular Biogenics VBLT May Report Negative Earnings Know the Trend Ahead of Next Week …>> Vascular Biogenics VBLT May Report Negative Earnings Know the Trend Ahead of Next Week s Release >> VBL Therapeutics to Report Fourth Quarter and Full Year Financial Results on March 25 >> Vascular Biogenics VBLT May Report Negative Earnings Know the Trend Ahead of Q4 Release >> VBL Therapeutics to Participate at Upcoming Virtual Investor Conferences >> VBL Therapeutics Announces Peer reviewed Publication of Positive Results of Pre specified Interim Analysis of OVAL a Phase 3 Registration Enabling Study of VB 111 in Ovarian Cancer |
Veru Inc …Veru Inc |
VERU (1150, 54.52, 2.91 %) | 13.76 | Looking Into Veru s Return On Capital Employed …>> Looking Into Veru s Return On Capital Employed >> Veru to Present at the Oppenheimer 31st Annual Healthcare Conference >> Veru Hires Advisor To Explore Alternatives For Female Health Business >> Veru mulls selling female health business >> Veru Exploring Strategic Alternatives for its Legacy Female Health Business |
Viela Bio Inc …Viela Bio Inc |
VIE (2910, 24.63, 7.79 %) | 53.01 | AstraZeneca to supply U S with extra 500 000 doses of COVID 19 antibody based cocktail …>> AstraZeneca to supply U S with extra 500 000 doses of COVID 19 antibody based cocktail >> ALERT Halper Sadeh LLP Investigates VIE CMD COHR PRSP Shareholders are Encouraged to Contact the Firm >> Lifshitz Law Firm P C Announces Investigation of MDCA PRSP PROS and VIE >> SHAREHOLDER ALERT Halper Sadeh LLP Continues to Investigate WIFI CHNG CUB VIE Shareholders Are Encouraged to Contact the Firm >> Recap Viela Bio Q4 Earnings |
Viking Therapeutics Inc …Viking Therapeutics Inc |
VKTX (491.34, 64.86, 12.98 %) | 6.21 | Viking Therapeutics to Participate at Upcoming Investor Conferences …>> Viking Therapeutics to Participate at Upcoming Investor Conferences >> Viking Therapeutics VKTX Q4 2020 Earnings Call Transcript >> Viking Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update >> Viking Therapeutics Inc to Host Earnings Call >> Viking Therapeutics to Report Financial Results for Fourth Quarter and Year End 2020 on February 17 2021 |
Vanda Pharmaceuticals Inc …Vanda Pharmaceuticals Inc |
VNDA (959.92, 53.1, 9.68 %) | 17.04 | Shuman Glenn amp Stecker Investigates Vanda Pharmaceuticals Inc …>> Shuman Glenn amp Stecker Investigates Vanda Pharmaceuticals Inc >> Return On Capital Employed Overview Vanda Pharmaceuticals >> SHAREHOLDER ALERT Barr Law Group Investigating VNDA VLDR RIDE and ABT Shareholders are Encouraged to Contact the Firm >> VANDA INVESTIGATION INITIATED by Former Louisiana Attorney General Kahn Swick amp Foti LLC Investigates the Officers and Directors of Vanda Pharmaceuticals Inc VNDA >> Shareholder Alert Robbins LLP Announces that Vanda Pharmaceuticals Inc VNDA Class Action Survives Motion to Dismiss |
Vertex Pharmaceuticals, Inc. …Vertex Pharmaceuticals, Inc. |
VRTX (56650, 259.37, 1.68 %) | 213.36 | Here Are 5 Undervalued Biopharma Stocks …>> Here Are 5 Undervalued Biopharma Stocks >> Heres Why Vertex VRTX Landed in Alger Spectras Detractor List >> Vertex Pharmaceuticals Incorporated s NASDAQ VRTX Stock Has Been Sliding But Fundamentals Look Strong Is The Market Wrong >> 3 Top Biotech Stocks to Buy in March >> 5 Disruptive Stocks to Buy for a Biden Bull Market |
Verastem Inc …Verastem Inc |
VSTM (416.1, 164.4, 3.88 %) | 2.37 | Verastem Oncology Reports Fourth Quarter and Full Year 2020 Financial Results Clinical Up …>> Verastem Oncology Reports Fourth Quarter and Full Year 2020 Financial Results Clinical Updates and Guidance for Key Milestones in 2021 and 1H 2022 >> Verastem Oncology to Participate in the H C Wainwright Global Life Sciences Conference >> Investors Who Bought Verastem NASDAQ VSTM Shares Five Years Ago Are Now Up 84 >> Frank Neumann M D Ph D to Depart Verastem Oncology >> Frank Neumann M D Ph D to Depart Verastem Oncology |
VistaGen Therapeutics Inc …VistaGen Therapeutics Inc |
VTGN (327.29, 109.05, 7.81 %) | 2.15 | VistaGen Therapeutics to Participate in Upcoming Investor Conferences in March …>> VistaGen Therapeutics to Participate in Upcoming Investor Conferences in March >> VistaGens PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study >> New Strong Sell Stocks for March 11th >> Why VistaGen Therapeutics Stock Is Soaring Today >> VistaGen Therapeutics NASDAQ VTGN Is In A Strong Position To Grow Its Business |
vTv Therapeutics Inc – Class A …vTv Therapeutics Inc – Class A |
VTVT (227.95, 14.03, 17.95 %) | 2.81 | vTv Therapeutics Announces Initiation of Study Evaluating TTP399s Potential to Reduce Risk …>> vTv Therapeutics Announces Initiation of Study Evaluating TTP399s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes >> vTv Therapeutics to Present at the H C Wainwright Global Life Sciences Conference >> How Much Are vTv Therapeutics Inc NASDAQ VTVT Insiders Spending On Buying Shares >> vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update >> vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT 1 Study of TTP399 in Patients with Type 1 Diabetes |
Wave Life Sciences Ltd. …Wave Life Sciences Ltd. |
WVE (473.45, 39.95, 12.31 %) | 9.59 | Wave Life Sciences to Present at the Third Annual Stifel CNS Day …>> Wave Life Sciences to Present at the Third Annual Stifel CNS Day >> Here s What Wave Life Sciences Ltd s NASDAQ WVE Shareholder Ownership Structure Looks Like >> Billionaire Jim Simons Snaps Up These 2 Biotech Stocks >> Looking Into WAVE Life Sciences s Return On Capital Employed >> Wave Life Sciences WVE Reports Q4 Loss Lags Revenue Estimates |
XBiotech Inc …XBiotech Inc |
XBIT (572.52, 17.73, 8.47 %) | 19.27 | Top Biotech Stocks for Q2 2021 …>> Top Biotech Stocks for Q2 2021 >> We re Not Very Worried About XBiotech s NASDAQ XBIT Cash Burn Rate >> Top Small Cap Stocks for March 2021 >> XBiotech Candidate True Human COVID 19 Therapy Found to Target Highly Infectious Emerging Strain >> XBiotech Announces Cerebrovascular Medical Advisory Board amp Development of New Stroke Therapy |
Xenon Pharmaceuticals Inc …Xenon Pharmaceuticals Inc |
XENE (810.86, 23.26, 4.06 %) | 18.38 | Xenon Pharmaceuticals Announces Closing of 115 Million Public Offering and Full Exercise …>> Xenon Pharmaceuticals Announces Closing of 115 Million Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares >> Xenon Pharmaceuticals Announces Pricing of 100 0 Million Public Offering >> Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares >> Xenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 Study of XEN1101 for the Treatment of Major Depressive Disorder MDD >> Xenon Pharmaceuticals XENE Reports Q4 Loss Tops Revenue Estimates |
Xeris Pharmaceuticals Inc …Xeris Pharmaceuticals Inc |
XERS (273.71, 47.02, 18.09 %) | 4.3 | SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Xeris …>> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Xeris Pharmaceuticals Inc XERS >> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Xeris Pharmaceuticals Inc XERS >> Xeris Pharmaceuticals Announces Pricing of 27 0 Million Registered Direct Offering >> Bronstein Gewirtz amp Grossman LLC Announces Investigation of Xeris Pharmaceuticals Inc XERS and Encourages Investors to Contact the Firm >> SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Xeris Pharmaceuticals Inc XERS |
Xencor Inc …Xencor Inc |
XNCR (2700, 56.29, 5.37 %) | 44.56 | Xencor to Present Preclinical Data from Four Preclinical XmAb Bispecific Antibody and Cy …>> Xencor to Present Preclinical Data from Four Preclinical XmAb Bispecific Antibody and Cytokine Programs at the American Association for Cancer Research AACR Annual Meeting 2021 >> Xencor to Present at the Barclays Global Healthcare Conference >> The Daily Biotech Pulse Merck Goes Shopping Decision Day For Sarepta Pfizer Moderna Unveil Vaccine Strategies For Coronavirus Variants >> Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb Therapeutics >> Xencor Inc XNCR Q4 2020 Earnings Call Transcript |
XOMA Corp …XOMA Corp |
XOMA (424.4, 10.41, 3.23 %) | 37.24 | Xoma XOMA Beats Q4 Earnings and Revenue Estimates …>> Xoma XOMA Beats Q4 Earnings and Revenue Estimates >> XOMA Reports Fourth Quarter and Full Year 2020 Financial Results and Operating Highlights >> What Type Of Shareholders Own The Most Number of XOMA Corporation NASDAQ XOMA Shares >> Xoma XOMA to Report Q4 Results Wall Street Expects Earnings Growth >> XOMA to Present at Upcoming Investor Conferences |
Yumanity Therapeutics Inc …Yumanity Therapeutics Inc |
YMTX (184.89, 6.52, 3.98 %) | 19.12 | Yumanity Therapeutics YTX 7739 Demonstrates Prevention of Motor Function Deficits in a Par …>> Yumanity Therapeutics YTX 7739 Demonstrates Prevention of Motor Function Deficits in a Parkinsons Disease Mouse Model >> Yumanity Therapeutics to Present at the H C Wainwright Global Life Sciences Conference >> Yumanity Therapeutics Provides Update on Its Lead Parkinsons Disease Clinical Program YTX 7739 >> Yumanity Therapeutics to Present at the H C Wainwright Virtual BioConnect Conference |
Zogenix Inc …Zogenix Inc |
ZGNX (1170, 55.37, 16.1 %) | 20.08 | Billionaire Jim Simons Snaps Up These 2 Biotech Stocks …>> Billionaire Jim Simons Snaps Up These 2 Biotech Stocks >> Zogenix to Participate in the Raymond James Institutional Investors Conference >> Zogenix Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results >> Zogenix Inc to Host Earnings Call >> Zogenix to Participate in the 10th Annual SVB Leerink Global Healthcare Conference |
Ziopharm Oncology, Inc. …Ziopharm Oncology, Inc. |
ZIOP (989.9, 200.43, 17.56 %) | 3.89 | Why Ziopharm Oncology Stock Is Sinking Today …>> Why Ziopharm Oncology Stock Is Sinking Today >> Why Ziopharm Oncology Stock Is Jumping Today >> Ziopharm Oncology Inc ZIOP Q4 2020 Earnings Call Transcript >> Ziopharm Oncology Provides Leadership and Corporate Updates Reports Fourth Quarter and Full Year 2020 Financial Results >> ZIOPHARM Oncology Inc to Host Earnings Call |
Zentalis Pharmaceuticals Inc …Zentalis Pharmaceuticals Inc |
ZNTL (1740, 36.65, 7.53 %) | 44.93 | Zentalis Pharmaceuticals Announces Late Breaker Oral Presentation on WEE1 Inhibitor ZN c3 …>> Zentalis Pharmaceuticals Announces Late Breaker Oral Presentation on WEE1 Inhibitor ZN c3 at the AACR Annual Meeting 2021 >> Zentalis Pharmaceuticals and Tempus Announce Strategic Collaboration to Advance Research and Development Capabilities >> Zentalis Pharmaceuticals to Present Initial Clinical Data on ZN c3 at the AACR Annual Meeting 2021 >> Zentalis Pharmaceuticals Announces the Appointment of Dr Enoch Kariuki to its Board of Directors >> Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences |
Zomedica Corp …Zomedica Corp |
ZOM (1950, 922.24, 5.9 %) | 2.1 | Zomedica Announces First Commercial Sale of Its Truforma Platform …>> Zomedica Announces First Commercial Sale of Its Truforma Platform >> Zomedica Retires Preferred Shares >> Zomedica Corp Announces Year End 2020 Financial Results >> All Bets are Off Whether Zomedica Stock Grows Into Its Valuation >> How to Navigate the Questionable Future of the Top 10 Meme Stocks |
Zosano Pharma Corp …Zosano Pharma Corp |
ZSAN (143.21, 101.7, 8.27 %) | 1.37 | Zosano Pharma Reports Fourth Quarter and Fiscal Year 2020 Financial Results …>> Zosano Pharma Reports Fourth Quarter and Fiscal Year 2020 Financial Results >> Bragar Eagel amp Squire is Investigating Certain Officers and Directors of Zillow Group and Zosano Pharma and Encourages Investors to Contact the Firm >> Zosano Pharma to Present at the H C Wainwright Global Life Sciences Conference >> Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA >> Zosano Pharma Announces NDA Resubmission Plans Following Type A Meeting with FDA |
Zoetis Inc – Class A …Zoetis Inc – Class A |
ZTS (74100, 474.48, 0.68 %) | 152.42 | Zoetis ZTS Down 7 5 Since Last Earnings Report Can It Rebound …>> Zoetis ZTS Down 7 5 Since Last Earnings Report Can It Rebound >> USNA vs ZTS Which Stock Should Value Investors Buy Now >> Catalyst CPRX Beats on Q4 Earnings Revenues Rise Y Y >> Why Zoetis Is the Pfizer of Animal Healthcare >> Roche RHHBY Inks Deal to Acquire GenMark Diagnostics for 1 8B |
Zymeworks Inc …Zymeworks Inc |
ZYME (1560, 36.91, 4.9 %) | 31.85 | Zymeworks Announces Five Presentations at the American Association for Cancer Research AA …>> Zymeworks Announces Five Presentations at the American Association for Cancer Research AACR Annual Meeting 2021 >> Zymeworks Reports 2020 Year End Financial Results >> The 12 Billion Market That Has Biotech Stocks Hijacking The Immune System >> Zymeworks to Participate in Upcoming Investor Conferences and Events >> Zymeworks Expands Commercial Team and Creates New R amp D Role |
Zynerba Pharmaceuticals Inc …Zynerba Pharmaceuticals Inc |
ZYNE (223.24, 28.6, 10.47 %) | 4.83 | Is Zynerba Pharmaceuticals NASDAQ ZYNE In A Good Position To Invest In Growth …>> Is Zynerba Pharmaceuticals NASDAQ ZYNE In A Good Position To Invest In Growth >> Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights >> Zynerba Pharmaceuticals ZYNE Gains But Lags Market What You Should Know >> Zynerba Pharmaceuticals to Participate in the 33rd Annual ROTH Conference >> Zynerba Pharmaceuticals ZYNE Gains As Market Dips What You Should Know |
[ [ Advertencia de riesgo ] ]
Por favor, recuerda que el Trading es una actividad que pone en riesgo tu dinero y antes de hacerlo debes entender y aceptar los riesgos que eso supone. TradingCero.com no ofrece recomendaciones sobre Inversión ni sobre compra o venta de acciones ni de ningún activo financiero.
TradingCero.com es una web que ofrece información sobre los mercados financieros y Criptodivisas – información de la que no nos responsabilizamos si tuviera algún error – además de publicar cursos de Trading que nos parezcan de calidad e interesantes para nuestros lectores. TODA la información que compartimos así como las sesiones de TRADING que hacemos en nuestro CANAL DE YOUTUBE es SÓLO con FINES EDUCATIVOS.
Es posible que la información mostrada en la Web de TradingCero.com y en el Escáner de Acciones Americanas contenga errores de los que no nos responsabilizamos. Usamos fuentes de información de distintos proveedores por lo que no nos podemos hacer responsables de los errores contenidos en dicha información. Si ves algún error en esta web o en los datos que muestra, por favor, escríbemos un email a pablo@tradingcero.com y lo corregiremos lo antes posible.
TradingCero.com forma parte del programa de afiliados de la Escuela de Trading Tradenet.com y como tal, no nos podemos responsabilizar de los errores o problemas incluídos en sus paquetes formativos y/o servicios profesionales que ofrezca como Escuela de Trading.
Puedes consultar nuestro aviso legal, política de privacidad y política de cookies cuándo lo desees !